Clinical, biochemical and genetic heterogeneity in lysosomal storage diseases by Reuser, A.J.J. (Arnold)
CLINICAL, BIOCHEMICAL AND GENETIC 
HETEROGENEITY IN 
LYSOSOMAL STORAGE DISEASES 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE 
GENEESKUNDE AAN DE ERASMUS UNIVERSITEIT TE 
ROTTERDAM, OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF. DR. B. LEIJNSE EN VOLGENS BESLUIT VAN HET 
COLLEGE VAN DEKANEN. DE OPENBARE VERDEDIGING 
ZAL PLAATSVINDEN OP VRIJDAG 1 JULI1977, 
DES NAMIDDAGS TE 4.15 UUR PRECIES 
DOOR 
ARNOLDUS J.J. REUSER 
GEBOREN TE AMSTERDAM 
1977 
DRUKKERIJ J.H. PASMANS, 'S-GRAVENHAGE 
Promotor 
Co-referenten 
Prof.Dr. H. Galjaard 
Prof.Dr. D. Bootsrna 
Dr. J.F. Koster 
Dit proefschrift werd bewerkt binnen de vakgroep 
Celbiologie en Genetica van de Erasmus Universiteit te 
Rotterdam met financiele steun van FUNGO, Stichting 
voor Medisch Wetenschappelijk Onderzoek. 
aan Mariette 
aan mijn ouders 
Chapter I 
Chapter II 
Chapter III 
Chapter IV 
SUMMARY 
SAMENVATTING 
REFERENCES 
NAWOORD 
CONTENTS 
GENERAL INTRODUCTION 
CLINICAL, BIOCHEMICAL AND GENETIC 
ASPECTS OF GM2-GANGLIOSIDOSIS, 
GM1-GANGLIOSIDOSIS AND GLYCOGENOSIS 
TYPE II 
THE EXPERIMENTAL WORK: INTRODUCTION, 
DESCRIPTION AND DISCUSSION 
GENERAL DISCUSSION· 
CURRICULUM VITAE 
PUBLICATIONS I-VIII 
PUBLICATION I 
H. Galjaard, A. Hoogeveen, H.A. de Wit-Verbeek, A.J.J. 
Reuser, W. Keijzer, A. Westerveld and D. Bootsma 
(1974) Tay-Sachs and Sandhoff's disease. Intergenic 
complementation after somatic cell hybridization. 
Exp. Cell Res. 87, 444-448 
7 
12 
20 
35 
42 
48 
54 
62 
64 
66 
PUBLICATION II 
H.L .. Hoeksema, A.J.J. Reuser, A. Hoogeveen, A. Wes-
terveld, I. Braidman and D. Robinson (1977) 
Characterization of fi-D-N-Acetylhexosaminidase iso-
enzymes in man-Chinese hamster somatic cell hybrids. 
Am. J. Hum. Genet. 29, 14-23 
PUBLICATION III 
A.J.J. Reuser and H. Galjaard (1976) Characterization 
of p-o-N-Acetylhexosaminidases C and S in fibroblasts 
from control individuals and patients with Tay-Sachs 
disease. FEBS Lett. 71, 1-5 
PUBLICATION IV 
H. Galjaard, A. Hoogeveen, W. Keijzer, H.A. de Wit-
Verbeek, A.J.J. Reuser, Mae Wan Ho and D. Robinson 
(1975) Genetic heterogeneity in GM1-gangliosidosis Nature 257, 60-62 
PUBLICATION V 
A.J.J. Reuser, G. Andria, H.A. de Wit-Verbeek, A. 
Hoogeveen, E. del Giudice and H. Galjaard (1977) 
Biochemical, immunological and cell genetic 
studies in a two year old patient with an atypical 
form af GM1-gangliosidosis. J. Neural. submitted 
PUBLICATION VI 
A.J.J. Reuser, J.F. Koster, A. Hoogeveen and H. 
Galjaard (1977) Biochemical, immunological and 
cell genetic studies in glycogenesis type II 
PUBLICATION VII 
A.J.J. Reuser, J.F. Jongkind and H. Galjaard (1976) 
Methods for the analysis of acid a-1,4-glucosidase 
activity in single (hybrid) cells. J. Histochem. 
Cytochem. 24, 578-586 
PUBLICATION VIII 
A. Reuser, D. Halley, H. de Wit-Verbeek, A. Hoogeveen, 
M. van der Kamp, M. Mulder and H. Galjaard (1976) 
Intercellular exchange of lysosomal enzymes: enzyme 
assays in single human fihroblasts after co-culti-
vation. Biochem. Biophys. Res. Comm. 69, 311-318 
71 
81 
86 
89 
104 
120 
129 
HERACLITUS 
7 
CHAPTER I 
GENERAL INTRODUCTION 
The history of lysosomal storage diseases dates back to the 
end of the last century when the first clinical reports 
appeared of patients suffering from these genetic, meta-
bolic disorders (Tay, 1881; Gaucher, 1882; Sachs, 1887; 
Fabry, 1898). About seventy years wouid pass before the 
term 11 lysosome" was introduced by De Duve and co-workers 
(1955, 1965) to indicate a membrane-surrounded cytoplasmic 
particle containing acid hydrolases that was isolated by 
centrifugal cell fractionation. Later, the lysosomes 
were cytochemically demonstrated by Novikoff (1961) using 
an appropriate staining reaction for acid phosphatase and 
some other acid hydrolases. In the period that followed an 
impressive amount of work has been carried out on the 
structure and function of lysosomes (see for review Dingle 
and Fell, 1969-1975) and at present a few dozen of dif-
ferent acid hydrolases is known to be localized within 
this organe-lle. The main function of the lysosomal enzymes 
is the degradation of material that is enclosed in secon-
dary lysosomes by fusion of the primary lysosome with 
hetero- and autophagosomes or by other processes (Fig. 1). 
The first genetic defect in one of these lysosomal enzymes 
was discovered by Hers (1963) who described that glycogene-
sis type II, Pompe's disease, was due to a deficiency of 
acid a-glucosidase. The lysosomal character of this glyco-
gen storage disease was confirmed by cell fractionation 
studies, indicating acid a-glucosidase as a lysosomal 
enzyme and morphological studies which demonstrated the 
deposit of glycogen within the lysosornes (Lejeune et al., 
1963; Baudhuin et al.,. 1964). 
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Fig. 1 Schematic representation of the lysosomal system and its function. 
During the last decade many other metabolic disorders have 
been recognized as lysosomal storage diseases and the 
responsible enzymatic defects were resolved for most of 
them. Genetic defects have now been found for enzymes in-
volved in the degradation of carbohydrates (Hers and De 
Barsy, 1973), mucopolysaccharides (Neufeld et al., 1975; 
Cantz and Gebler, 1976), lipids (Brady, 1972, 1976) and 
various other metabolites. In most instances the enzyme 
deficiencies were discovered after the accumulating sub-
stances had been analyzed and the main catalytic activity 
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of the particular enzymes had been determined. Once the 
enzyme defects were known the diagnosis of many of these 
diseases has been facilitated by the development of arti-
ficial substrates providing simple procedures to assay the 
enzyme activities (Leaback, 1976). 
The diagnosis has further been facilitated by the fact that 
quite a number of lysosomal enzyme deficiencies can be 
demonstrated in leucocytes and cultured skin fibroblasts 
(see for review Nadler, 1972; Nitowsky, 1972). The expres-
sion of the enzymes in cultured cells has opened the way 
to prenatal diagnosis of these diseases (see for review 
Milunsky, 1973; Galjaard et al., 1975) and has allowed to 
use cultured cells as model system to study biochemical and 
genetic aspects of lysosomal storage diseases. For instance 
the cell culture system has widely been used to study the 
mucopolysaccharide storage diseases. 
Danes and Bearn (1965) described that the accumulation of 
acid mucopolysaccharides (glycosaminoglycans) occurred in 
cultured skin fibroblasts from patients with certain ~ypes 
of mucopolysaccharidosis. Subsequently Fratantoni et al. 
(1968) demonstrated that the intracellular accumulation of 
mucopolysaccharides was due to an impaired degradation and 
that the accumulation could be corrected by co-cultivation 
of cells from the patient with cells from a control indivi-
dual or from a patient with another type of mucopolysaccha-
ridosis (Fratantoni et al., 1969). In the years to follow 
these "corrective factors 11 were purifi.ed and identified as 
lysosomal enzymes involved in the degradation of mucopoly-
saccharides. The specific enzyme deficiencies have now 
been resolved for each of the clinical forms of mucopoly-
saccharidoses (McKusick, 1975; Neufeld et al. ,_ 1975; 
Dorfman and Matalon, 1976). 
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The cell culture system has also provided the means to 
study the genetic background of metabolic disorders which 
is especially of interest in those cases where apparently 
the same metabolic defect leads to different clinical and 
pathological manifestations. For example, the technique of 
somatic cell hybridization fo"llowed by an analysis of 
heterokaryons was first used by De Weerd-Kastelein et al. 
(1972) to investigate the genetic background of clinical 
heterogeneity in the skin disease xeroderma pigmentosum. 
Subsequently this method was used by Thomas et al. (1974) 
and Galjaard et al. (l974a), who demonstrated independently 
that two different forms of the lysosomal storage disease 
GM2-gangliosidosis were based on a separate gene defect. 
During the past ten years much has been learned about lyso-
somal storage diseases. The diagnosis has been extended 
from the exact description of the clinical symptoms to the 
morphological and biochemical characterization of the 
accumulated products, the demonstration of the enzyme or 
isoenzyme deficiency and sometimes even to the identifica-
tion of the type of gene mutation. Compared with the 
development in diagnosis less is known about the patho-
genesis of lysosomal storage diseases. The consequence of a 
lysosomal enzyme deficiency will be that cellular ~nd extra-
cellular constituents that cannot be degraded accumulate in 
residual bodies which after loss of their lysosomal enzymes 
are called postlysosomes (Daems et al., 1972). Since most 
cells are not able to discharge their residual bodies in 
the extracellular fluid, the accumulation of undigestable 
material in the lysosomal system continues gradually and 
this may at last severely interfere with the function of 
the cells of which ·many will degenerate. The clinical ex-
pression of the enzyme defect will of course largely 
depend on the type and number of cells that are affected 
and the particular function of the deficient enzyme in the 
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metabolism of these cells. However, also the clinical 
manifestation of a distinct lysosomal enzyme deficiency 
may vary extremely within the same metabolic disorder and 
the reason for this clinical heterogeneity is not yet 
sufficiently understood. Finally there is much to be 
learned about the correlation between the degree of enzyme 
deficiency, the disturbance of certain metabolic pathways 
and the resulting impairment of cellular functions. 
The present thesis deals with the study of some of these 
problems related to the clinical, biochemical and genetic 
heterogeneity in GM2-gangliosidosis, GM1-gangliosidosis 
and glycogenesis type II. 
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CHAPTER II 
CLINICAL, BIOCHEMICAL AND GENETIC ASPECTS OF GM2-GANGLIOSI-
DOSIS, GM1-GANGLIOSIDOSIS AND GLYCOGENOSIS TYPE II 
GM2-gangliosidosis 
(Tay-Sachs disease, Sandhoff's disease) 
GM2-gangliosidoses are autosomal recessive diseases 
characterized by the lysosomal accumulation of GM2-ganglio-
side due to a deficiency of N-acetyl-~-hexosaminidase 
(EC.3.2.1.30). The vast majority of cases concerns type 1 
GM2-gangliosidosis or Tay-Sachs disease, a smaller propor-
tion of patients are suffering from type 2 GM2-gangliosido-
sis, known as Sandhoff's disease. 
The clinical manifestation of the disease is rather similar 
in both types. The first clinical symptoms become apparent 
between the third and sixth month after birth, the children 
are apathetic, ·the psychomotoric development is retarded 
and the muscular tonus is low. After one year a rapid 
psychomotor deterioration is noticed and spasticity deve-
lops. Ophtalmologic investigation reveals the typical 
11 cherry red spot 11 as a result of macular degeneration, 
blindness and deafness occur and the patients expire 
between one and a half year and five years, usually from 
recurrent infections (see for review O'Brien, 1973; Sand-
hoff and Harzer, 1973; Galjaard and Reuser, 1977). 
The most stricking pathological manifestations occur in the 
brain. Ganglion cells of the cerebral cortex and Purkinje 
cells are packed with vacuoles, that contain concentric 
layers of lipid, representing deposits of GM2 - and asialo 
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GM2-ganglioside. A considerable number of ganglion cells is 
lost and many axons are demyelinated. Lipid inclusions are 
only occasionally found in liver and spleen. In Sandhoff's 
disease an additional accumulation of globoside waS demon-
strated in the visceral organs (Sandhoff et al., 1968). 
There is also evidence that the S-hexosaminidase deficiency 
affects the degradation of certain glycoproteins (Stricker 
and Montreuil, 1971), glycosaminoglycans (Cantz and Kresse, 
1974) and oligosaccharides (Tsay and Dawson, 1976). 
A third form of GM2-gangliosidosis has been distinguished 
as a juvenile form of Tay-Sachs disease, which is· in com-
parison with the other two forms characterized by a later 
onset and a longer survival of the patients. In the first 
years of life the accumulation of GM2- and asialo GM 2-
ganglioside seems to be less prominent than in the infan-
tile form of Tay-Sachs Oisease, but at a more advanced age 
a progressive neurological deterioration develops and death 
occurs between 5 and 15 years (Bernheimer and Seitelberg, 
1968, ;Suzuki et al., 1970). In additon to these three main 
forms of GM.2-gangliosidosis, patients have been reported 
incidentally with. an atypical expression of GM 2-gangliosi-
dosis (Sandhoff et al., 1971; Spence et al., 1974; Navon et 
al., 1973; Dreyfus et al., 1975). 
In 1966 it was suggested by Svennerholm that GM2-gangliosi-
dosis would be due to a hexosarninidase deficiency. Subse~ 
quently Robinson and Stirling (1968) identified two iso-
enzymes of a-hexosaminidase, A and B, and Okada and O'Brien 
(1969) discovered that Tay-Sachs disease was caused by a 
deficiency of hexosaminidase A which enzyme is able to 
hydrolyze GM2- and asialo GM2-ganglioside (Sandhoff et al., 
1971). In Sandhoff's disease, originally presented as a 
variant of ~ay-Sachs disease, a deficiency of both iso-
!4 
enzymes was demonstrated (Sandhoff et al., 1968). 
The activity of S-D-N-acetylhexosaminidase A and B (Hex A 
and Hex B) is expressed in most human tissues as well as in 
cultured skin fibroblasts and amniotic fluid cells, which 
latter allows the prenatal detection of the disease. The 
prenatal diagnosis has especially contributed to the pre-
vention of the disease, when combined with a population 
screening program for heterozygous carriers among Askenazy 
jews (Kaback et al., 1974). The en.zyme assay can be carried 
out with the artificial substrates p-·nitrophenyl-8-D-N-
acetylglucosaminide (or-galactosaminide) and 4-methyl-
umbelliferyl-2-acetamido-2-deoxy-S-D-glucopyranoside (or 
galactopyranoside). Furthermore, Hex A releases the 
terminal N-acetylgalactosamine from GM2- and asialo GM 2-
ganglioside and globoside. Hex B- WO\J.ld not be active to-
wards GM2-ganglioside (Sandhoff and Wassle, 1971) but this 
has been disputed by Tallman and co-workers (1974a). 
The juvenile form of Tay-Sachs dlsease seems to reflect a 
partial deficiency of Hex A (O'Brien, 1969). The other 
clinical variants that have been described, may result from 
a partial deficiency of Hex A and Hex B (Spence et al., 
1974) or from a specific l.oss of activity towards the 
natural substrate (Sandhoff et al., 1971). On the other 
hand healthy individuals have been described with an enzyme 
deficiency towards the artificial substrate (Navon et al., 
1973, 1976; Dreyfus et al., 1975). 
Several components of S-hexosaminidase activity exist in 
addition to Hex A and Hex B which are called Hex c (Hoogh-
winkel et al., 1972), Hex S (Ikonne et al., 1975), r 1 and 
r 2 (Ellis et al., 1975; Price and Dance, 1972) and Hex P 
(Swallow et al., 1974). Hex A and Hex B have been purified 
from human liver and placenta.and were found to have a 
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molecular weight of 1-1,5 x 10 5 , and to be composed of sub-
units with a molecular weight of about 25 x 10 3 (Srivasta-
va et al., 1974a,b; Tallman et al., 1974; Lee and Yoshida, 
1976). The interrelation between the various isoenzyrnes 
and the exact nature of the enzyme defects in various 
types of GM2-gangliosidosis have been extensively studied 
by biochemical, immunological and cell genetic analyses. 
The results of these studies will be discussed in more 
detail in chapter III. 
GM1-gangliosidosis 
(Landing's disease, pseudo-Hurler disease, generalized 
gangliosidosis) 
GM 1-gangliosidoses are autosomal recessive disorders cha-
racterized by the storage of GM1-gangliosides and glyco-
saminoglycans due to a deficiency of acid S-galactosidase 
(EC.3.2.1.23). Patients with distinct clinical forms of 
the disease have been described (see for reviews Van Hoof, 
1973; O'Brien, 1975; Galjaard and Reuser, 1977). 
Patients with the infantile (type 1) form of GM 1-ganglio-
sidosis develop symptoms shortly after birth. The main 
clinical features are severe psychomotor retardation, bone 
deformities and hepatosplenomegaly. The disease is rapidly 
progressive and patients die mostly in the second year of 
life. The juvenile (type 2) form of GM 1-gangliosidosis is 
milder. The first symptoms appear between six and twenty 
months after birth, the visceral organs are not or much 
less involved and bone deformities are minimal (Derry et 
al., 1968; Wolfe et al., 1970; Lowden et al., 1974). 
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Progressive mental and motoric retardation are the main 
clinical symptoms and in general these ·patients die between 
their sixth and tenth year of life. 
Pinsky et al. (1974) and more recently Andria et al. (1977) 
described patients with some of the characteristic features 
of GM1-gangliosidosis but without signs of psychomotor 
retardation. Finally a number of patients with an adult 
form of GM1-gangliosidosis has been reported who showed 
late onset of neurological abnormalities and slow psycho-
motor regression whereas in some instances skin lesions 
like angiokeratomata were observed {Loonen et al., 1974; 
Yamamoto et al., 1974;. Wenger,et al., 1974; Orii et al.,l975) 
The pathological manifestations co~prise of lysosomal 
inclusions which are either of lamellar membranous nature 
or they are granular or amo,rphous. These inclusions are 
mostly seen in neuronal cells, histiocytes and p·arenchymal 
cells of liver and spleen. The accumulation of GM1-ganglio-
side is most pronounced in brain and accounts for 60 t6 80% 
of the total amount of gangliosides. The amount of GM 1-
ganglioside in visceral organs varies but the content of 
keratansulphate like mucopolysaccharide iS always increased 
(Suzuki et al., 1971). 
In 1968 Okada and O'Brien and also Van Hoof and Hers demon-
strated that a deficiency of the lysosomal enzyme S-galac-
tosidase is responsible for GM1-gangliosidosis. Later, a 
partial or total deficiency of acid S-galactosidase was 
found in all forms of the disease both using the natural 
substrate or one of the artificial substrates p-nitrophenyl 
-S-D-galactoside or 4-methylumbelliferyl-S-D-galactopyrano-
side. The enzyme has been demonstrated in brain, kidney, 
liver and spleen and it can also be detected in leucocytes, 
17 
cultured skin fibroblasts and amniotic fluid cells. The 
latter has enabled prenatal monitory for the disease (Low-
den et al., 1973; Kleijer et al., 1976). 
From human liver two main forms of acid 8 -galactosidase 
were separated: a low molecular weight form (MW = 7 x 10 4 ) 
which is thought to be a monomer and a high molecular 
weight form (MW = 7 x 10 5 ), which might represent an 
aggregate of identical monomers (Norden et al., 1974) or 
may represent the low molecular form of the enzyme bound t.o 
lysosomal membrane fragments (Cheetham and Dance, 1976}. 
It has been demonstrated that the enzyme may also occur as 
dimer and that the low molecular forms can be generated 
from the high molecular form (Hultberg and Ockermanr 1972; 
Cheetham and Dance, 1976). In patients with GM 1-gangliosi-
dosis all these forms of S-galactosidase are deficient. The 
purified enzyme exhibits activity. towards GM 1-ganglioside, 
asialo fet-uin, keratansulphate, oligosaccharides and the 
artificial substrates mentioned above. 
In addition to GM1-s -galactosidas-e there is another acidic 
S-galactosidase which is deficient in Krabbe•s disease 
(Suzuki and Suzuki, 1970; Malone, 1970) and a neutral form 
of S-galactosidase that does not have activity towards GM 1-
ganglioside (Robinson et al., 1967; Ho and o•srien, 1969; 
Ockerman and Hultberg, 1968). 
Glycogenosis type II 
(Generalized glycogenesis, Pompe•s disease) 
Glycogenesis type II is an autosomal recessive disorder, 
18 
characterized by the ly.sosomal accumulation of glycogen and 
the deficiency of acid a-glucosidase (EC.3.2.1.20). It was 
first recognized by Pompe in 1932 as a generalized glycogen 
storage disease, fatal in the first years of life and 
classified as glycogenosis type II by Cori (1957). The 
enzyme defect was discovered by Hers (1963) and the lyso-
somal character of the disease was established (Lejeune et 
al., 1963; Baudhuin et al., 1964). Once the enzyme defect 
was known clinical variants of acid a-glucosidase deficien-
cy were recognized which differed in time of onset and 
severity of the symptoms. Infantile, juvenile and adult 
forms of glycogenesis type II bave been reported. 
In the classical, infantile, form cardiac enlargement is 
usually detectable shortly after birth, skeletal muscles 
are firm but hypotonia is severe and neurological ·defects 
might be present. Sometimes patients have a protruding 
tongue and hepatosplenomegaly may occur although the liver 
function is mostly undisturbed. In general these patients 
die in their first year of life because of cardiorespiratory 
insufficiency {Di Sant 1 Agnese et al., 1950). 
Patients suffering from the adult form of glycogenesis 
type II have less abundant accumulation of glycogen in their 
skeletal muscles and cardi.ac symptoms are not prominent. 
The acid a-glucosidase deficiency is mainly manifested by 
progressive muscular weakness, starting in the second or 
third decade of lif.e (Engel, 1970). Often the muscular 
weakness is misinterpreted as polymyositis or muscular 
dystrophy. 
The juvenile form is in most respects an intermediate one 
between the infantile and adult form (Hers, 1965; Hers and 
Van Hoof, 1968; Hudgson et al., 1968). 
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Acid a-glucosidase activity has been demonstrated in most 
tissues including lymphocytes, skin fibroblasts and amnio-
tic fluid cells (Nitowsky and Grunfeld, 1967; Salafsky and 
Nadler, 1971; Hers and De Barsy, 1973). The latter has 
enabled prenatal diagnosis in pregnancies at risk (Nadler 
and Messina, 1969~ Galjaard et al., 1973; Niermeijer et al., 
1975). 
Acid a-glucosidase has been purified from rat and bovine 
liver (Bruni et al., 1969; Jeffrey et al., 1970a), from 
rabbit muscle (Palmer, l97la,b} and from human placenta and 
liver (De Barsy et al., 1972; Belenky and Rosenfeld, 1975; 
Koster et al., 1976). The molecular weight of acid a-gluco-
sidase is about 10 5 and the enzyme is thought to consist 
of different subunits (Belenky and Rosenfeld, 1975). 
Evidence was presented that the enzyme has two separate 
catalytic sites, one for oligosaccharides and one for gly-
cogen (Jeffrey et al., 197Gb; Palmer, 197la,b; Koster and 
Slee, 1977). Acid a-glucosidase activity can be determined 
with glycogen or maltose as substrate but also with the 
artificial substrates p-nitrophenyl-a-Q-glucoside or 
4-methylumbelliferyl-a-D-glucopyranoside. Besides hydro-
lytic activity the enzyme exhibits glucosyl transferase 
activity. The main catalytic function in vivo seems to be 
the degradation of lysosomal g_lycOgen but the enzyme might 
also be involved in the degradation of glycoproteins or 
oligosaccharides (Wolfe and Cohen, 1968; Schnabel, 1971). 
In addition to acid a-glucosidase there exist several 
forms of a-glucosidase with a pH optimwn around 6.5. The 
activities of these 11 neutral 11 a-glucosidases towards glyco-
gen are very low but they exhibit activity towards maltose 
and the artificial substrates (Ushakova and Lukomskaya, 
1976). 
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CHAPTER III 
THE EXPERIMENT AI WORK: INTRODUCTION, DESCRIPTION AND 
DISCUSSION 
Introduction 
The lysosomal storage diseases discussed before are 
genetically determined and must be based on the mutation of 
a gene involved in the 11 realization 11 of the relevant enzyme. 
The term 11 enzyme realization11 , introduced by Paigen (1971) 
covers the whole set of processes that is required to pro-
duce a catalYtically active enzyme, including transcription, 
translation and post translation events. Several genes, 
each with a particular function, will be involved in this 
process. The structural gene determines the amino acid 
sequence of the polypeptide chains and thereby to a great 
extent the specific catalytic properties of an enzyme. 
Depending on the nature and the position of the structural 
mutation the enzyme that is coded by the gene may loose its 
catalytic activity completely or partially. In case an 
enzyme acts on several substrates it is also possible that 
the activity towards only one of the several natural sub-
strates is lost. Other structural mutations may completely 
block the synthesis of the enzyme. In addition to struc-
tural genes there may be regulator genes, which control the 
rate of enzyme synthesis and degradation and the activity 
of the enzyme. According to Paigen (1971) architectual 
genes have a function to direct the enzymes to their proper 
location whereas temporal genes would control the timing 
of the various events. Also a mutation in one of these 
latter genes might in principle lead to an enzyme deficien-
cy. Different gene mutations may result in different proper-
ties of the 11 mutant enzyme" and this in turn might have con-
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sequences for the clinical and pathological manifestation 
of the disease. 
The most direct approach to investigate whether clinical 
heterogeneity is based on different gene mutations is to 
perform complementation analyses as generally used for the 
genetic characterization of bacterial mutants (see for re-
views Fincham, 1966; Ratner and Rodin, 1976). Complemen-
tation studies to investigate genetic heterogeneity were 
first described by De Weerd-Kastelein et al. (1972), who 
demonstrated that two clinical forms of xeroderma pigmento-
sum were based on different gene mutations. In the follow-
ing years a number of other complementation studies in-
cluding some on lysosomal s·torage diseases were reported 
(see for reviews Ruddle and Creagan, 1975; Ringertz and 
Savage, 1976; Galjaard and Reuser, 1977). In complementa-
tion studies cultured fibroblasts from patients with 11 the 
samen enzyme deficiency are fused and multinuclear hetero-
karyons are formed, which carry the genetic information of 
both mutant cell strains. If the combination of the two 
genomes in heterokaryons results in a restoration of the 
metabolic defect, this is called complementation. When 
complementation occurs, it is a proof that the enzyme 
deficiency in both patients from whom the cells were 
derived, is caused by two different gene mutations. When 
restoration of the enzyme activity results from the coope-
ration of two different genes, it is called intergenic com-
plementation. When both mutations are located in the same 
gene and complementation occurs, it is called interallelic 
or intragenic complementation. 
A second approach to identify different gene mutations is 
to characterize the product that is coded for by the mutant 
gene. An excellent example of this approach is the study of 
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variant forms of human haernoglobins which indicated the 
existence of a large number of mutations in the genetic 
code for the polypeptide chains that form the haemoglobins 
(see for review Harris, 1975). The biochemical or immuno-
logical characteristics of the mutant gene product might 
at the same time be informative about its disturbed meta-
bolic function and about the clinical expression of the 
genetic defect. 
The third strategy that can be followed is that of gene 
localization, where human fibroblasts or leucocytes are 
fused with cultured fibroblasts from Chinese-hamster or 
mouse origin. After nUclear fusion has occurred prolife-
rating human-rodent hybrid cells {synkaryons) can be 
isolated using selective culture media. In such prolife-
rating hybrids a preferential loss of human chromosomes 
occurs.Correlation of the human chromosome content and the 
expression of human gene products in various hybrid clones 
enables· the localization of genes ( see for review Ruddle 
and Creagan, 1976) and information may be obtained about 
the number of genes that code for a particular enzyme. 
In our experimental work on the relation between clinical, 
biochemical and genetic heterogeneity of some lysosomal 
storage diseases, all three approaches, as mentioned 
above, have been used. The results will be discussed 
separately for GM2-gangliosidosis, GM1-gangliosidosis and 
glycogenesis type II. 
Experimental studies on GM2-gangliosidosis 
At the beginning of our investigations the enzyme defects 
responsible for type 1 GM2-gangliosidosis (Tay-Sachs dis-
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ease) and for the type 2 variant (Sandhoff's disease) had 
been elucidated (Okada and O'Brien, 1969; Sandhoff et al., 
1968). 
The purpose of the experiments described in Publication I 
was to investi.gate whether different gene mutations were 
responsible for the deficiency of hexosaminidase A (Hex A) 
in Tay-Sachs disease and for the absence of Hex A and Hex B 
in Sandhoff's disease. Cultured skin fibroblasts from 
patients with these two variant forms of GM2-gangliosidosis 
were hybridized using inactivated Sendai virus and the 
Hex A activity was measured in the heterokaryons 2-7 days 
after cell fusion. The activity of Hex A was determined 
by selective heat inactivation of the enzyme and by electro-
phoretic separation of Hex A and Hex B. Both methods 
revealed the restoration of Hex A activity in the hetero-
karyons. A similar iesult was obtained independently by 
Thomas et al. (1974) and later by Ropers et al. (1975) and 
Rattazzi et al. (1976). 
The occurrence of genetic complementation meant a definite 
proof for the existence of two different gene mutations in 
Tay-Sachs and Sandhoff's disease. We ascribed the restora-
tion of Hex A activity to intergenic. cqrnplementation, which 
would fit the hypothesis that Hex A and Hex B share a 
common subunit, whereas in addition Hex A would have a 
specific subunit (Robinson and Carroll, 1972; Ropers and 
Schwantes, 1973; Srivastava and Beutler, 1973). This theory 
explained Sandhoff's disease on the basis of a defect in 
the common subunit and Tay-Sachs disease by a defect in the 
specific Hex A subunit. The complementation studies, how-
ever, did not rule out the original hypothesis by Robinson 
and Stirling (196.8) that Hex B would be a_precursor of Hex 
A explaining Tay-Sachs disease by a defect in the 
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conversion of Hex B to Hex A and Sandhoff's disease by a 
deficiency of Hex B, thereby also resulting in a deficiency 
of Hex A (Tateson and Bain, 1971; Goldstone et al .. 1971). 
To further investigate the relationship between Hex A and 
Hex B we have performed gene localization studies on man-
Chinese hamster hybrids, which are described in Publication 
II. 
The results of previous gene localization studies concerning 
the isoenzymes of hexosaminidase had been somewhat confusing. 
A gene coding for Hex A had been assigned to chromosome 15 
and a gene coding for Hex B to chromosome 5, but there was 
disagreement about the question whe~her the expression of 
Hex A was dependent on that of Hex B (Van Sorneren and 
Beyersbergen van Henegouwen, 1973; Lalley et al., 1974; 
Gilbert et al., 1974; Van Cong et al., 1975). The immuno-
logical characterization of hexosaminidase isoenzymes 
occurring in different clones of man-Chinese hamster hybrids 
(see Publication II) provided the explanation for this dis-
crepancy by showing that a band of activity formerly iden-
tified as Hex A and expressed in the absence of Hex B, in 
fact did not represent Hex A but a heteropolymeric molecule 
consisting of subunits of Chinese hamster hexosaminidase 
and a-subunits specific for human Hex A. The gene coding 
for the specific a-subunit was localized on human chromosome 
15, the gene coding for the ~-subunit on chromosome 5. 
Other groups of workers also using man-rodent hybrids, came 
to similar conclusions although with slightly different 
methods (Van Cong et al., 1975; Lalley and Shows, 1976; 
Chern et al., 1976; Swallow et al., 1977). 
In the meantime biochemical and immunological studies showed 
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that Hex A and Hex B indeed consist of several subunits ahd 
that Hex A is a heterpolymeric molecule containing a-and 
Ssubunits whereas Hex B is a homopolymeric molecule only 
containing S-subunits {Srivastava and Beutler, 1973; 
Srivastava et ~1., 1974a,b; Bartholomew and Rattazzi, 1974). 
A third isoenzyme of S-hexosaminidase was discovered by 
Hooghwinkel and co-workers (1972) and was called Hex C. 
The biochemical and immunological properties of this iso-
enzyme turned out to be quite different from those of Hex 
A and Hex B: the enzyme is not lysosomal, has a neutral pH 
optimum and does not cross react with anti Hex A or anti 
Hex B antisera (Braidman et al., 1974; Penton et al., 1975) 
There was, however, a discrepancy between these biochemical 
data and cell genetic data. The latter suggested a relation 
between Hex A and Hex C because of a simultaneous absence 
of Hex A and Hex C in Tay-Sachs disease (Van Cong et al., 
1975; Ropers and Schwantes,l973). In addition gene locali-
zation studies suggested that Hex C was composed of a-sub-
units which are also present in Hex A (Van Cong et al,l975) 
The detection of Hex S as the major component of hexosami-
nidase activity in tissues from patients with Sandhoff's 
disease has helped to resolve this discrepancy. It was 
demonstrated immunologically that Hex S comprises a sub-
units and that in some electrophoretic systems, the mobi-
lity of Hex C and Hex Sis nearly identical (Ikonne et al., 
1975;. Beutler et al., 1975). 
The purpose of studies described in Publication III was to 
investigate the expression of Hex C and Hex S in cultured 
skin fibroblasts from patients with Tay-Sachs disease and 
control individuals. To enable these studi"es a method was 
deviced to identify Hex C and Hex S separately. The proce-
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dure described in Publication III is based on the specific 
activity of Hex C and Hex S towards 4-methylumbelliferyl-
~-D-glucosaminide and 4-methylumbelliferyl-~-D-galactosami­
nide substrate as well as on their different pH optima and 
immunological characteristics. It was demonstrated that in 
control fibroblasts both Hex C and Hex S are present where-
as in fibroblasts from patients with Tay-Sachs disease Hex 
c is expressed but Hex s is absent. Using a different method 
Swallow et al. (1976) also demonstrated Hex C activity in 
several tissues from patients with Tay-Sachs disease. 
These findings fit the hypothesis that Tay-Sachs disease 
is caused by a mutation in the a subunit. It was concluded 
that Hex C and Hex S migh-t have been confused in previous 
studies. 
Studies on the dissociation and recombination of subunits 
as performed by Beutler and Kuhle (1975) provided definite 
proof for the proposed subunit structure of the hexosamini-
dases. They showed that Hex A could be generated from Hex 
B and Hex S after dissociation of these latter isoenzymes 
and recombination of the subunits. In a similar way Hex B 
and Hex S could be formed after dissociation of Hex A. The 
subunit structures for the isoenzymes of fi-hexosaminidase 
according to Beutler et al. (1976) are as follows: 
Hex A: a 2 ~2 ; Hex B: ~4 ; Hex S: a 4 . The molecular structure 
of Hex C is still unknown. 
Experimental studies on GM 1-gangliosidosis 
Soon after the metabolic defect in GM1-gangliosidosis had 
been elucidated and the infantile and juvenile forms of the 
disease were recognized, attempts were made to explain the 
differences in clinical expression of ~-galactosidase defi-
ciency. 
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Three isoenzymes of 8-galactosidase were initially 
separated from human liver, two lysosomal enzymes and one 
with a neutral pH optimum (Ockerman and Hultberg, 1968; 
Van Hoof and Hers, 1968; Ho and O'Brien, 1969). It was 
originally thought that all three isoenzymes were deficient 
in the infantile, type 1, form of the disease, but only the 
two acidic isoenzyrnes would be deficient in the juvenile, 
type 2, form (O'Brien, 1969). However, this finding was not 
confirmed by others and at present the general opinion is 
that there is no relation between the activity of the 
neutral isoenzyme and the pathogenesis of GM 1-gangliosi-
dosis (Suzuki et al., 1971; Van Hoof, 1973; O'Brien, 1975) 
According to O'Brien (1975) the later onset and slower pro-
gression of type 2 GM 1-gangliosidosis might be correl-
lated with a somewhat higher level of residual S-galacto-
sidase activity in this type. Also a number of young 
adult patients with GM 1-gangliosidosis were described and 
a residual S-galactosidase activity of 10-20% was found in 
various tissues (Goldberg et al., 1971; Yamamoto et al., 
1974; Loonen et al., 1974; Wenger et al., 1974; Orii et 
al, 1975). The same was, however, true for skin fibro-
blasts from a seven year old girl (Pinsky et al., 1974) 
and a two year old boy (Andria et al., 1977), who both 
showed an atypical form of GM1-gangliosidosis without 
severe mental retardation. 
The purpose of the experimental work described in 
Publication IV was to investigate the genetic background 
of this clinical and biochemical heterogeneity. Cultured 
skin fibroblasts from patients with the infantile type 1 
and juvenile type 2 form of GM1-gangliosidosis and fibro-
blasts derived from the patient described by Pinsky (type 3) 
and from an adult patient (type 4) discovered in our own 
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centre {Loonen et al., 1974), were fused with each 
other. Two days later the S-galactosidase activity was ana-
lyzed using both the natural substrate GM 1-ganglioside and 
the artific-ial 4-methylumbelliferyl substrate, for which 
similar results were obtained. No restoration of S-galacto-
sidase activity was observed after fusion of type 1 with 
type 2 cells nor after fusion of type 3 with type 4 cells. 
However, complementation was found when type l or type 2 
cells were fused with type 3 or type 4 cells. From these 
results we concluded that at least two different gene 
mutations are involved in the different clinical forms of 
GM1-gangliosidosis. A complementation analysis performed 
on single binuclear cells after fusion of type 1 with 
type 4 cells demonstrated that S-galactosidase activity 
was restored to the level of mononuclear control cells. 
The mechanism of complementation still remairis obscure. 
To explain the increase of S-galactosidase activity in 
heterokaryons on the basis of intergenic complementation 
we have to postulate that at least two genes are involved 
in the production of active S-galactosidase. However, 
studies by Norden et al. (1974) on S-galactosidase purified 
from human liver, suggest that the enzyme contains only 
one polypeptide chain. Also in gene localization studies 
on man-Chinese hamster hybrids only one_ gene locus coding 
for p-galactosidase was found which is located on chromo-
some 22 (De Wit et al., 1977). The possibility remains 
that other genes as postulated by Paigen, are involved in 
the expression of S-galactosidase, which are yet to be 
demonstrated. 
The increase of S-galactosidase activity in heterokaryons 
after certain fusion combinations might also be the result 
of intragenic complementation. This would imply that two 
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variants that complement each other are based on structu-
ral alterations of the same polypeptide, but at different 
sites. Such allelic mutations might have different meta-
bolic and therefore clinical consequences. After cell fusion 
interaction of the two abnormal polypeptide chains might 
in principle lead to a restoration of normal activity of 
the enzyme. This type of complementation is known to occur 
in micro organisms {see for review Fincham, 1966; Ratner 
and Rodin, 1976). More experimental work is required to 
elucidate b1e exact mechanism of complementation. 
The nature of the gene mutation responsible for the de-
crease of fi-galactosidase activity was studied in detail 
in fibroblasts from a two year old patient with an atypical 
form of GM 1-gangliosid0sis without apparent psychomotor 
retardation, which was discovered recently by Andria. The 
results of these studies are described in Publication V. 
A residual ~-galactosidase activity of 10-20% was found in 
cultured fibroblasts from this patient whereas activities 
less than 1% are usually observed in patients ~ith the in-
fantile or juvenile form of the disease. The enzyme kinetic 
properties of the mutant enzyme as determined with 4-methyl-
urnbelliferyl substrate were normal but immunological studies 
pointed to a structurally altered enzyme. On the basis of 
genetic complementation studies this patient could be clas-
sified in the same group as the adult, type 4, patient 
(Loonen et al., 1974; Galjaard et al., 1975) and the type 3 
patient described by Pinsky et al. (1974). The genetic 
defect in this patient was thus different from that in type 
1 or type 2 GM 1-gangliosidosis. It should be awaited whether 
the clinical course of this patient who is still very young 
will be similar to that of Pinsky's patient and an adult 
variant. In the interpretation of the analytical data it 
should be ·realized that the activity of p-galactosidase for 
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natural substrates and under in vivo conditions might be 
quite different from that in the test tube. Yet, it is the 
in vivo activity which determines the clinical manifestations. 
Experimental studies on glycogenesis type II 
In the infantile form of glycogenesis type II the acid a-glu-
cosidase deficiency is expressed by the lysosomal storage 
of glycogen in nearly all tissues. Patients with this form 
of the disease usually die in their first years of life 
because of cardiorespiratory failure. In patients with the 
adult form of glycogenesis type II storage of glycogen seems 
to be restricted to the skeletal muscles, the heart is not 
involved and patients reach the adult age and some of them 
even become older than sixty years. Various explanations 
have been given for the different clinical expression of 
the acid a-glucosidase defect but none of these seemed very 
satisfactory. 
It has been suggested that a compensatory mechanism exists 
in the adult form preventing the extensive accumulation of 
glycogen in the lysosomes (Hudgson et al.,l968) but no ex-
perimental data have yet been presented to suppor:.t this idea. 
The group of Engel (1973) suggested that neutral a-glucosi-
dase would play a role in the pathogenesis of glycogenesis 
type II. They reported that in cardiac muscle, skeletal 
muscle and liver from patients with the infantile form of 
the disease not only the acid a-glucosidase activity was 
deficient but also the activity of the neutral enzyme 
(Angelini et al., 1972). Other groups however, found a normal 
activity of the neutral enzyme in the heart and skeletal 
muscle from patients with the infantile form of glycogenesis 
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type II (Illi~gworth and Brown, 1965; De Barsy and Hers, 1975; 
Mehler and Di Mauro, 1977). It is difficult to envisage an 
important role of the neutral ~glucosidase in the clinical 
expression of glycogenesis II since the activity of this 
enzyme towards glycogen is very low (Rosenfeld, 1975; Ushakova 
and Lukomskaya, 1976) 
Another possible explanation for the different degree of 
cardiac involvement in the adult and infantile form could be 
the existence of a specific isoenzyme in heart muscle which 
would have a normal activity in the adult form but which is 
deficient in the infantile form. However, there is no evidence 
that such a tissue specific isoenzyme exiSts (Koster et al., 
1976). 
The purpose of the experimental work described in Publication 
VI was to investigate whether different levels of residual 
acid a-glucosidase activity in the var.ious forms of the 
disease could account for the clinical heterogeneity. There-
fore the acid and neutral a-glucosidase activity was measu~ed 
in cultured skin fibroblasts derived from 7 patients with the 
infantile form and 5 patients with the adult or juvenile form 
of glycogenesis type II. In all instances a residual acid 
a-glucosidase activi~y of 10-20% was found in fibroblasts 
from patients with the late onset form , whereas the activity 
in patients with the infantile form of the disease was always 
less than 1%. An inverse correlation was thus observed between 
the level of residual acid a-glucosidase activity in the fi-
broblasts and the clinical severity of the disease. The acti-
vity of neutral a:·-glucosidase was similar in cells from all 
types of patients and in controls. If our results on fibro-
blasts would be representative for the enzyme activity in 
skeletal muscle this would explain why the accumulation of 
glycogen in skeletal muscle from adult patients is less than 
in case of the infantile form. The presently available data 
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from the literature on this point are however conflicting 
and can not easily be compared. 
Our immunological studies, described in Publication VI, showed 
the absence of cross reacting inactive acid a-glucosidase in 
fibroblasts from patients with the infantile form of glyco-
genesis type II which is in agreement with data on liver and 
fibroblasts from these patients reported by others (De Barsy 
et al., 1972; Brown et al., 1975; Koster et al., 1976). In 
cells from the various patients with the adult forms we ob-
served a decrease in the number of acid a-glucosidase mole-
cules which was proportional with the hydrolytic activity. 
Since the activity per enzyme molecule was similar as in 
controls we suggest that the gene mutation involved in these 
adult forms of glycogenesis type II affects the steady state 
level of the enzyme. It may either be a mutation which de-
creases the rate of synthesis of the enzyme or a mutation 
which enhances its breakdown. 
To investiga-te whether different gene mutations would be in-
volved in the infantile and adult form of glycogenesis type II 
complementation analyses were performed after somatic cell 
hybridization. Fibroblasts from clinical variants were fused 
in different combinations but in none of the experiments 
restoration· of acid a-glucosidase activity was found (Publica-
tion VI). In order to rule out the possibility that a partial 
restoration of acid a-glucosidase activity in multinuclear 
heterokaryons would be masked by "dilution" with non fused 
parental cells we have also performed complementation analyses 
in single binuclear cells, half of which will contain the 
genome of both patients. In order to be able to perform such 
studies a microchemical method had to be developed which 
allows the determination of acid ~-glucosidase activity in a 
single cultured cell. Publication VII describes the details 
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of such a micro method and it also gives an example of its 
applic'ation in somatic cell hybridization studies. Again 
after fusion of fibroblasts from the infantile and adult type 
no evidence for genetic complementation was found. Unlike the 
observations made in GM2-gangliosidosis and GM 1-gangliosidosis 
complementation studies did not provide evidence that dif-
ferent gene mutations would be responsible for the clinical 
forms of glycogenesis type II, but judging from the various 
levels of residual activities the existence of different 
mutations is likely. 
Experimental studies on the intercellular exchange of 
lysosomal enzymes 
In the beginning of this chapter it was mentioned that the 
function_ of architectual genes might be to direct enzymes 
to their correct location. This might also be true for lyso-
somal enzymes. Mucolipidosis II, or I-cell disease might re-
present an example of a lysosomal storage disease where such 
a mutation is involved. It has been described by Leroy and 
Spranger (1970) that cultured fibroblasts from patients suf-
fering from this disease are deficient in several lysosomal 
enzymes whereas the activity of these enzymes in the culture 
medium is increased. Hickman and Neufeld_ (1972) showed that 
the cellular uptake of these lysosomal enzymes is less ef-
ficient than is the case for enzymes secreted by normal cells. 
They postulated that in general lysosomal enzymes have to be 
secreted and subsequently to be taken up via specific re-
cognition sites before they reach their correct location in 
the lysosomes. The genetic defect in I-cell disease would 
affect the recognition site on some lysosomal enzymes resul-
ting in an insufficient uptake and hence a deficient intra 
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cellular activity. 
Such a mechanism could in principle be responsible for other 
genetic enzyme deficiencies and the purpose of the experi-
ments described in Publication VIII was to investigate whether 
the hypothesis of Hickman and Neufeld had a more general 
validity. For this purpose we have co-cultivated skin fibro-
blasts from control individuals with those from patients 
with GM 2-gangliosidosis, GM1-gangliosidosis ahd glycogenesis 
type II. Methods were developed to assay the activities of 
the lysosomal enzymes concerned in single cultured cells 
Galjaard et al., l974b; and Publications IV and VII). After 
2-10 days co-cultivation in confluent cultures single cells 
were isolated and the enzyme activity was determined in in-
dividual control and mutant cells; these could be identified 
because they were prelabeled with latex or c~rbon particles 
respectively. The results described in Publication VIII 
indicated that during co-cultivation p-hexosaminidase was 
transferred from control cells to enzyme deficient Sandhoff 
cells. No such transfer was found for acid a-glucosidase or 
~-galactosidase. On the basis of these results it was con-
cluded that the Hickman and Neufeld hypothesis might be 
valid for some of tPe lysosomal enzymes but that it does not 
seem to have a general validity. 
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CHAPTER IV 
GENERAL DISCUSSION 
Clinical heterogeneity among patients with the "same" gene-
tic metabolic disease may be the result of genetic hetero-
geneity i.e. different mutations in the genes coding for 
the enzyme concerned (see for review McKusick, 1973 and 
1975) • Different mutations may lead to different degrees of 
functional impairment of the enzyme and the clinical ex-
pression of this will depend on the tissue dis.tibution of 
the enzyme, its particular function in the metabolic pro-
cesses in different cell types and also on the degree of 
residual activity towards its natural substrates. Finally 
we should be aware that a number of secondary genetic and 
metabolic factors may influence the expression of a parti-
cular enzyme deficiency. 
The studies on variant human haemoglobins have contributed 
significantly to our insight in the nature of ~ene mutations 
and their effect. These studies may serve as a model for the 
understanding of heterogeneity in genetic enzyme deficien-
cies. At present more than 130 variant forms of haemoglobins 
have been detected of which more than 90% is based on single 
amino acid substitutions (see for review Stamatoyannopoulos, 
1972). Many other protein variants are known to be the result 
of different gene mutations and there is no reason to suppose 
that lysosomal enzymes are not subject to mutations. The in-
vestigation of mutant lysosomal enzymes however, is more 
difficult than in the case of haemoglobin which is present 
in relatively large quantities in erythrocytes which can 
easily be isolated. Also the pathological and clinical con-
sequences of a defective lysosomal enzyme are more difficult 
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to predict. Haemoglobin has one well defined function per-
formed in one cell type, but lysosomal enzymes are widely 
distributed among the various tissues and they are often 
involved in the degradation of several substances. 
A genetic defect of a lysosomal enzyme may be differently 
expressed ±n various tissues •. An example of this is found in 
GM1-gangliosidosis where the ~-galactosidase deficiency re-
sults in the accumulation of GM1-ganglioside and asialo GM 1-
ganglioSide in neuronal tissues whereas glycosaminoglycans, 
glycoproteins and oligosaccharides are stored in the vis-
ceral organs. The nature of the organ involvement in this 
case is thus determined by the tissue specific distribution 
of the natural substrate of the enzyme. 
Another example is GM2-gangliosidosis where in the Sandhoff 
variant globoside accumulates in the visceral organs of the 
patients because of a deficiency of both isoenzymes of N-
acetyl-B-hexosaminidase (Hex A and Hex B) whereas GM2- and 
asialo GM2-ganglioside accumulate predominantly in the neu-
ronal tissues. In the Tay-Sachs variant where only isoenzyme 
A is deficient the main pathological finding is the accu-
mulation of gangliosides in neuronal cells. Here the dif-
ferent expression of the disease is due to a different iso-
enzyme deficiency but also to the tissue distribution of the 
natural substrates of these isoenzymes. 
Finally specific organ involvement can also be caused by 
the tissue distribution of the defective enzyme. For example 
in glycogenesis type I (Von Gierke disease) the accumulation 
of glycogen as a result of glucose-6-phosphatase deficiency 
is primarily restricted to the liver where this enzyme is 
normally located (Cori and Cori, 1952). In glycogenosis type 
V (McArdle disease) glycogen storage due to a specific mus-
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cle phosphory1ase deficiency will primarily occur in the 
skeletal muscles (Schmid et al., 1959). 
Also the level of residual activity O-f a defective enzyme 
might account for clinical heterogeneity. This seems to be 
the case in glycogenesis type II where there is no indica-
tion that tissue specific isoenzymes would account for the 
different expression of acid a-glucosidase deficiency in the 
adult and infantile form. Our experiments described in 
Publication VI suggest that the different levels of residual 
activity in both forms of the disease would be the primary 
basis of the clinical heterogeneity, a possibility considered 
earlier by Zellweger and coworkers (1965). The higher resi-
dual acid a-glucosidase activity in the adult form might 
account for the lower glycogen content of the skeletal mus-
cles compared with that in patients with the infantile form 
of glycogenesis type II. Such an inverse correlation between 
residual enzyme activity and severity of clinical symptoms 
has also been described for variant forms of glucose-6-
phosphate-dehydrogenase deficiency (Yoshida, 1973) and dif-
ferent types of Gaucher disease (Brady et al., 1966). Also 
in GM1-gangliosidosis differences in the expression of~­
galactosidase deficiency might be caused by different levels 
of residual activity of the mutant enzyme. In tissues from 
patients with the infantile or juvenile form of the disease 
the activity of ~-galactosidase is always less than 1%. In 
cells from adult patients with ~-galactosidase deficiency 
activities between 5 and 20% of the control value were found 
(Yamamoto et al., 1974; Orii et al., 1975; Wenger et al., 
1974; Loonen et al., 1974; Galjaard et al., 1975; Suzuki et 
al., 1977). Comparably high residual activities were also 
detected in cells from some younger patients with a mild 
form of the disease without severe psychomotor retardation 
(Pinsky et al., 1974; Reuser et al. in Publication V; O'Brien 
et· al.·, 
allow 
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1976). These latter patients are however to young to 
definite. conclusions and the further course 
of their clinical manifestations must be awaited. Also in 
Tay-Sachs disease patients with the juvenile form seem to 
have some residual activity of ~-hexosaminidase A whereas 
patients with the infantile form of the disease have no de-
tectable Hex A activity (O'Brien, 1973). 
For a correct interpretation of the relationship between 
clinical symptoms and residual enzyme activity one should 
be aware of possible differences between the conditions of 
an in vitro enzyme assay and the in vivo situation. One also 
has to realize that the activity of the mutant enzyme does 
not have to be reduced to the same extent for all its dif-
ferent substrates. In our studies on different variants of 
GM1-gangliosidosis (see Publication IV) similar activities 
of ~-galactosidase were found towards the natural substrate 
GM1-ganglioside and the artificial methylumbelliferyl sub-
strate. The same is true for acid a-glucosidase in fibro-
blasts from patients with different clinical variants of 
glycogenesis type II {see Publication VI) where similar ac-
tivities were found towards glycogen, maltose and methyl-
umbelliferyl substrate. On the other hand healthy indivi-
duals were described with a profound ~-hexosaminidase de-
ficiency towards the artificial substrate whereas the acti-
vity for the natural substrate was higher {Tallman et al., 
1974; Dreyfus et al., 1975; Navon et al., 1976). A reverse 
situation has also been reported in a patient where ~-hex­
sosaminidase A and B were active towards the artificial sub-
strate and presumably inactive towards GM2-ganglioside 
(Sandhoff et al., 1971). 
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At present it seems too early to generalize about the rela-
tionship between the residual lysosomal en?.yme activity 
and the severity of clinical manifestations. In metachro-
matic leucodystrophy for instance which is 'another lysoso-
mal storage disease such relation seems not to exist (see 
for review Austin, 1973). Although some aspects of clini-
cal heterogeneity in GM2-gangliosidosis, GM1-gangliosidosis 
and glycogenesis type II can be explained on the basis of 
different levels of residual enzyme activity we have no 
idea about the minimum level of activity that is required 
for a normal development. A further complication is that 
the activity in cultured s.kin fibroblasts does not necessa-
rily reflect the situation in other cell types like neurons 
and liver cells. On the other hand the cell culture system 
has· provided an extremely useful model for studies on the 
correction of a metabolic defect. 
Correction of mucopolysaccharide storage in cultured fibro-
blasts from patients with different types of mucopolysaccha-
risosis could be realized by co-cultivation with cells of a 
different genotype (see for review Neufe1d, 1974). Such me-
tabolic 'correction appeared to be based on the uptake by 
deficient cells of the nec~ssary enzyme which had been se-
creted by the other cell type. s.ubsequen tly, it was shown 
that addition of purified a-iduronidase to cells from a 
patient with Hurler's disease (Bach et al., 1972) and of 
N-acetyl-a-hexosaminidase to cells of a patient with San-
filippo B disease (O'Brien et al., 1973) resulted in correc-
tion of the intra cellular storage of mucopolysaccharides. 
Interestingly in this situation an intra cellular activity 
of only 10 % of the control value was enough for metabolic 
correction. Of course these results can not directly be 
extrapolated to the in vivo situation but they may suggest 
·that in certain circumstances even low levels of enzyme 
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activity may be sufficient to prevent serious physical and 
mental damage in the patient. 
As described in chapter III the enzyme defects in the cli-
nical variants of GM2-gangliosidosis, GM 1-gangliosidosis 
and glycogenesis type II can be caused by various gene mu-
tations any of which may result in a different impairment 
of the in vivo function of the particular enzymes. Like in 
haernoglobinopaties, in the majority of cases the mutation 
will be in the structural gene but a mutation in other 
genes can not always be excluded. The occurrence of a mul-
tiple lysosomal enzyme deficiency as in I-cell disease for 
instance indicates that the lysosomal enzyme deficiency 
might also be caused by the mutation of a gene responsible 
for the correct location of the enzyme. However, for reasons 
mentioned in Publication VIII it is unlikely that the en-
zyme deficiencies in any of the three lysosomal storage di-
seases described in this thesis is due to such a gene muta-
tion. 
Complementation analyses and studies concerning the expres-
sion of human (iso)enzymes in man-rodent somatic cell hy-
brids seem promising ways to investigate whether different 
gene mutations are involved in the "same" enzyme deficiency. 
Biochemical and immunological studies on the mutant enzyme 
might further help to elucidate the nature of the genetic 
defect. Studies concerning the recognition and uptake of 
lysosomal enzymes may give a better understanding of cell 
biological processes. The combined use of these approaches 
as described in this thesis has provided more insight in 
the relationship between clinical, biochemical and genetic 
heterogeneity in GM2-gangliosidosis, GM1-gangliosidosis and 
glycogenesis type II. These fundamental investigations may 
in future be essential as a basis for therapeutic approaches. 
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They may well reveal that therapy is only feasible for 
some lysosomal storage diseases and that different clinical 
forms of the same disease require a different treatment. 
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SUMMARY 
The main function of lysosomes is the degradation of bio-
logical material from the intracellular or extracellular 
space. The degradation of these substances is performed by 
hydrolytic enzymes which are localized in these cell orga-
nelles. If one of these enzymes is absent or when its 
function is disturbed, a lysosomal storage of one or seve-
ral substances may occur. As a result of this the cell 
might be damaged and may loose its function as well as the 
organ comprising these cells. At present a few dozen of in-
herited metabolic diseases are known to be due to a lyso-
somal enzyme defect. The severity of the physical and men-
tal handicaps of the patient suffering from these diseases 
varies depending on the nature of the organs involved and 
the degree of functional impairment of the cells. However, 
it becomes more and more clear that also within one parti-
cular metabolic disease considerable variation in clinical 
expression may occur. Some patients suffering from a certain 
lysosomal enzyme deficiency already show severe symptoms 
shortly after birth and a progressive course of the disease 
leads to early death. In other patients the first clinical 
signs become apparent at a more advanced age and some of 
these patients may survive into late adulthood. 
The purpose of tne experiments described in this thesis 
was to get a better insight in the relationship between 
genetic, biochemical and clinical heterogeneity in three 
lysosomal storage diseases i.e. GM2-gangliosidosis, GM1 -
gangliosidosis and glycogenesis type II. The investigations 
were performed on cultured skin fibroblasts of patients 
suffering from these diseases. 
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Three different approaches were used: 
- Complementation analyses were performed to answer the 
question whether different gene mutations are involved 
in the deficiency of the same enzyme in various clinical 
forms of the disease. In these studies fibroblasts 
derived from different patients are fused and Subse-
quently it is examined whether the enzyme defect is res-
tored by the cooperation of both genomes. 
- Gene localization studies were performed to obtain infor-
mation about the number of genes involved in the produc-
tion of the deficient enzyme concerned, and about the 
molecular structure of the enzyme. In these studies human 
fibroblasts and Chinese hamster fibroblasts are fused and 
proliferating hybrids are selected. These hybrids prefe-
rentially loose human chromosomes which allows a coriela-
ticin between the loss of human genes and the expression 
of specific human (iso)enzymes. 
- Biochemical and immunological studies were performed to 
characterize the mutant enzyme in order to get informa-
tion about the nature of the gene mutation and its effect 
on the function of the enzyme. 
The most important findings, which are described in detail 
in the Publications I - VIII, are summarized below. 
GM2-gangliosidosis 
Several clinical and biochemical variants of GM2-ganglio-
sidosis have been described. Tay-Sachs disease the variant 
that occurs most frequently, is due to a deficiency of the 
44 
isoenzyme A of S-D-N-acetyl hexosaminidase. In addition 
there is another variant called Sandhoff's disease in 
which both the isoenzyme A (Hex A) and the isoenzyme B 
(Hex B) are deficient. Complementation analyses using 
fibroblasts from these two types of patients demonstrated 
that Tay-Sachs disease and Sandhoff's disease are based on 
mutations in two different genes (Publication I). Further, 
gene localization studies in man-Chinese hamster cell 
hybrids have shown that two different genes are coding for 
Hex A which are localized on chromosome 5 and 15 respec-
tively. Also it appeared that the expression of Hex A was 
dependent on that of Hex B which is coded by a gene loca-
lized on chromosome 5. It turned out that conflicting 
results in different studies concerning the interrelation-
ship between Hex A and Hex B were based on the mis-inter-
pretation of an isoenzyme expressed in these hybrids. As 
is shown in Publication II this isoenzyme represents a 
heteropolymeric molecule consisting of subunits of human 
Hex A and subunits from Chinese hamster hexosaminidase. 
The characterization of this hybrid molecule and a better 
identification of Hex C and Hex S, which are two other 
hexosaminidase isoenzymes (Publication III) in combina-
tion with the results of other groups have finally 
elucidated the nature of the mutation in the two most fre-
quent variants of GM2-gangliosidosis. Tay-Sachs disease is 
caused by a mutation in the a-subunit which is part of Hex 
A and Hex S. The Hex A en Hex B deficiency in Sandhoff 1 s 
disease is caused by a mutation in the S-subunit which 
forms Hex B but which is also part of Hex A. 
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GM1-gangliosidosis 
Als.o in GM1-gangliosidosis which is due to a deficiency of 
the lysosomal en4yme S-galactosidase, several clinical va-
riants occur. Complementation analyses as described in 
Publication IV show that at least two gene mutations are 
involved in these variants. In addition it was found tha·t 
in the infantile and juvenile forms of the disease, indi-
cated as type 1 and type 2 respectively, less than 1% of 
a-galactosidase activity is present in cultured ~kin 
fibroblasts. In cells from a patient with the adult form 
(type 4) and of a younger patient (type 3), without severe 
mental retardation, 10-20% residual activity was demonstra-
ted for both an artificial substrate and the natural sub-
strate GM1-ganglioside. Publication V describes a two year 
old boy with a S-galactosidase deficiency and who so far 
had a normal psychomotor development. In view of the resi-
dual enzyme activity in the fibroblasts (10-20%) and the 
fact that complementation occurred when fibroblasts from 
this patient were fused with those from type 1 or type 2 
patients it could be concluded that this patient does not 
represent the type 1 or type 2 vaiiant of GM 1-gangliosi-
dosis. Immunological studies on the S-g·alB.ctosidase in 
fibroblasts from the patient described in Publication V 
showed a decrease in the hydrolytic activity per enzyme 
molecule which points to a structural mutation. Until now 
it is not clear whether the different clinical variants of 
GM 1-gangliosidosis are based on different mutations in 
the same gene or in separate genes. 
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Glycogenesis type II 
Generalized glycogenesis type II or Pompe's disease is the 
form that occurs most frequently. It is due to a deficien-
cy of the lysosomal enzyme acid a-glucosidase which results 
in accumulation of glycogen in heart, skeletal muscles, 
liver and other organs leading to early death. In addition 
patients have been described with an acid a-glucosidase 
deficiency where the disease is less severe and less pro-
gressive·. In this adult form the cardiac involvement is 
minimal and hypotonia of skeletal muscles is the most pro-
minent feature. The patients may reach a high advanced age. 
Publication VI describes that in cultured fibroblasts from 
all adult patients tested a residu~l acid a-glucosidase 
activity of 10-20% was found towards an artificial substrate 
as well as towards maltose, and the natural substrate gly-
cogen. An inverse correlation was found between the level 
of the residual acid a-glucosidase. activity in the fibro-
blasts on the one hand and the extent of glycogen accumu-
lation in skeletal muscles and the severity of the clini-
cal manifestations on the other hand. In none of the cases 
a residual acid a-glucosidase activity was found in cultu-
red fibroblasts from patients with the infantile form of 
glycogenesis type II. Biochemical and immunological analy-
sis of the acid a-glucosidase in the fibroblasts from 
adult patients showed that the enzyme had normal physico-
chemical and kinetic properties and that it was present in 
reduced amounts (Publication VI) . These facts point to a 
mutation in the adult form that either results in a de-
creased rate of enzyme sYnthesis or in an increased rate 
of its degradation. Complementation analyses in multi-
karyons or individual binuclear hybrid cells did not pro-
vide evidence for genetic heterogeneity {Publications VI 
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and VII). The exact nature of the gene mutations leading 
to a different degree of enzyme deficiency in the adult and 
infantile form of glycogenesis type II is still unknown but 
it seems likely that different gene mutations are involved. 
Exchange of lysosomal enzymes 
According to a hypothesis by Hickman and Neufeld (1972) 
lysosomal enzymes have to be secreted by the cell and sub-
sequently are taken up via specific recognition sites at 
the cell surface, before they reach their lysosomal loca-
tion. In Publication VIII we have investigated whether 
such a defective uptake me.chanism could account for the 
enzyme deficiencies in GM2-gangliosidosis, GM 1-gangliosi-
dosis or glycogenesis type II. We have studied the inter-
cellular exchange of S-D-N-acetyl hexosaminidase, S-galac-
tosidase and acid a-glucosidase by enzyme analyses in 
single fibroblasts isolated after co-cultivation of control 
fibroblasts and enzyme deficient cells. No transfer of 
S-galactosidase or acid a-glucosidase from control to enzym 
deficient cells was found but for S-hexosaminidase a trans-
fer from control to enzyme deficient cells from a patient 
with Sandhoff' s. disease was demonstrated. From these results 
it was concluded that the hypothesis mentioned above does 
not seem to be valid for all lysosomal enzymes. Further stu-
dies on the secretion, recognition and uptake of lysosomal 
enzymes are not only necessary for a better understanding 
of the exact nature of the different genetic metabolic 
diseases but they also may provide a basis for future 
treatment. 
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SAMENVATTING 
Lysosomen spelen een belangrijke rol bij de afbraak van 
biologisch materiaal afkomstig uit het intra- en extra 
cellulaire milieu. De afbraak vindt plaats door middel van 
hydrolytische enzymen die zich in deze celorganellen bevin-
den. Bij afwezigheid of het niet voldoende functioneren 
van een van deze enzymen kan lysosomale stapeling van een 
of meerdere producten ontstaan. De cellen waarin stapeling 
optreedt kunnen hun ftinctie verliezen, evenals het orgaan 
waarvan deze cellen dee! uit maken. Mornenteel zijn enkele 
tientallen erfelijke stofwisselingsziekten bekend waarvan 
is aangetoond dat ze op een lysosomaal enzym defect berus-
ten. De ernst van de klinische symptomen bij patienten die 
aan dit soort ziekten lijden varieert afhankelijk van de 
aard van de betrokken organen en van de mate van het 
functieverlies van de daarin ·aanwezige cellen. Het wordt 
echter voor steeds meer erfelijke stofwisselingsziekten 
duidelijk dat ook binnen een bepaalde ziekte nag grate 
klinische heterogeniteit kan bestaan. Bij eenzelfde erfe-
lijke enzy~ deficientie vertonen sornrnige patienten al kart 
na de geboorte ernstige, progressief verlopende ziektever-
schijnselen waaraan zij vroeg overlijden, terwijl bij 
andere patienten pas op latere leeftijd merkbare afwij-
kingen optreden met een milder verloop waardoor deze pa-
tienten soms een hogere volwassen leeftijd bereiken. 
Doel van het in dit proefschrift beschreven onderzoek is 
geweest meer inzicht te krijgen in de relaties tussen 
genetische, biochemische en klinische heterogeniteit bij 
een drietal lysosomale stapelingsziekten met name: GM2 -
gangliosidosis, GM1-gangliosidosis en glycogenesis type II. 
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Bij het onderzoek werd gebruik gemaakt van gekweekte huid-
fibroblasten van patienten met deze ziekten. 
Er werden drie methoden van onderzoek toegepast: 
·- Met behulp van complementatle analysen werd getracht de 
vraag te beantwoorden of er een of meerdere genmutaties 
betrokken zijn bij een deficientie van hetzelfde enzym 
in verschillende klinische varianten. Hierbij worden 
fibroblasten afkomstig van verschillende patienten met 
elkaar gefuseerd en wordt onderzocht of door het samen-
werken van beide genornen het enzymdefect wordt opgeheven. 
- Met behulp van genlocalisatie studies werd getracht te 
bepalen hoeveel genen betrokken zijn bij de productie 
van het betreffende (deficiente) enzym en werd de rnole-
culaire structuur van het enzyrn onderzocht. Hierbij 
wordt het verlies van menselijke chrornosomen in hybride 
cellen, verkregen door fusie van menselijke en Chinese 
hamster fibroblasten, gecorreleerd met het verlies van 
expressie van rnenselijke (iso)enzyrnen. 
- Met behulp van biochernische en immunologische rnethoden 
werd getracht het gernuteerde enzyrn te karakteriseren 
teneinde een indruk te krijgen van de aard van de gen-
rnutatie en de invloed hiervan op het functioneren van 
het enzyrn. 
De belangrijkste conclusies van het experirnentele werk dat 
beschreven wordt in Publicaties I tot en met VIII worden 
onderstaand sarnengevat. 
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GM2_gangliosidosis 
Er zijn meerdere klinische en biochemische varianten van 
GM2-gangliosidosis beschreven. De meest voorkornende vorrn is 
de ziekte van Tay-Sachs, die berust op een defici6ntie van 
het isoenzym A van S-D-N-acetyl-hexosaminidase. Daarnaast 
bestaat er de ziekte van Sandhoff waarbij zowel het iso-
enzym S-hexosaminidase A (Hex A) als het isoenzym S-hexo-
saminidase B (Hex B) deficient zijn. Complernentatie analy-
sen met fibroblasten van deze typen patienten toonden aan 
dat deze twee biochemische varianten berusten op mutaties 
in twee verschillende genen (Publicatie I). 
Vervolgens kon met behulp van genlocalisatie studies in 
mens-Chinese hamster celhybriden worden aangetoond dat 
hexosaminidase A gecodeerd wordt door twee-verschillende 
genen welke respectievelijk op de chromosoffien 5 en 15 
liggen. Verder bleek de expressie van Hex A afhankelijk te 
zijn van de aanwezigheid van Hex B, dat gecodeerd wordt 
door het gen gelegen op chrornosoom 5. De discrepantie we·lke 
er in verschillende genlocalisatie studies bestond met 
betrekking tot de onderlinge relatie tussen Hex A en Hex B 
bleek veroorzaakt door een verschillende interpretatie van 
een heteropolymeer molecule dat in deze mens-Chinese ham-
ster celhybriden wordt gevormd. Nadere karakterisering van 
dit enzym door middel van imrnunologische methoden (Pu-
blicatie II) en een betere identificatie van Hex C en Hex S, 
twee andere isoenzymen van 8-D-N-acetyl-hexosaminidase 
(Publicatie III) hebben tenslotte in cornbinatie met de 
resultaten van andere groepen geleid tot de opheldering 
van de aard van de mutaties in de twee meest voorkomende 
varianten van GM2-gangliosidosis. De ziekte van Tay-Sachs 
blijkt te rusten op een mutatie in de a-subunit die onder-
deel uitmaakt van Hex A en Hex S, terwijl de ziekte van 
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Sandhoff het gevolg is van een mutatie in de S-subunit 
waaruit Hex B bestaat maar die oak een onderdeel vormt van 
Hex A, waardoor zowel Hex A als Hex B deficient zijn. 
GM1_gangliosidosis 
Ook van de ziekte GM1_gangliosidosis _die veroorzaakt wordt 
door een deficientie van het lysosomale enzym S-galactosi-
dase zijn meerdere klinische varianten bekend. Comple-
mentatie analysen beschreven in Publicatie IV toonden aan 
dat er bij deze varianten tenminste twee verschillende gen-
mutaties zijn betrokken. Tevens werd gevonden dat bij de 
infantiele en juveniele vormen, respectievelijk type 1 en 
type 2 minder dan 1% S-galactosidase activiteit aanwezig 
is in gekweekte fibroblasten. In cellen van patienten met 
een volwassen vorm (type 4) of een vorm zonder duidelijke 
rnentale retardatie (type 3) werd steeds 10-20% restactivi-
teit gevonden, zowel voor een artificieel substraat als 
voor het natuurlijke substraat GM1-ganglioside. In Publi-' 
catie V wordt een tweejarig jongetje met een a-galactosi-
dase deficientie beschreven waarbij tot nu toe de psycho-
motore ontwikkeling normaal verloopt. Zowel op grand van 
de gevonden restactiviteit van S-galactosidase (10-20%) 
als het optreden van complementatie na fusie van fibroblas-
ten van deze patient met die van type 1 en 2 patienten kon 
worden vastgesteld dat het hier geen infantiele of juveniele 
vorm van .GM1-gangliosidosis betreft. Irnmunologische studies 
van de S-galactosidase in fibroblasten van deze in Publi-
catie V beschreven patient toonden voorts aan dat de hydro-
lytische activiteit per enzym molecuul verlaagd was hetgeen 
zou duiden op een structurele rnutatie. Tot nu toe is het 
niet d~idelijk of de diverse klinische varianten berusten 
op verschillende rnutaties van een gen dan wel van meerdere 
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genen coderend voor S-galactosidase. 
Glycogenesis type II 
De meest voorkornende vorm van glycogenesis type II is de 
gegeneraliseerde ziekte van Pompe waarbij ten gevolge van 
een deficientie van het lysosomale enzym zure a-glucosi-
dase stapeling van glycogeen optreedt in skeletspieren, 
hart, lever en andere organen waardoor de patienten vroeg 
overlijden. Er zijn echter oak patienten beschreven met 
een zure a-glucosidase deficientie waarbij de ziekte een 
veel minder ernstig verloop vertoont en waarbij de patien-
ten zonder rnerkbare hartafwijkingen een hoog volwassen 
leeftijd kunnen bereiken met als voornaamste syrnptoom 
spierzwakte. In Publicatie VI wordt beschreven dat in 
gekweekte huidfibroblasten van alle onderzochte patienten 
met deze volwassen vorm van glycogenesis II een residuele 
zure a-glucosidase activiteit van 10-20% aanwezig is. Dit 
geldt zowel voor een artificieel substraat, voor maltose 
als voor het natuurlijk substraat glycogeen. 
Verder werd er een omgekeerde relatie gevonden tussen de 
hoogte van de restactiviteit in de fibroblasten enerzijds 
en de mate van glycogeenstapeling in skeletspieren en de 
ernst van de klinische verschijnselen anderzijds. In cel-
materiaal van patienten met de infantiele vorm werd 
nooit een restactiviteit gevonden hager dan 1%. Biochemi-
sche en irnrnunologische analyse van de zure a-glucosidase 
in fibroblasten van patienten met de volwassen vorm toonde 
aan dat de kinetische en physische eigenschappen van het 
enzym normaal waren maar dat de totale hoeveelheid enzym 
verlaagd was (Publicatie VI). Dit wijst erop dat de muta-
tie in de volwassen vorm leidt tot een verminderde syn-
these van het lysosomale a-glucosidase of tot een versnelde 
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afbraak van het enzym. Uit complementatie analysen in multi-
karyons en individuele binucleaire hybride cellen werden 
geen aanwijzingen verkregen voor genetische heterogeniteit 
(Publicatie VI en VII). De precieze aard van de genmutaties 
is nog niet bekend maar het lijkt waarschijnlijk dat ver-
schillende genrnutaties leiden tot een verschillende mate 
van enzyrn deficientie in de volwassen en infantiele vorm 
van glycogenesis type II. 
Uitwisseling van lysosomale enzymen 
Naar aanleiding van een hypothese v.an Hickman en Neufeld 
(1972) dat lysosomale enzymen eerst door de eel worden uit-
gescheiden en vervolgens weer worden opgenomen via een 
specifiek herkenningsrnechanisme aan het celoppervlak voor-
dat zij het lysosoom bereiken werd in Publieatie VIII nage-
gaan of dergelijke afwijkingen in het opname meehanisme ook 
een rol spelen bij GM2-gangliosidosis, GM 1-gangliosidosis 
en glycogenesis type II. Door middel van enzym analyse in 
individuele fibroblasten na samenkweken van eontrole eel-
len en cellen met een enzymdeficientie werd onderzoeht of 
er intercellulair transport van de betreffende enzymen 
plaatsvond. Voor a-glucosidase en 6-galactosidase werd 
geen overdracht vanuit norrnale eellen naar deficiente eel-
len gevonden doeh voor S-N-acetyl-hexosaminidase werd wel 
opname door cellen van een patient met de ziekte van Sand-
hoff geeonstateerd. Hieruit werd geeoneludeerd dat de 
bovengenoemde hypothese in ieder geval niet voor alle lyso-
somale enzymen geldt. Verdere studies op het terrein van de 
afgifte, herkenning en opname van lysosomale enzymen zijn 
noodzakelijk, niet alleen om inzieht te verkrijgen in de 
precieze aard van de verschillende erfelijke stapelings-
ziekten maar oak om als basis te dienen van een eventuele 
therapie. 
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Tay-Sachs and Sandhoff's disease: 
Intergenic complementation after somatic 
cell hybridization 
H. GALJAARD, A. HOOGEYEEN, H. A. de 
WIT-VERBEEK, A. J. J. REUSER, W. KEIJZER, 
A. WESTE.RVELD and D. BOOTSMA, Department 
of Cell Biology and Genetics, Medical Faculty, 
Erasmus University, Rotterdam, The Netherlands 
Summary. Cultivated skin fibroblasts from patients 
with Tay-Sachs and Sandhoff's disease were fused 
and the isoenzymes of N-acetyl-!3-o-hexosaminidase 
were investigated after 2 and 7 days of subsequent 
cultivation. Enzyme analyses after heat inactivation 
showed a clear increase in the thermolabile com-
ponent of hexosaminidase when compared with 
assays on fusion of each of the parental cell strains. 
Electrophoretic studies revealed that in cell homo-
genates prepared at various time intervals after cell 
fusion of Tay-Sachs with Sandhoff's fibroblasts, 
all three hexosaminidase isoenzymes were present, 
including hexosaminidase A which lacks in both 
parental cell strains. These results show that genetic 
complementation has occurred, which indicates that 
two different gene mutations are involved in these 
variants of GM2-gangllosidosis. The relevance of the 
data obtained for the elucidation of the molecular 
properties of the (iso)enzymes involved is discussed. 
In various normal human tissues [5, 10, ll] 
and in cultured skin fibroblasts [13] three 
isoenzymes of N-acetyH~-o-hexosaminidase 
have been observed which differ in tempera-
ture stability, specificity towards natural sub-
strates, electrophoretic mobility and im-
munological properties [1, 9, 17]. In patients 
with GM2 gangliosidosis type l (Tay-Sachs 
disease) hexosaminidase A is deficient [10], 
whereas in the type 2 variant (Sandhoff's 
disease) both hexosaminidase A and B are 
deficient [14]. Several hypotheses about the 
relationship between the different isoenzymes 
have been postulated in order to understand 
the isoenzyme deficiencies [1, 4, 12, 13, 15, 16, 
17]. Complementation analysis in hetero-
karyons obtained after cell fusion of fibro-
blast strains from different patients with a 
metabolic disorder proved to be a useful 
tool for the demonstration of different gene 
mutations [19]. 
The present paper deals with the assay 
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of hexosaminidase isoenzymes in cultured 
fibroblasts from normal individuals, from 
patients with Tay-Sachs and Sandhoff's 
disease and in homokaryons and hetero-
karyons after somatic cell hybridization of 
these cell strains. Enzyme assays after .heat 
inactivation and electrophoretic studies 
showed the first example of complementation 
after hybridization of cells from two variants 
of a lysosomal storage disease indicating that 
wo different gene mutations are involved. 
Methods and Materials 
Subcultures of skin fibroblasts from a normal 
individual and from patients with Tay-Sachs and 
Sandhoff's disease were cultured for 2~7 days in 
small falcon flasks in Ham F I 0 medium with 10% 
fetal calf serum. Cell hybridization was carried out 
between 2 x IO£ cells of each parental cell strain 
using ina<;:tivated Sendai virus (I ml I 000 HAU/ 
ml added to 1 ml cell suspension). The mixture was 
kept 4 min at 4°C and then incubated for 20 min 
at 37°C under continuous stirring. Cell fusion was 
followed by 2 or 7 days' subsequent cultivation with 
a cell density such that contact inhibition was reached 
within 1-2 days. Enzyme assays were carried out 
after harvesting by trypsinization, rinsing in saline 
and disruption by sonication. Protein was determined 
according to Lowry {8] using microvolumes [2]. 
The overall hexosaminidase activity was measuted 
according to a modified procedure as described by 
Kaback [6]. To enable multiple assays on a small 
amount of cell material incubation of I pl cell homo~ 
genate and 2 pi bovine serum albumin (0.2 ~o w/v) 
was performed during 1 h at 37"C with 2 1d mM 
4-methylumbelliferyl-2, acetamido-2, deoxy-tJ-o-glu-
copyranoside at pH 4.4 using microprocedures 
described earlier [2]. Fluore;cence readings of 4-
methylumbelliferone were made in a Perkin~Elmer 
fluorometer (exc. 365 nm, 448 nm) after addition of 
500 1!1 0.5 M carbonate buffer pH 10.7. Heat in-
activation was carried out after addition of l pi 
cell homogenate to 2 pl bovine serum albumin 
(0.1 o~ wjv) during 2 hat 50'C. 
Electrophoresis was performed on Phoroslide 
cellulose acetate strips (Millipore Corp.), 2-4 !d 
cell homogenate (7 '; 103 - 12" 10'' cells correspond-
ing to I 2-4 pg protein) was applied to each strip 
and run in 0.05 M phosphate buffer pH 6.0 during 
45 min at 20"C (3 rnA/strip, 150 V). The isoenzyme 
pattern was photographed at 365 nm after 30 min 
incubation with 5 mM methyl-umbelliferyl substrate 
in citrate/phosphate buffer pH 4.5 followed by spray-
ing with carbonate buffer (pH 10.7). 
Biochemical assays were performed in triplo on 
cell homogenates from cultured fibroblasts from a 
normal individual, a patient with Tay-Sachs disease 
and a patient with SJ.ndhoffs disease and also in 
homogenates 2 days after cell fusion of these cell 
strains with themselves (parental fusion) and after 
fusion of Tay-Sachs with Sandhoff fibroblasts. The 
whole experiment was repeated twice and in addition 
the cell fusion between Tay-Sachs and Sandhoff 
fibroblasts was also analysed after 7 days' subsequent 
cultivation. In one experiment equal numbers 
(about 1-10" cells) of Tay-Sachs and Sandhoff 
fibroblasts were co-cultivated during 2 days under 
conditions as described above. 
Results 
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Heat inactivation studies after cell hybridiza-
tion. The overall hexosaminidase activities 
and the ratio of the thermolabile (mainly 
hex. A) and thermostabile (hex. B) isoenzymes 
were determined in cultured fibroblasts from 
a normal individual and from patients witn 
Tay-Sachs and Sandhoff's disease. Similar 
values were obtained in different experi-
ments on the same cell strain. Th~se data 
were compared with those obtained after 
cell fusion of each cell strain with itself 
(parental fusion) followed by 2 days' sub" 
sequent cultivation. For none of the cell 
strains was any effect of parental fusion ob-
served on_ the total hexosaminidase activity 
and the ratio hex. A : hex. B. Fig. 1 sum-
marizes the mean values obtained in three 
experiments. Both in non-fused control 
fibroblasts and at 2 days' cultivation after 
parental fusion, the ratio of hex. A : hex. B 
activity is about 1 : 1. After parental fusion 
of Sandhoff fibroblasts hardly any hexos-
aminidase activity is detected (about 1 % 
of the control value) whereas in parental 
fusions of Tay-Sachs fibroblasts the overall 
activity is higher than in control cells. In 
the former, heat inactivation results in a 
decrease of only 14% of the activity. 
Two days after cell fusion of Tay-Sachs 
with Sandhoff fibroblasts (last 2 columns of 
fig. 1) the overall activity is about the average 
of that of both parental cell strains. A longer 
cultivation period in contact inhibition (7 
days) after cell fusion results in an increase 
of the overall activity which has also been 
observed in control cell strains. However, 
~,~ 
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Fig. I. Ordinate: N-acetyl-P-o-hexosaminidase activity 
x I0-6 molejh/mg protein. Comparison of the overall 
hex. activity and of the ratio hex. A and Bin different 
cell fusions. C, normal fibroblast culture; Cx C, 
parental fusion of control fibroblasts; S >< S, parental 
fusion of Sandhoff fibroblasts, TS x TS, parental 
fusion of Tay-Sachs fibroblasts; S+ TS, co-cultiva-
tion for 2 days of Sandhoff and Tay-Sachs fibroblasts; 
S x TS, c~ll fusion between Sandhoff ar1d Tay-Sachs 
fibroblasts followed by 2 days and 7 days subsequent 
cultivation. o, percentage thermostabile component 
(mostly hex. B); !iii, thermolabile component (mostly 
hex.A). The mean activities of 3 experiments (at 
least 6 analyses per experiment) are presented and the 
standard deviation (S.D./M) was 4-10%. The last 
experiment (7 days after S x TS fusion only represents 
1 experiment (6 analyses). 
at both time intervals after fusion of Tay~ 
Sachs with Sandhoff fibroblasts the percent-
age of che heat-labile component of hexos-
aminidase has increased to 27 % of the total 
activity. 
This increase, which is probably due to the 
formation of hexosaminidase A, absent in 
both parental cell strains, must be the result 
of genetic interaction in those heterokaryons 
which contain the genomes of both parental 
cell strains. As is shown in fig. 1 (5th column) 
2 days co-cultivation of Sandhoff and Tay-
Sachs fibroblasts, does not result in an 
increase of thermolabile hexosaminidase. 
Electrophoretic studies after cell hybridization. 
The nature of the thermolabile component 
c 
A 
-B 
a 
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Fig. 2. Cellulose acetate electrophoresis of N-acetyl-tl-o hexosaminidase isoenzymes after cell hybridization 
of cultured fibroblasts. Equal amounts (about 3 x IO-" mg protein) of cell homogenate (obtained after 2 days' 
cultivation after cell fusion) were applied to each strip and run for 45 min in phosphate buffer at pH 6.0. In-
cubation with 4-methyl-umbelliferyl. 2, acetamido-2, deoxy-tl-o-glucopyranoside in citrate/phosphate buffer 
pH 4.5 was carried out during 30 min at 20"C. (a), parental fusion of control fibroblasts; (b), parental fusion 
of Tay-Sachs fibroblasts; (c), parental fusion of Sandhoff fibroblasts; (d), eel! fusion between Sandhoff x 
Tay-Sachs fibroblasts. Reproducible results were obtained in three independent experiments and in repeated 
runs of the same cell homogenate. 
resulting from cell fusions between Sandhoff 
and Tay-Sachs fibroblasts was further in-
vestigated by electrophoresis. Equal amounts 
of cell homogenates of the various cell fusion 
combinations were applied to different strips 
and analysed under similar conditions. Fig. 
2a shows that after parental fusion of control 
fibroblasts three isoenzymes are detectable. 
Hex. B is migrating towards the cathode, 
hex. A migrates towards the anode and hex. C 
is the fastest moving band towards the anode. 
The activities of hex. A and B are about the 
same whereas hex. C is hardly visible, even 
in fresh cell homogenates. After storage 
at - 20°C the C-hand is no longer visible. 
Parental fusion of Tay-Sachs fibroblasts 
results only in strong activity of the B-band 
(fig. 2b). After parental fusion of Sandhoff 
fibroblasts hardly any activity could be 
detected at the localization of the B- and 
A-band but the C-hand was clearly visible 
(fig. lc). 
However, at 2 and 7 days after cell hybridi-
zation of Tay-Sachs with Sandhoff fibroblasts 
all three isoenzymes were observed (fig. 2d). 
These results indicate that in heterokaryons 
containing both the genome of Tay-Sachs and 
Sand hoff fibroblasts hex. A activity is present 
even if this isoenzyme lacks in both parental 
cell strains. Co-cultivation during 2 days of 
these two cell strains, without prior cell 
fusion does not result in the formation of 
hex. A (fig. 3b), whereas it does occur when 
cell fusion was carried out (fig. 3a). 
c 
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Fig. 3. Comparison of N-acetyl-P-n-hexosaminidase 
isoenzymes after 2 days co-cultivation of Tay-Sachs 
and Sandhoff fibroblasts 3 (b) and after cell fusion 
of these cell strains followed by 2 days cultivation (a). 
Assay conditions were the same as mentioned in 
fig. 2. 
After heat inactivation of Tay-Sachs with 
Sandhoff fusions electrophoresis did not show 
any hex. A or hex. C whereas the B band 
remained present. These electrophoretic 
studies indicate that the increase of the 
thermolabile component occurring after cell 
fusion of Tay-Sachs with Sandhoff fibroblasts 
(fig. 1) is due to the formation of hexosamini-
dase A as a result of genetic complementation. 
Discussion 
The data illustrated in fig. I show that for 
each cell strain tested the parental cell hybri-
dization procedure does not affect the total 
hexosaminidase activity nor the isoenzyme 
pattern. The ratio of the thermolabile and 
the thermostabile components observed in 
control fibroblasts (about I: I) is in agree-
ment with findings by other investigators 
[7]. The reduction of 14% of the total activity 
by heat inactivation of Tay-Sachs fibroblasts 
is most probably due to an inactivation of 
hex. C and a partial inactivation of hex. B. 
It does not seem to be the result of inactiva-
tion of a residual activity of hex. A as Beutler 
& Srivastava [1] could not show any cross 
reacting material in cells from Tay-Sachs 
patients with specific hex. A antisera. The 
fact that we did not observe any hex. A and 
hex. C activity at low pH in Tay-Sachs fibro-
blasts, as also shown by others [5, 13] might 
suggest the presence of a common polypeptide 
subunit in these two isoenzymes. 
Biochemical and immunological studies 
suggest that hex. A and hex.B have a common 
subunit [1, 17] and the deficiency of hex. A 
and Bin Sandhoff's disease could be explained 
by a genetic defect in this polypeptide sub-
unit. The hex.A deficiency in Tay-Sachs 
disease might then be based on a defect in 
another sub-unit, specific for hex. A and 
possibly also occurring in hex. C. 
Our data indicate that genetic comple-
mentation for hex. A occurs in heterokaryons 
containing the genomes of Sandhoff and 
Tay-Sachs fibroblasts each of which cell 
strains lacks hex. A activity (fig. 2). Such 
a genetic complementation fits in the hypo-
thesis assuming that the genetic information 
for the common subunit in hex. A and B 
is provided by the nucleus of Tay-Sachs 
fibroblasts whereas the genetic information 
for the specific hex. A (and hex. C ?) subunit 
is present in the nucleus of Sandhoff fibro-
blasts. It is interesting to note that in the 
heterokaryons recognition occurs of different 
polypeptide subunits coded for by two differ-
ent nuclei to form the hex. A isoenzyme which 
must also be transported into the lysosomes 
as is evident by its low pH optimum. These 
processes were shown to be completed within 
2 days after cell hybridization and did not 
change the following 5 days as judged by the 
percentage of heat-labile component (fig. 1). 
Our experiments do not permit a definite 
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conclusion about the exact molecular prop-
erties of the hexosaminidase isoenzymes. 
Gene localization studies with interspecies 
cell hybrids as first reported by van Someren 
et al. fl6] and confirmed by others [4] 
demonStrated independent segregation of the 
gene loci for hex. A and B which makes it 
unlikely that hex. A is a conversion product 
of hex. B [12, 15}. Furthermore, immuno-
logical [l, 17] and biochemical studies [18] 
are at variance with this latter hypothesis. 
~he absence at low pH of hex. C activity 
and increased activity of hex. B in Tay-Sachs 
fibroblasts (fig. 2), the immunological experi-
ments [I, 17], the studies in interspecies 
hybrids [4, 16] and our complementation 
studies could be explained· by either of the 
following two models 
Hex.B ~ pp; Hex. A~ py; Hex.C ~yy 
requiring two gene loci [13], or: 
Hex.B = {Jy; Hex. A= {Ja; Hex.C = ay 
requiring three gene loci. A disadvantage 
of the latter hypothesis is that one also would 
expect mutations in the y polypeptide chain 
leading to deficiencies of hex. B and C, but 
this has never been observed. Further in-
vestigations of interspecies hybrids with 
special emphasis on the segregation be-
haviour of hex. C might give a definite answer. 
Our present studies indicate that the bio-
chemical analysis of heterokaryons containing 
the genetic information of two different 
mutant human cell strains is a useful tool for 
the elucidation of the genetic background of 
different phenotypic variants of inborn errors 
of metabolism. As there is no selective system 
for the isolation of human heterokaryons the 
use of micromethods enabling the assay of 
some lysosomal enzymes in single binuclear 
heterokaryons [3] may further contribute to 
such complementation studies. 
Dr M. F. Niermeijer and Dr H. Kresse were kind 
to provide cultured fibroblasts from patients with 
Tay-Sachs and Sandhoff's disease. The illustrations 
were prepared by Mr P. Hartwijk and Mr T. van Os. 
This study was in part financed by The Netherlands 
Foundation for Medical Research. 
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PUBLICATION 11 
Characterization of /3-D-N-Acetylhexosaminidase Isoenzymes in 
Man-Chinese Hamster Somatic Cell Hybrids 
H. L. HoEKSEMA, 1 A. J. J. REUSER,' A. HooGEVEEN, 1 A. WESTERVELD, 1 
I. BRAIDMAN, 2 AND D. ROBINSON 2 
INTRODUCTION 
Se:;erai forms of {3-o-N-acetyihexosaminidase (E.C.3.2.1.30) have been demonstrated 
in different human tissues [I-3]. Four isoenzymes, characterized by immunological and 
biochemical techniques [4-8], have been designated {3-o-N-acetylhexosaminidase A, 
B, C and S, further to be referred to as hex A, hex B, hex C, and hex S. 
Deficient hex A activity and an increased activity of hex B is found in GM2 
gangliosidosis type I or Tay-Sachs disease, whereas GM2 gangliosidosis type 2 or 
Sandhoff disease is associated with a deficiency of both hex A and hex B [9-12]. 
Biochemical, immunological, and genetical studies suggest a structural relationship 
between hex A and hex B [I , 5, I 0, I3- 19]. Robinson and Carroll [ 19] and Desnick et 
al. [IO] suggested that both isoenzymes are compo~ed of multiple subunits, one of which 
is common to both forms. Two subunit models have been suggested: (I) the three locus 
model [10]: hex A= (a/3)., hex B = (/3-y)n; and (2) the two locus model: hex A= (a/3)., 
hex B = (f3f3)n. Tay-Sachs disease can be explained by a defective a subunit specific for 
hex A and Sandhoff disease, by a defective common f3 subunit. Recently, strong 
evidence in favor of the two locus model has been presented by Beutler and Kuhl [20] in 
in vitro enzyme hybridization studies. 
Studies of the segregation of the hexosaminidase markers in man~rodent somatic cell 
hybrids can discriminate between the different subunit theories. The results however are 
contradictory. Lalley eta!. [21] found that hex A was never expressed in these hybrids in 
the absence of hex B, which fits the two locus model. Gilbert eta!. [15] and van Someren 
and Beyers bergen van Henegouwen [14], however, reported an independent loss of hex 
A and hex B in cell hybrids, which favors the three locus model. 
These conflicting results may be due to a misinterpretation of the electrophoretic 
patterns obtained from hybrid lines, if one relies solely on electrophoretic mobility. The 
formation of heteropolymeric molecules, especially forms with nearly the same 
electrophoretic mobility as hex A, might confuse the interpretation of the segregati<in 
Received April 7, 1976; revised August 16, 1976. 
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results. Therefore, a further characterization of the hexosaminidase isoenzymes in 
hybrid lines is needed. It is possible to obtain information about the presence of possible 
heteropolymeric molecules in hybrid cell lines by using specific antisera against human 
and Chinese hamster hexosaminidase. 
In the present study, a series of man-Chinese hamster hybrids were investigated using 
an anti-Chinese hamster hexosaminidase serum, a specific anti-human hex A serum, and 
an anti-human hex B serum. It was found that a hex A-like enzyme present in the hybrid 
lines consists of both Chinese hamster and specific human hex A moieties. The 
expression of human hex A was found to be dependent on the presence of hex B, and it 
was shown that a gene, coding for a specific hex A subunit is syntenic with the 
mannosephosphate isomerase (MPI) and pyruvate kinase (PK-3) loci, assigned to 
chromosome 15. 
MATERIALS AND METHODS 
Purification of Chinese Hamster Hexosaminidase 
Chinese hamster hexosaminidase was purified 290 times from pooled homogenates of liver and 
kidney. The 20,000 g supernatant was applied on a ConA sepharose column, equilibrated with 10 
mM sodium-phosphate buffer, pH 7 .0, containing 0.1 roM CaCI2 , 0.1 mM MnS04 , and 0.5 M 
NaCI. Hexosaminidase was eluted with 1 M a-methylglucoside in the same buffer solution; pooled 
fractions were dialyzed and applied to a second affinity column. N-acetylglucosamine, bound to 
CN-Br activated sepharose as described by Lotan et al. [22] was used as affinity ligand. 
Hexosaminidase was eluted with 10 mMN-acetylglucosamine and 0.2 M NaCl in 10 mM sodium-
phosphate buffer, pH 6. 0. Pooled fractions, containing hexosaminidase were lyophilized and used 
to raise antisera. 
Antisera 
Antisera against purified human hex A, hex B, and Chinese hamster hexosaminidase were 
raised in New Zealand white rabbits by a slight modification of the method described by Carroll 
and Robinson [23]. Specific human hex A antiserum was prepared by absorption of anti-hex A 
serum with human liver hex B, according to Bartholomew and Rattazzi [24]. 
Cell Lines 
Normal fibroblasts, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficient fibro-
blasts, or normal leukocytes were used as human parental cell lines in the fusion procedure. The 
Chinese hamster parental cell lines used were thymidine kinase (TK) or HPRT deficient 
fibroblasts. Details of the fusion procedure and the isolation and propagation of the hybrid cell 
lines have been described previously [25]. Preparation of celllysates was carried out as described 
by Meera Khan [26]. The human controls used were a tetraploid epithelial kidney cell line (T -cell) 
[27] and a normal fibroblast cell strain. 
Electrophoresis 
Electrophoresis of hexosaminidase, MPI, and PK-3 was carried out on cellulose acetate gel 
(Cellogel, Chemetron, Milan, Italy). Hexosaminidase electrophoresis was performed in 0.05 M 
potassium-phosphate buffer, pH 6.6, for I hr at 4°C. The staining procedure for hexosaminidase 
was carried out according to Okada and O'Brien [11]. The electrophoresis and staining procedures 
of MPI and PK-3 have been published by van Someren et al. [28]. 
Immunoprecipitation 
Lysates were incubated with antiserum overnight at ooc. After incubation, .. the treated Iysates 
were centrifuged at 35,000 g for 20 min. The supernatant was used for electrophoresis. 
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Electrophoresis of lysates of normal human fibroblasts reveals three bands of activity: 
hex B, hex A and hex C (fig. la, lane l). In lysates of Chinese hamster fibroblasts, two 
bands of activity, described as hex land hex 2 (fig. lb, lane l), were found. 
The specificity of,the antisera against Chinese hamster hexosaminidase and against 
human hex A and hex B was tested with lysates of human and Chinese hamster 
fibroblasts. The resulting electrophoretic patterns are illustrated in figure la and lb, 
lanes 2, 3, and 4. With the concentrations used, the antiserum against Chinese hamster 
hex 1 does not cross-react with human hex A, hex B, and hex C (fig. la, lane 2) nor with 
FiG. I. -Electrophoretic patterns of human (a) and Chinese hamster (b) fibroblast lysates. Lane 1, A, B. C 
refer to hex A, hex B, and hex C; 1 and 2 to Chinese hamster hex 1 and hex 2: lane 2, after treatment with 
anti-Chinese hamster hexosaminidase serum; lane 3, after treatment with specific anti-human hex A serum; 
lane 4, after treatment with anti-human hex B serum. The amount of lysate used in the various lanes depended 
on the antibody concentrations of the antisera, explaining differences in staining intensity. 
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the fastmoving Chinese hamster hex 2 band. The specific anti-human hex A serum does 
not remove hex B and hex C, whereas hex A disappeared (fig. !a, lane 3). The 
anti-human hex B serum reacts with both hex A and hex B but not with hex C (fig. Ia, 
lane 4). No reaction of specific anti-human hex A and anti-human hex B sera with the 
Chinese hamster hexosaminidases was observed (fig. !b, lane 3 and 4). These results 
were .confirmed with double immunodiffusion in agarose gels [29] and by antigen-
antibody titrations in various combinations of antigens and antisera. 
Four types of hybrid lines could be distinguished by electrophoresis of different 
man-Chinese hamster cell hybrids (fig. 2). They are indicated as hex A' +/hex B+, hex 
A'+/hex B-, hex A'-/hex B+, hex A'-/hex B-. The band of activity with a 
mobility comparable to hex A is called hex A'. 
Lysates prepared from these four different types of hybrid clones were treated with the 
various antisera, and the resulting isoenzyme patterns of hexosaminidase were studied 
by electrophoresis. The results obtained with a hex A' +/hex B- hybrid are shown in 
figure 3. After treatment with anti-Chinese hamster hex 1 serum, both the Chinese 
hamster hex 1 and the hex A' band disappear. The specific anti-human hex A serum 
removes the hex A' activity, whereas no reaction with Chinese hamster hexosaminidase 
was observed. Anti-human hex B serum does not change the electrophoretic pattern. 
Nine hex A' +/hex B- hybrid clones from five independent fusion experiments were 
tested in this way; they invariably showed the same immunological characteristics. 
Eight hex A' +/hex B+ hybrid cell lines from independent fusion experiments were 
also studied with antisera (fig. 4). After treatment of the lysates with anti-Chinese 
hamster hex I serum, the hex I band disappears along with part of the activity of the hex 
A' band (fig. 4, lane 3). Various concentrations of the anti-Chinese hamster hex I serum 
were used, but a complete removal of the activity on the hex A 1 position could not be 
attained. The activity of hex B does not seem to be affected. With specific anti-human 
hex A serum, all the activity is removed at the hex A 1 position. whereas hex ·B and 
FIG. 2. -Hexosaminidase electrophoretic patterns. From right to left: H = human T -cell (Electrophoretic 
mobility of hex isoenzymes ofT -cell and human fibroblast are comparable; the only difference is the intensity 
of the fastest moving band.) A' +IB+ = hybrid clone with activities at hex A' and hex B position; A' +/B- = 
hybrid clone with activity at hex A' position; A' -/B + =hybrid clone with activity at hex B position; A' -/B-
= hybrid clone having lost the activities at hex A' and hex B position. 
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FIG. 3.-Electrophoretic patterns of a hex A' +/hex B- hybrid, following treatment with different antisera. 
Lane 1, human T -ceU; Jane 2, hybrid without antiserum treatment; lane 3, hybrid following treatment with the 
anti-Chinese hamster hexosaminidase serum; lane 4, hybrid following treatment with the specific anti-human 
hex A serum; lane 5, hybrid following treatment with the anti-human hex B serum. 
FIG. 4. -Electrophoretic patterns of a hex A' +/hex B + hybrid, following treatment with different 
antisera. Lane 1 , human T -cell; lane 2, hybrid without antiserum treatment; lane 3, hybrid following treatment 
with the ariti-Chinese hamster hexosaminidase serum; lane 4, hybrid following treatment with the specific 
anti-hex A serum; lane 5, hybrid following treatment with the anti-hex B serum. 
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Chinese hamster hex 1 activities remain unchanged. When treated with anti-human hex 
B serum, part of the activity at the hex A' position remains, and a normal Chinese 
hamster activity was detected. Also in this case, various dilutionS of the antiserum were 
tested, and always residual activity at the hex A' position remained present. Figure 5 
illustrates the typical electrophoretic patterns of a hex A' -/hex B+ hybrid after 
incubation with the three antisera. Seven clones were tested. Hex B could be removed 
only by the anti-human hex B serum. The Chinese hamster hex I band cross-reacts with 
the anti-Chinese hamster hex I serum. In hex A' -/hex B- hybrids, changes in the 
electrophoretic pattern were observed only after treatment with the anti-Chinese hamster 
hex I serum, which removes the Chinese hamster hex I band. 
A relationship between the absence and the presence of the hex A' band, MPI and 
PK-3 was established, as shown by the data from several fusion experiments (table 1). 
No syntenic relationship was found with 24 other enzyme markers tested. 
DISCUSSION 
The discrepancies in the literature between data obtained in various experiments with 
man-rodent somatic cell hybrids [14, 15, 21) may be due to different interpretations of 
the hexosaminidase electrophoretic patterns from hybrid cell lines with particular regard 
to the activity at the human hex A position. The characterization of the isoenzymes in the 
hybrid cell lines can be greatly improved by the use of anti-Chinese hamster and 
anti-human hexosaminidase sera, as seen in the present study. 
In hex A' +/hex B- hybrid clones, the hex A' band was shown to interact with both 
FIG. 5.-Electrophoretic patterns of a hex A'-/hex B+ hybrid, following treatment with different 
antisera. Lane 1, human T "cell. In fresh homogenates an additional band of activity can be found between hex 
A and hex B. This band corresponds to the intermediate forms 11, ! 2, as seen by DEAE cellulose 
chromatography [34]. Lane 2, hybrid without antiserum treatment; lane 3, hybrid following treatment with the 
anti"Chinese hamster hexosaminidase serum; lane 4, hybrid following treatment with the specific anti"hex A 
serum; lane 5, hybrid following treatment with the anti"hex B serum. 
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TABLE 1 
ABSENCE AND PRESENCE OF HEX A', MPI, AND PK-3 IN PRIMARY AND SECONDARY HYBRID LINES 
MPI PK-3 
+ + 
Hex A': 
+ ......... 30 3 27 3 
0 28 0 35 
PK-3' 
+ 33 0 
............. 0 29 
the anti-Chinese hamster hex and the specific anti-human hex A sera, whereas no 
cross-reaction with the anti-human hex B serum was found. This finding indicates, that 
in these hybrids the isoenzyme at the hex A 1 position is not a normal human hex A, but a 
heteropolymeric molecule, containing both specific human hex A and Chinese hamster 
hexosaminidase moieties. The formation of heteropolymeric hexosaminidase molecules 
in man-Chinese hamster hybrids has been suggested before by Ropers and Schwantes 
[17], who supposed a heteropolymeric molecule at the hex A position to consist of 
Chinese hamster and human hex C subunits. In their theory, hex B and hex C are 
homopolymers, (f3/3ln and (aa)., respectively, whereas hex A consists of B- and C 
subunits (a/3) •. Van Cong eta!. [30] described a band of activity comparable with hex 
A', which they called "hex A fast." A relationship was demonstrated between the 
presence and absence of "hex A fast," MPI, and hex C. Following the subunit model of 
Ropers [16], "hex A fast" was explained as a heteropolymeric molecule with a subunits 
from human hex C and ,8-like subunits from Chinese hamster hexosaminidase. Recently 
it has been shown that at the hex C position two isoenzymes (hex C and hex S) can be 
detected [3, 20]. In view of these studies, it is likely that the fastest moving hex band 
described by Van Cong is identical with hex S. Our electrophoresis system does not 
discriminate between hex S and hex C. 
The residual activity in hex A' +/h~x B +hybrid clones that could be detected at the 
hex A' position after treatment with the anti-Chinese hamster hex 1 or anti-human hex B 
serum indicates the presence of two different isoenzymes at the hex A' position. Since no 
activity is left after treatment with the specific anti-human hex A serum, a 
heteropolymeric molecule is thought to be present, similar to the heteropolymeric 
moleculefound in hex A' +/hex B- hybrid clones at the hex A' position, which consists 
of human hex A and Chinese hamster hex 1 moieties. The other isoenzyme at the hex A' 
position cross-reacts with specific anti-human hex A and anti-human B sera and appears 
to represent a normal human hex A molecule. 
From these studies, we conclude that normal human hex A is present only in the 
presence of hex B, which is in agreement with the results of Lalley et a!. [21]. A 
heteropolymeric isoenzyme can be present independently of human hex B. The results of 
our present study fits into the two locus subunit model. According to this theory, the 
heteropolymeric isoenzyme at the hex A' position has been shown to possess a subunits 
from human hex A and {3-like subunits from Chinese hamster hex I. The formation of 
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other heteropolymeric molecules, in particular between the human {3 subunit and an 
a-like subunit from the Chinese hamster cannot be excluded. The resolution of our 
electrophoresis system in the hex 1 and the hex B region is, however, insufficient to 
distinguish possible heteropolymeric molecules. 
Evidence for the syntenic relationship between hex A, MPI, andPK-3 [14, 27, 31, 32] 
and the assignment of MPI to chromosome 15 [33] puts this synteny group on 
chromosome 15. Our results show a relationship between the absence or presence of the 
isoenzymes on the hex A' position, and that ofMPI and PK-3. With respect to the two 
locus subunit model, the gene coding for the a subunit of hex A is localized on 
chromosome 15. Previously, hex B has been assigned to chromosome 5 by Gilbert et al. 
[14]. According to this model, it should be the gene, coding for the f3 chain which was 
localized on chromosome 5. 
Studies of the expression of hexosaminidases in man-Chinese hamster hybrid cell 
lines can be a tool for understanding the molecular structure of hexosaminidase, 
provided that the characterization of human, Chinese hamster, and possible 
heteropolymeric components does not rely solely on electrophoretic mobilities. 
SUMMARY 
A series of man-Chinese hamster hybrids were investigated with the use of an 
anti-Chinese hamster hexosaminidase serum, a specific anti-human hex A serum and an 
anti-human hex B serum. The expression of human hex A was found to be dependent on 
the presence of hex B. A heteropolymeric molecule is formed independently of hex B, 
which consists of Chinese hamster and specific hex A moieties. It has an electrophoretic 
mobility nearly identical to hex A. A relationship between the absence and presence of 
the heteropolymeric molecule, mannosephosphate isomerase (MPI), and pyruvate 
kinase (PK-3), assigned to chromosome 15, was established. With respect to the two 
locus subunit model, the gene coding for the a subunit, specific for hex A, has been 
localized on chromosome 15. 
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1. Introduction 
Among the different isoenzymes of {J-D-N-acetyl-
hexoaminidase that occur in human tissues most 
attention has been paid to the major forms called 
Hex A and Hex B. A deficiency of Hex A was shown 
to be responsible for the metabolic defect in GM2-
gangliosidosis type B (Tay-Sachs disease) [ 1]. In 
Sandhoff-Jatzkewitz disease, another form of this 
lysosomal storage disease, both Hex A and Hex B are 
deficient [2]. It has been suggested that the simul-
taneous absence of Hex A (o:P)n and Hex B (J3P)n 
activity is caused by a defect in"the common ~-subunit 
[3}. A third isoenzyme called Hex C was first 
described by Hooghwinkel eta! [4]. In contrast to 
Hex A and Hex Bit failed to hydrolyse 4·methylum-
belliferyl-~-D-galactosaminide. Subsequent studies 
revealed other differences between Hex C and the 
lysosomal isoenzymes Hex A and Hex B such as a 
neutral pH-optimum, extralysosomallocalization and 
different immunological properties [5-9]. Recently 
another isoenzyme of ~-hexosaminidase has been 
characterized and was called Hex S [10-12]. It is the 
major component of ~-hexosaminidase activity in 
Sandhoff-Jatzkewitz disease and is absent in tissues 
from patients with Tay-Sachs disease. At acid pH Hex 
S exhibits activity towards 4-methylbelliferyl-jJ-D-
glucosaminide and 4-methylumbelliferyl-~-D-galacto­
saminide. From immunological and biochemical 
studies it was concluded that Hex S shares the 
C.l'-subunit with Hex A but not the ~-subunit [11-13]. 
It has long been a question whether there is a 
structural relationship between Hex C and Hex A. 
Ropers eta!. [14] suggested a common subunit 
structure for Hex A and Hex C. This was based on 
studies that claimed a deficiency of Hex C in tissues 
from patients with Tay-Sachs disease [4,14]. The 
isoenzyme pattern of hexosaminidase in man-rodent 
hybrids seemed to support this hypothesis [15,16]. 
Other reports however described the presence of Hex 
C in Tay-Sachs disease [5-9]. To find a reason for 
this discrepancy we have investigated the electro-
phoretic pattern of ~-hexosaminidase in fibroblasts 
from control subjects and patients with T ay-Sachs 
disease using different staining conditions. With 
reference to the recent characterization of Hex S 
special attention was given to the distinction of Hex 
C and Hex S. 
Our findings suggest that there is no evidence for 
a structural relationship between Hex C and Hex A, 
and the results rather favor a different interpretation 
of the studies with man-rodent hybrids. 
2. Materials and methods 
Skin fibroblasts from three different control 
individuals and six unrelated patients with Tay-Sachs 
disease were cultured in Falcon Flasks in Ham's FlO 
medium supplemented with 15% fetal calf serum and 
antibiotics as described before [17]. Homogenates of 
3 X I 0 6 cells per I 00 pi were prepared by sonication 
in distilled water. Electrophoresis was performed on 
cellulose acetate gels (Cellogel, Chemetron, Italy) in 
50 mM potassium phosphate, pH 6.8, at 4°C, for 
90 min at 200 V. 10 pl Cell homogenate was used per 
lane and the gels were stained with either 4-methylum-
belliferyl-2-acetamido-2-deoxy-~-D-galactopyranoside 
(MU-galactosaminide 1.5 mM) or 4-methylumbelli-
fery 1-2 -ace tami do-2 -de oxy -~-D-gl ucopy ran osi de (M U-
glucosaminide. I.S mM) in phosphate (0.2 M) citrate 
(0.1 M) buffer, pH 4.0 or pH 7.0 (1 h 37uC). Photo-
graphs were t~ken after exposure of the gels to 
ammonia vapor. Preparation of antiserum against 
purified human liver Hex A has previously been 
described [18). 10 ,ul cell homogenate was incubated 
overnight at 4°C with 10 11! antiserum. The 40 000 X g 
supernatant was applied to the gels. 
3. Results 
The isoenzyme pattern of ~-hexosaminidase was 
studied using different staining conditions. When 
4-methyl u mbellif ery 1-2 -ace tamid o-2 -de oxy -~-D-
glucopuranoside (MU-glucosaminide) is used as sub-
strate, at either pH 4 or pH 7, a band of activity 
shows up anodal to Hex A both in fibroblasts from 
control subjects and patients with Tay-Sachs disease 
{fig.l). We have indicated this band as C/S because 
activity of Hex.S as well as Hex C might be expected 
at this position using MU-glucosaminide as substrate 
[I I]. At pH 4 tills band shows up more strongly in 
control fibroblasts than in those from the patient. It 
was further noticed that in fibroblasts from the 
patient the band exhibits a higher activity at pH 7 
pH4.0 
C/S 
A 
8 
- N TS 
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than at pH 4. This was presumably because only 
the neutral isoenzyme Hex Cis present in fibroblasts 
from the patient with Tay-Sachs disease. 
When 4-methylumbelliferyl-2-acetamido-2-
deoxy-~-D-galactopyranoside (MU-galactosaminide) 
is used as substrate instead of MU-glucosaminide the 
activity of all isoenzymes is lower, but the most anod~l 
band still shows up in normal fibroblasts both at acid 
and neutral pH (fig.2). At pH 4 the band is indicated 
as Hex S, the acid isoenzyme, bec:wse it does not 
show up under these conditions in fibroblasts from 
the patient. At pH 7 the neutral isoenzyme Hex C 
contributes to the activity of this band. This is indicat-
ed by the weak band of activity at the C/S position at 
this pH in fibroblasts from patients with Tay-Sachs 
disease. 
To establish that the activity at the C/S position 
only represents Hex S when the gels are stained at pH 
4 with MU-galactosaminide we treated the homo-
genates with anti-Hex A antiserum before electro-
phoresis. Figure 3 shows the isoenzyme pattern in 
fibroblasts from control individuals and from patients 
with Tay-Sachs disease both with and without anti-
serum treatment. The band of activity that shows in 
control fibroblasts at the C/S position using these 
staining conditions is removed completely by the 
antiserum. This indicates that the activity was due to 
Hex S only. The activity that is left at the Hex A 
position and the origin after antiserum treatment 
might be caused by unprecipitated immune complexes. 
pH7.0 
cjs 
A 
8 
-N TS 
Fig. I. Isoenzyme pattern of .8-hexosaminidase in fibroblasts using MU·glucosaminide as substrate. N "'-control subject. TS"' patient 
with Tay-Sachs disease. 
83 
pH4.0 pH7.0 
+ 
s C/5 
A A 
B B 
- -N TS N TS 
Fig.2. Isoenzyme pattern of ,6-hexosaminidase in fibroblasts using MU-galactosaminide as substrate. N ==control subject. TS == 
patient with Tay-Sachs disease. 
As described above there is no activity at the C/S 
position in Tay-Sachs fibroblasts under these condi-
tions. Antiserum treatment results in loss of Hex B 
activity. Hex C can be demonstrated in normal fibro-
plasts and those from the patient after precipitation 
of Hex S using MU-glucosaminide at pH 7 (fig.4). 
With this substrate Hex C activity was also found at 
pH 4 after antiserum treatment although it was much 
less. 
s 
A 
B 
N N+ 
antiserum 
Three different control fibroblasts strains and six 
cell strains from unrelated patients with Tay-Sachs 
disease were investigated in this way and similar 
patterns were observed. In all three control strains 
Hex C and Hex S activity could be demonstrated, 
whereas in none of the fibroblasts strains from the 
patients was Hex S activity detected. Hex C activity 
could always be demonstrated. 
+ 
-
TS TS+ 
antiserum 
Fig.3. Effect of anti Hex A antiserum on the pattern of !)-hexosaminidase in fibroblasts. Gels were stained with MU-galacto-
saminide at pH 4.0. N =control subject. TS =patient with Tay-Sachs disease. 
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fig.4. Effect of ann-Hex A antiserum on the pattern of iJ-hexosaminidase in fibroblasts. Gels were stained with MU-g!ucosaminide 
at pH 7 .0. N =control subject. TS =patient with Tay-Sachs disease. 
4. Discussion 
Hex C activity has been demonstrated by several 
authors in tissues from patients with Tay-Sachs 
disease [5-9,20]. Others however did not succeed in 
detecting Hex C in Tay-Sachs disease [4,14,15,16,19]. 
These conflicting results seem to be explained by the 
recent characterization of Hex S by Ikonne et al. [II] 
and Beutler et al. [12] and by the fact that Hex S 
and Hex C are difficult to seperate in many electro-
phoretic systems. Also, in the system we used Hex S 
and Hex C have the same mobility. 
Using MU-galactosaminide as substrate at pH 4 
conditions were found for the specific staining of 
Hex S. With MU- glucosaminide no proper distinction 
could be made between Hex Sand Hex C, but Hex C 
could be demonstrated with this substrate after precip-
itation of Hex S with anti-Hex A antiserum. At low 
pH the band of activity at the C/S position might be 
missed in tissues from patients with Tay-Sachs disease 
because it only represents the neutral isoenzyme Hex 
C. In tissues from control subjects Hex S contributes 
to the activity of this band which makes it easier to 
detect at low pH. 
Regarding this we suggest a different interpretation 
of results obtained by Van Cong et al. [15 ,16} with 
man-rodent hybrids. An isoenzyme was detected 
that was not present in either of the parental strains. 
It was called 'Hex A fast' and was thought to be 
composed of human 0'-subunits and rodent ~-like 
subUnits. It was demonstrated that the formation of 
this heteropolymeric molecule was dependent on the 
presence of Hex C. However, taking into account the 
substrate and the low pH that was used to stain the 
gels, it may well be that Hex S was scored instead of 
Hex C. The results would then have to be interpreted 
as synteny of Hex S and Hex A. This would be com-
patible with the proposed (o:O')n subunit structure of 
Hex S [11 ,12] and the different iJl1munological and 
biochemical properties of Hex C [5-9,20] in compar-
ison with the other isoenzymes of 13-hexosaminidase. 
We have recently identified a hexosaminidase 
isoenzyme in man-chinese hamster hybrids as a 
heteropolymeric molecule [18]. It has the immuno-
logical properties of the a-subunit of human Hex A 
and chinese hamster he::cosaminidase and it segregates 
with markers of human chromosome 15. One there-
fore might expect that Hex Sis localized on this 
chromosome unless Hex S has subunits different 
from a:. The present data suggest another locus for 
Hex C, but this has not been confirmed by gene 
localization studies. The method described in this 
paper and the procedures described by Swallow et a!. 
[20] to discriminate between Hex S and Hex C might 
facilitate these studies. 
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PUBLICATION IV 
Genetic heterogeneity in GMl-gangliosidosis 
GM!·GANGL!OSIDOSIS is an inherited lysosomal storage disease 
which is due to a deficiency of the acid hydrolase GMJ-13-
galactosidase1. During the past few years several clinical 
variants have been described~-· that differ in time of onset of 
symptoms, involvement of visceral organs or skeletal tissue and 
in the degree of neuronal and mental deterioration. Some of 
these variants have been related to different properties of the 
deficient J3-galactosidases"·' but the significance of the exper-
imental data' has been questioned. Several investigators have 
speculated on the genetic-· background of the different 
variants'·'·' but no C?tperimenta! evidence has been provided to 
support the hypotheses. 
Using somatic: cell hybridisation techniques'"·'~ we ha\'e 
investigated whether different gene mutations are involved in 
clinical variants of GMI-gangliosidosis. Fibroblasts from a 
patient with the infantile type 1 and the juvenile type 2 (refs 
l-3), and from the type 3 patient without mental retardation 
described by Pinsky e/ a/. 5 were fused with cells from an adult 
(type 4) patient reported by our group'. Two days after hybrid-
isation the occurrence of genetic complementation v.as tested 
by )3-galactosidase assays with both synthetic and natural 
substrates. These experiments showed that the gene mutation 
in types 1 and 2 is different from that in types 3 and 4. Enzyme 
assays perfOrmed in single heterokaryons containing the 
genomes of type 1 and type 4 cells showed that genetic com-
plementation results in complete restoration of normal enzyme 
activity. 
Normal skin fibroblasts and cells from patients with the 
different types of GMl-gangliosidosis were grown in Ham 
FlO medium supplemented with 10% foetal calf serum and 
antibiotics. In homogenates of fibroblasts from patients with 
the type I or type 2 variant, )3-galactosidase activity was less 
than 1% of control values when measured with the 4-methyl-
umbe!liferyl (Mli) substrate. Homogenates of fibroblasts from 
patients with type 3 or type 4 GMI-gangliosidosis had a residual 
activity of 15-20%. In type 4 cells a 5% and 8% residual 
activity with the natural substrates GMJ-ganglioside and 
asialofetuin was found by Dr J. S. O'Brien (Department of 
Neurosciences, University of California, La Jolla). 
Cells from the adult type 4 patient were hybridised with those 
from the other three variants and each cell strain was also fused 
with itself (parental fusion) as a control. The results of 
)3-galactosidase assays with synthetic substrate are shown in 
Fig. I. Levels of activity in unfused cells were similar to those in 
the parental fusions, which indicated that somatic cell hybrid-
isation did not affect enzyme activity. The )3-galactosidase 
activities in fusions of type 1 x type 2 and of type 3 X type 4 
cells remain unchanged relative to the average level expected in 
a mixture of equal numbers of parental cells. Fusion of type I 
x type 4 cells, however, resulted in a six- to sevenfold increase 
in enzyme activity. Also there was a markedly increased enzyme 
activity i·n fusions oftype4 x type 2cells. 
Similar results were obtained When ·the )3-galactosidase 
activity was measured with the natural substrate GMt-
ganglioside (Table 1), Conditions for cell cultivation, fusion, 
collection and protein determination v.ere identical to those 
described in Fig. I. Whereas no enzyme activity was detected 
after type 1 :< type 2 fusion a marked increase in GMl-)3-
galactosidase activity was observed after hybridisation of type 
4 x type 1 cells. An additional fusion experiment oftype4 x type 
1 cells was carried out with inactivated serum in the culture 
medium. This will inhibit proliferation of the unfused parental 
cells and thus the proportion of heterokaryons will be higher 
than if normal serum is used. This is reflected in the higher 
)3-galactosidase activities in the last type 4 x type I fusion 
shown in Table 1. 
/1-galactosidase activity 
(X 10- 9 mol per h 
per mg protein) 
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Fig. l 0-Galactosidase assays on cell homogenates after fusion of 
cultured fibroblasts from patients with different variants of GM !-
gangliosidosis. 2 x tO' cells from each strain were hybridised 
with inactivated Sendai virus" under such conditions" that 
50-SO% of the nuclei were present in multinucleates. Two days 
after fusion cells were trypsinised, rinsed 111 saline and disrupted 
by sonicatiOn (2x30 s), and after protein analysis" the 
0-galactosidase activity was assayed with 1m M 4-methylumbelli· 
feryl-j3-o-galactopyranoside, pH 4.2, as described previously". 
--, Independent experiments with the same cell strain: as 
controls three different normal strains were used; -- -· --, 
expected enzyme activity if no complementation occurs, that is 
the mean enzyme activity as a result of mixing equal numbers of 
both parental cells. 
These results showed that genetic complementation had 
occurred in the fusion between type 4 cells and type 1 or type 2 
cells. Thus the adult form of GMl gangliosidosis (type 4 
variant) is caused by a different gene mutation than is present 
in the types 1 or 2 variants. Since there was no complementation 
after fusion of type 4 x type 3 cells these variants might be 
identical or determined by allelic mutations, as is the case for 
types I and 2 GMI-gangliosidosis". 
Although complementation could be detected by enzyme 
analyses in homogenates of heterokaryons it is not possible to 
evaluate the degree of restoration of activity since the pro-
portions of nuclei from each parental cell present in the multi-
nucleates are unknown. To solve this problem microchemical 
techniques were developed which facilitated quantitative 
enzyme assays in individ'ual binuclear heterokaryons"·". 
Fibroblasts from the adult patient with type 4 GMI-
gangliosidosis were hybridised with those from a type I variant 
under such conditions thal about 8% of the hybrid cells are 
binucleate". After fusion cells were grown for 24 h in a Falcon 
flask, they were then trypsinised and 2 x I 0'--4 x 10• cells were 
fable 1 0-Galactosidase assays using natural substrate after somatic 
cell hybridisation of different GMI- gangliosidosis variants 
Enzyme activity { x w-• mol per h per mg protein) 
G M 1-0-galactosidase 4-M U -~-galactosidase 
Type 1 x type I 3.5 1.8 
Type 2 x type 2 4.3 4.0 
Type4xtype4 10.5 13.4 
Typelxtype2 <I <1 
Type I X type 4 44.1 38.6 
Type 1 x type 4* 99.8 75.3 
Control 193.8 246.7 
*After fusion, cells were grown on medium with 10% foetal calf 
serum that had been treated with alkali (pH 10.7) for 3 h at 37 oc 
to destroy enzyme activity in the medium. Conditions of cell culture. 
hybridisation and collection were similar to those described earlier. 
GM l-galactoside-j3 -galactosidase activity was measured according w 
Ho er af.l'. 
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seeded in a dish with a thin plastic bottom. After 24-48 h of 
subsequent cultivation these dishes were frozen and freeze-
dried immediately and small pieces of plastic each containing 
one binuclear cell or one non-fused mononucleate cell were 
dissected under microscopic control. ~-Galactosidase assays in 
individual cells were carried out with synthetic substrate in 
submicrolitre volumes and fluorescence· measurements were 
made in a microspectrofluorometer as described earlier'"·' 1• 
The distribution of ~-galactosidase activity in individual 
unfused control fibroblasts is shown in Fig. 2a. Results from 
three different cell strains were pooled. but also in celts from 
each cell strain there was a considerable variation of activity 
in the range 4 x 10-"-40 x 10 -u mol h -•. In considering these 
data it should be realised that the enzyme activity is expressed 
per cell and that the total cellular dry mass and protein content 
in individual fibroblasts also show marked variations18 •10 . 
The mean ~-galactosidase activity in control cell strains 
varied from 19xJQ-u to 26xtO-"molh-1. Earlier exper-
iments" showed that the level of activity in parental fusions of 
control fibroblasts was approxi01ately twice that of mono-
nucleates. No ~-galactosidase activity could be detected in 
Frequency 
J2l 
::~ mffh 
:1 ,+ri+-+1~, +1-+ I+-[ H-h1Tt~, -~--+--c-, 
~ 
48 56 
4-MU-~-galactosidase activity ( x IO-"' mol h-1 cell-') 
Fig. 2 ~-Galactosidase assays in individual heterokaryons after 
fusion of type 4xtype 1 variants of GMt-gangliosidosis. 
~-Galactosidase activity was measured by incubating individual 
cells in 0.2 ).ll 1 mM 4-methylumbelliferyl-~-D-galactopyranoside 
in 0.1 M-acetate buffer (pH 4.2) containing 0.02% (w/v) bovine 
albumin. Incubation was carried out during 2 hat 37 'C under 
paraffin oil using Lowry's "oil well technique""·"; after addition 
of I ).ll 0.5 M carbonate buffer (pH 10.7) the fluorescence was 
measured in 1-mm glass capillaries with a Leitz rnicrospectro-
fluorometer15·" (objective 2.5 pi). a, Distribution of enzyme 
activities in non fused mononuclear control fibroblasts as 
measured in three different cell strains; b, enzyme activities in 
individual binuclear cells after parental fusion of type I x I (open 
columns) and type 4 x 4 (hatched columns) cells each measured 
in two independent experiments; c, enzyme activities in binuclear 
heterokaryons after fusion of type 4 xI cells as measured in three 
independent experiments. 
individual binuclear cells after parental fusions of type 1 cells 
while in parental fusions of typ~ 4 cells mean activities of 
3 x to-14 and 5 x JQ-11 mol h-1 were found in two experiments; 
this is 10-20% of the activity in parental fusions of control 
fibroblasts (fig. 2b). 
After fusion of type 4 x type 1 cells in 21% of the binucleates 
no ~-galactosidase activity could be detected; these probably 
represent fusions of type 1 x type 1 cells. In 27% of the 
binuclear cells the enzyme activity was similar to that in 
parental fusions of type 4 cells. But in 52% of the binuclear 
heterokaryons p-galactosidase activity was in the range 8 x 10_,. 
to 40x IQ-14 mol h - 1 (Fig. 2c). This is greater than in either of 
the parental cells before or after fusion and the range of activity 
is similar to that in mononuclear control fibroblasts. Thus 
genetic complementation .after fusion of type 4 x type 1 cells 
results in -restorat'ion of p-galactosidase activity tp normal 
control levels. 
The mechanism responsible for the genetic complementation 
observed after fusion of type 4 cells with type 1 or type 2 cells is 
not yet understood. In human liver two forms of GMJ-
ganglioside-~-galactosidases (A and B) have been identified'"·'0 
both of which are deficient in GMI-gangliosidosis2 ". It has 
been proposed that the A form of ~-galactosidase consists of a 
single polypeptide chainz1 and that the B form is a multimeric 
aggregate of the A monomer". On this basis the results of our 
hybridisation studies would indicate the occurrence ofintragenic 
complementation. In a recent review, O'Brien" does not exclude 
the possibility that the B form of P-galactosidase also contains 
amino acid sequences which are not common to the A form. In 
that case the complementation in type 4 x type 1 or 2 hetero-
karyons could still be intergenic. A third possibility is that the 
gene mutation in type 4 GMl-gangliosidosis involves a regulator 
whereas the mutations in type I and type 2 are structural 
mutations. The latter is supported by immunological studies~· 2 ~ 
which revealed the presence of cross-reactive material in cells 
from all patients tested with type I and type 2 GMI-gangliosi-
dosis. Preliminary analyses of the deficient ~-galactosidase in 
type 4 cells and cocultivation studies are suggestive for a 
regulator mutation in the adult type 4 GMI-gangliosidosis. 
Further investigations on the immunological and biochemical 
properties of the deficient enzyme and of the restored enzyme 
activity after genetic complementation are required to prove 
this hypothesis. 
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PUBLICATION V 
BIOCHEMICAL, IMMUNOLOGICAL AND CELL GENETIC STUDIES IN 
A TWO YEAR OLD PATIENT WITH AN ATYPICAL FORM OF 
GM1-GANGLIOSIDOSIS 
A.J.J. Reuser, G. Andria 1 ), H.A. de Wit-Verbeek, 
A. Hoogeveen, E. del Giudice 1 ) and H. Galjaard 
Dept. of Cell Biology and Genetics 
Erasmus University, Rotterdam, The Netherlands 
and 
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Universita di Napoli, Italy 
SUMMARY 
Cultured skin fibroblasts from a two year old boy with 
an atypical form of G -gangliosidosis have been studied. 
With the artificial_ s~strate 4-methylumbelliferyl-p-D-
galactopyranoside, 10-20% residual p-galactosidase 
activity was found in fibroblasts from this patient. 
MOst of the residual enzyme activity was in the monomeric 
A form, very little in the multimeric B form. The Km 
value, pH profile and heat lability of the mutant enzyme 
were comparable with that of p-galactosidase from control 
fibroblasts. Immunological studies showed crossreaction 
of the mutant enzyme with an antiserum raised against 
human liver p-galactosidase, but the catalytic activity 
per unit antigenic activity was about three times lower 
than normal, which suggests a structural mutation of the 
enzyme. It was demonstrated by somatic cell hybridization 
that the gene mutation in the present patient is different 
from that in patients with type 1 or type 2 G -gangliosi-
dosis. No genetic complementation was found a~!er fusion 
with cells from two other clinical forms, designated 
type 3 and adult type 4 GM 1-gangliosidosis. 
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INTRODUCTION 
GM1-gangliosidosis is an autosomal recessive disorder, 
characterized by the lysosomal storage of GM1-ganglioside 
and of proteoglycans due to a deficiency of GM 1 p-galacto-
dase activity ( acid-p-galactosidase EC 3. 2. l. 2 3) (Okada 
and O'Brien, 1968, O'Brien, 1972). 
There is a considerable clinical heterogeneity among 
patients with ~-galactosidase deficiency. Patients with 
the infantile form of GM 1-gangliosidosis (type 1) develop 
symptoms shortly after birth. There is a rapid progressive 
psychomotor deterioration, severe bone deformities, 
pronounced hepatosplenomegaly and the patients usually 
die by two years of age. In patients with the juvenile 
type 2 form the symptoms appear later and progression is 
slower, hepatosplenomegaly is absent, bone abnormalities 
are minimal and the patients may survive to 10 years of 
age (Wolfe et al., 1970; O'Brien et al., 1972b). In 
addition to these two types several patients have been 
reported with a different clinical manifestation of p-
galactosidase deficiency. Among these are children without 
severe mental retardation (Pinsky et al., 1974; Wenger 
et al., 1974; O'Brien et al., 1976) and patients where 
symptoms became manifest in early adulthood (Yamamoto et 
al., 1974; Loonen et al., 1974; Orii et al., 1975). 
In earlier studies we were able to classify some of 
these clinical variants in genetically distinct groups 
by complementation analysis in somatic cell hybrids 
(Galjaard et al., 1975). It was found that the gene 
mutation in type 1 and type 2 GM 1-gangliosidosis was 
different from that in the variants type 3 described by 
Pinsky et al. (1974) and the adult type 4 reported by 
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Loonen et al. (1974). 
The present report deals with biochemical, immunological 
and cell genetic studies of a two year old patient with 
only 10-20% of the normal ~-galactosidase activity in 
leucocytes and cultured skin fibroblasts. The study was 
undertaken to investigate the nature of the mutant 
enzyme and to extend our knowledge about the relation 
betwe·en clinical and genetic heterogeneity in GMl ganglio-
sidosis. 
MATERIALS AND METHODS 
The patient concerned is the son of. healthy, non consangui-
neous parents from South Italy who developed normally 
after uneventful pregnancy and delivery. At 14 months of 
age he was admitted td the hospital because of broncho-
pneumonia. A rnucopolysaccharidosis was suspected because 
of peculiar facies with depressed nasal bridge, low set 
ears, thick eyebrows and small epicanthal folds. Further 
examinations revealed hepatosplenomegaly, dorsolumbar 
kyphosis and bilateral hydrocele. Psychomotor development 
appeared normal and no ophthalmologic abnormalities were 
found. An extensive clinical report will be published 
elsewhere by Andria et al. On the last admission, at 28 
months of age the psychomotor development was still 
undisturbed. 
Fibroblasts obtained from skin biopsy were cultured in 
Ham's FlO medium supplemented with 15% fetal calf serum 
and antibiotics. Confluent cultures were trypsinized and 
cell homogenates were made in 0,9% NaCl by sonication. 
Enzyme activities were measured with 4-methylumbelliferyl 
(MU) substrates (Koch Light) using the following conditions. 
a-glucosidase: 2.2 rnM MU-a-glucopyranoside in 0.2 M 
acetate pH 4.4; ~-galactosidase: l mM MU-~-galactopyrano­
side (MUGal) in 0.1 M acetate buffer pH 4.4 containing 
0.1 M NaCl; 
~-N-acetylhexosaminidase: 5 mM MU-~-glucosaminide in 
phosphate (20 mM)-citrate (12 mM) pH 4.4, a-mannosidase: 
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4 rnM MU-a-mannoside in 0.2 M acetate buffer pH 4.4; ~­
glucuronidase: 2 mM Mu-a-glucuronide in 0.1 M acetate 
buffer pH 4.4; 
a-galactosidase: 1.5 mM MU-a-galactopyranoside in 0.05 M 
acetate buffer pH 4.5; ~-glucosidase: 5 rnM MU-~-gluco­
pyranoside in 0.2 M acetate buffer pH 4.4. 
In each assay 10 ~l cell homogenate was incubated with 
20 ~l substrate for 1 hour at 37°C. The reaction was 
stopped by adding 500 pl 0.5 M carbonate buffer pH 10.5 
and the fluorescence of liberated rnethylumbelliferone was 
measured. For gel filtration a microcolurnn of sephadex G 
150 superfine was used (15 ern x 0,5 em). The column was 
equilibrated and eluted with 10 mM sodium phosphate pH 
6.5 containing 5 mM NaCl, as described by Ho and O'Brien 
(1971). Fractions of 150 ~l were collected. 
For immunological studies an antiserum was used, that was 
raised against partial purified human liver ,8-galactosida-
se. Details of the preparation procedures have been 
described by J. de Wit et al (1977). An aliquot of 15 ~l 
cell homogenate was incubated overnight at 4°C with an 
equal volume of serial dilutions of the antiserum. Immune-
complexes were removed by centrifugation at 40,000 x g 
for 30 minutes. The activity of unprecipitate'd enzyme was 
measured in the supernatant using MUGal substrate. 
Complementation studies were performed by fusion 
of a million of cells from each parental strain and 
subsequent assay of ~-galactosidase activity as described 
before by Galjaard et al. (1974). 
RESULTS 
The activities of several lysosomal hydrolases in fibro-
blasts from this patient were compared with those of 
control strains (Table l). The activity of ~-galactosidase 
measured with 4-rnethylurnbelliferyl-~-D-galactopyranoside 
(MUGal) was found to be only 10-20% of the control value, 
whereas the other activities were in the normal range, ~­
glucosidase and a-mannosidase activity being increased. 
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TABLE 1. LYSOSOMAL ENZYME ACTIVITIES IN FIBROBLASTS FROM OUR PATIENT Z.R. 
AND CONTROLS 
ENZYME 
fo-hexosaminidase 
fo-galactosidase 
a-galactosidase 
.£l-glucosidase 
a-glucosidase 
f3-glucuronidase 
et-mannosidase 
4000 -
500 -
27 -
30 -
104 -
41 -
CONTROLS 
12,000 In 23} 
1,200 In 20} 
20 In 1} 
80 In 11} 
150 In 26} 
230 In 7} 
140 In 16} 
Activities are expressed in moles MU x 10-7 per hour per 
mg protein. n = number of strains tested. 
PATIENT Z.R. 
7,600 
180 
25 
140 
70 
200 
180 
The reduction of ~-galactosidase activity was not due to 
the presence of an inhibitor since a mixture of cell homo-
genates from fibroblasts derived from our patient and 
from a control individual exhibited an activity which was 
the average value of the two parental strains. 
The high residual activity in the patient's fibroblasts 
allowed us to examine the physico-chemical and immunologic-
al characteristics of the mutant enzyme. As shown in Fig. 
1, no differences were detected in the pH profile uf the 
Fig. 1 pH profile of ~-galactosidase in human fibroblasts. 
.6.---.11. patient, e--e control 
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mutant enzyme compared to that of the control fibroblasts 
except that the activity of the former was decreased over 
the whole pH range. Also the Km value of the mutant 
enzyme for MUGal was similar to that of ~-galactosidase 
in normal cells i.e. 0.49 mM. 
The heat lability of the normal and the mutant enzyme was 
studied at 41°C, using 0.1 M acetate pH 4.4, containing 
0.1 M NaCl as incubation mixture. The protein concentra-
tion of the fibroblast homogenate from the patient was 
brought to l mgr/ml by dilution with buffer. The homogenate 
of control cells was diluted until equal ~-galactosidase 
activity per ml was obtained. Subsequently the protein 
concentration was brought to 1 mgr/rnl by addition of a 
concentrated homogenate of fibroblasts from a type 1 
patient of which the p-galactosidase activity was neglect-
able. Fig. 2 shows that the heat inactivation curves for 
the normal and the mutant enzyme are similar . 
Fig. 2 
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Heat lability of p-galactosidase in human fibroblasts . 
.lt-----.6. patient,..__. control 
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Gel filtration on sephadex G 150 was carried out to study 
the isoenzyme pattern of the mutant enzyme. For this 
purpose the cell homogenates were prepared by freezing 
and thawing instead of sonication, since a loss of the 
high molecular form was sometimes noticed after sonication. 
Cell debris was removed by centrifugation and the super-
natant was applied to the column. As illustrated in Fig. 
3 most of the mutant enzyme elutes with the low molecular 
weight form of ~-galactosidase from a control strain and 
very little activity comes of the column together with 
the high molecular weight form. 
Fig. 3 
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Gel filtration of p-galactosidase in human fibroblasts. 
.~.---.&. patient,...._.control, V0 =void volume. Hex: position 
of peak of p-hexosaminidase (MW 10 5 - 1.5 x 10 5 ). Cyt c: 
position of cytochrome c (MW 12 x 10 3 ) 
The immunological characteristics of the normal and the 
mutant ~-galactosidase were compared by irnrnunotitration 
with anti ~-galactosidase antiserum. Fixed amounts of 
cell homogenate were incubated with increasing amounts of 
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antiserum at 4°C overnight. The unprecipitated activity 
in the 40,000 g supernatant was measured with MUGal as 
substrate. Fig. 4 shows that under these circumstances ~­
galactosidase from control fibroblasts is precipitated 
three times as effective as ~-galactosidase from the 
patient. This indicates that either the specific catalytic 
activity or the antigenic activity per molecule of the 
mutant enzyme is less than normal. 
Fig. 4 
, no 
, 
' 
" 
100 ~ 
' ~ BO 
.~ 
' 1l 
j 60 
~ 40 
• 
0 
~ 
2 
·g. 20 
~ 
§ 
0 
0.1 02 0.3 
amount oi antiserum ( orbotrary units) 
Immune precipitation of ~-galactosidase in human fibroblasts 
by an antiserum raised against human liver ~-galactosidase . 
.lr---::.6. patient, e---4tcOntrol 
The nature of the gene mutation in our patient was further 
investigated by somatic cell hybridization studies. 
Fibroblasts from this patient were fused with equal 
numbers of fibroblasts derived from patients with different 
clinical types of GM1-gangliosidosis. Fig. 5 shows that 
fusion of fibroblasts from our patient with those from an 
infantile type 1 or a juvenile type 2 patient results in 
an increase of p-galactosidase activity. No complementation 
occurs after fusion with fibroblasts from an adult type 4 
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patient nor with cells from the type 3 patient. The ~­
galactosidase activity after fusion of type 1 and type 4 
fibroblasts, as published before (Galjaard et al., 1975) 
is given as a reference for a positive complementation 
result. 
sssj, 
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Fig. 5 
-
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type-1 type2 Pollsky adult present control typel type2 type3 type4 typel 
type 3 type4 patient • • • 
39ZR 39ZR 39ZR 39ZR 39ZR typt?4 
Genetic complementation studies after £usion of 
fibroblasts from patients with different clinical forms of 
GM1-gangliosidosis. Columns 1-6 show the mean activity of 
3-5 analyses of mononuclear fibroblasts. Columns 7-11 show 
the mean activity of multikaryons after cell fusion. 
The dotted line indicates the rnep.n .activity of the ctwo 
fusion partners before fusion, i.e. the activity to be 
expected if no complementation would occur after cell fusion. 
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DISCUSSION 
The enzymatic studies described in this paper are 
suggestive for the diagnosis GM 1-gangliosidosis {Andria 
et al., 1977). Normal or increased activities were found 
for all lysosomal enzymes tested except for ~-galactosidase, 
the activity of which was highly reduced. The decreased 
enzyme activity was not due to inhibition by accumulated 
products as described for the liver jl-galactosidase in 
cases of mucopolysaccharidosis (Ho and Fluharty, 1975) 
since a mixture of mutant fibroblasts and control cells 
gave average values of ~-galactosidase activity. It was 
recently demonstrated by O'Brien et al. (1976) that the 
clinical rnanifesta.tions might depend on different residual 
activities of ~-galactosidase for various natural sub-
strates. Yet, in earlier studies on different mutant cell 
strains and control fibroblasts a good agreement between 
assays with the artificial substrate 4-methylumbelliferyl-
p-o-galactopyranoside and the natural substrate GM 1-
ganglioside was found (Galjaard et al., 1975). We there-
fore like to conclude that the decrease of p-galactosidase 
activity as measured with methylumbelliferyl substrate is 
correlated· with a genetic defect of the enzyme that is 
normally involved in the degradation of GM 1-ganglioside. 
The activity of p-galactosidase in fibroblas-ts varies 
with cell culture conditions (Heukels and Niermeijer, 
1976). It is therefore difficult to make a proper estima-
tion of the level of residual activity unless strictly 
standardized conditions are used and cultures are followed 
over a longer period. The p-galactosidase activity in 
fibroblasts from our patient varied from 7 to 16 percent 
in different experiments. This activity is significantly 
higher than that found in patients with type 1 or type 2 
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GM 1-gangliosidosis (Galjaard et al., 1975; Norden and 
O'Brien, 1975). Although there are no sufficient data to 
support a clear correlation between the degree of enzyme 
deficiency and the severity of the clinical manifestations, 
it s'eems that in a number of cases where the residual 
activity is relatively high the symptoms are milder and 
the patients survive longer {Pinsky et al., 1974; Loonen 
et al., 1974; Wenger et al., 1974, Yamamoto et al., 1974;. 
Orii et al., 1975). 
The patient described here is too young to allow con-
clusions about the further clinical course, but the 
absence of psychomotor retardation and severe bone de-
formities as well as the relatively high residual ~­
galactosidase activity are atypical for GM 1-gangliosidosis 
with such early onset of symptoms. 
The results obtained by Galjaard et al. (1975) indicate 
that two different mutations are involved in the various 
clinical forms of GM1-gangliosidosis. Our complementation 
studies described in the present paper indicate that our 
patient should not be classified as type 1 or type 2 
since the gene mutation is not the .same as in these 
forms. The fact that fusion of fibroblasts from our 
patient with cells from Pinsky•s type 3 and the adult 
type 4 patient does not result in an increase of ~-galacto­
sidase activity, could mean that the mutations in these 
three variants are located in the same gene. It should be 
awaited whether the two year old boy described in this 
paper and Pinsky•s patient who is now 7 years old, will 
develop a similar clinical course as the patient with the 
adult form of GM 1-gangliosidosis. (o•Brien, 1975; 
Galjaard et al., 1975; Galjaard and Reuser, 1977). 
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The molecular basis of complementation in GM1-gangliosi-
dosis is still unknown. To discriminate between inter-
allelic and intergenic complementation, it will be a 
great help to know the molecular structure of GM 1-~­
galactosidase. If the conclusion of Norden et al. (1974) 
is correct that fi-galactosidase exists both as a monomer 
and as an aggregate of identical monomers the increase 
of p-galactosidase activity in heterokaryons after fusion 
must ~e explained by intragenic complementation. This 
would require polypeptide chains with structural altera-
tions at different sites able to interact in such a way 
that the hydrolytic activity is restored. When p-galacto-
sidase consists of more than one different subunit the 
situation might be comparable with that in ,8-N-acetyl-
hexosaminidase deficiency where the appearance of hexo-
saminidase A after fusion of fibroblasts from patients 
with Tay-Sachs and Sandhoff's disease most likely results 
from intergenic complementation (Galjaard et al., 1974; 
Thomas et al., 1974). 
The immunological studies on the fibroblasts from the 
patient described in this paper provide evidence for a 
structural mutation because the activity of the mutant 
enzyme per unit antigenic activity was reduced to 30% 
whereas the specific ,8-galactosidase activity in the 
cell homogenate is 10-20%. These combined data might 
indicate that the mutant enzyme is more rapidly degraded 
than the normal enzyme. This has also been described for 
structural altered p-galactosidase in E. Coli mutants by 
Zipser et al. (1976). Using the artificial substrate we 
did not detect any abnormal physico-chemical properties 
of the mutant enzyme such as described for another variant 
of GM1-gangliosidosis by Norden and O'Brien (1975). 
However, similar to these studies we found that nearly 
I 01 
all residual activity consisted of the low molecular (A) 
form of ~-galactosidase (Fig. 3). This might indicate 
that the structural mutation interferes with the aggrega-
tion of monomers to decamers (Norden and o•Brien, 1975). 
Further studies are in progress to elucidate the mechanism 
of genetic complementation in order to obtain further 
insight in the clinical, biochemical and genetic hetero-
geneity in GM 1-gangliosidosis. 
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ABSTRACT 
Fibroblasts from patients with the adult, juvenile and 
infantile form of glycogenesis type II (M. Pompe) were 
cultured under standardized conditions and the activity 
of acid a-glucosidase (EC 3.2.1.20) towards glycogen, 
maltose and 4-methylumbelliferyl-a-D-glucopyranoside was 
measured. Also the amount of glycogen in muscle biopsies 
and in cultured fibroblasts from patients was determined. 
Residual enzyme activities varying from 7-22% were detected 
in fibroblasts from patients with the adult form but not 
in cells from patients with the infantile form of glyco-
genesis II. An inverse correlation was found between the 
severity of the clinical manifestation and the degree of 
residual enzyme activity in the fibroblasts. The kinetic 
and electrophoretic properties of acid a-glucosidase in 
fibroblasts from the adult patients and from· control 
individuals were similar. Immunological studies demonstra-
ted that the decrease of acid a-glucosidase activity in 
all clinical forms of glycogenesis II was attended with a 
proportional reduction of the total number of enzyme 
molecules. The results suggest that acid a-glucosidase 
deficiency is caused by a mutation that affects the 
production or degradation of the enzyme rather than its 
catalytic activity. Complementation studies were carried 
out by fusing fibroblasts from patients with the adult, 
juvenile and infantile form of glycogenesis II, but 
conventional assays on multi heterokaryons nor enzyme 
assays on single binuclear heterokaryons gave any evidence 
for genetic heterogeneity among these forms. 
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INTRODUCTION 
Glycogenesis type II (Pompe's disease) is an autosomal 
recessive inherited disorder, characterized by the lyso-
somal accumulation of glycogen (1,2). The impaired glyco-
gen degradation is 
dase (EC 3.2.1.20) 
due to a deficiency of acid a-glucosi~ 
(3). Several clinical forms of glyco-
genesis II have been recognized which differ in age of 
onset, organ involvement and progression of the disease 
(4-6). In the infantile form (generalized glycogenesis 
II) nearly all tissues are affected and symptoms become 
apparent shortly after birth. Hepatosplenomegaly and 
muscular weakness are present and cardiac failure caused 
by the extensive accumulation of glycogen usually results 
in death within the first year of life. In the juvenile 
form there is no or minimal cardi.ac involvement, difficul-
ty in walking is generally the first symptom and pro-
gressive weakness of the skeletal muscles is the main 
clinical feature. In patients with the adult form symptoms 
do not appear until the second or third decade of life 
and the myopathy, usually beginning in the l.ower limbs, 
develops with different degrees of progres$ion. Patients 
over six.ty years have been described (6-8). 
During the past decade several investigators have tried 
to explain how these different clinical forms can result 
from apparently the same enzyme deficiency. No clear 
answer could be given but it seems that glycogen accumula-
tion in skeletal muscles of patients with the adult form 
is less pronounced than in cases of the infantile type 
(6,8,9). Recently Mehle~ and DiMauro (10) found residual 
acid a-glucosidase activity in muscles from patients with 
the adult or juvenile form of glycogenesis II but not in 
the infantile form. 
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The present paper deals with a study of the level of resi-
dual acid a-glucosidase activity in cultured fibroblasts 
derived from patients with the adult, juvenile and 
infantile form of glycogenesis II. The kinetic, electro-
phoretic and immunological properties of the residual a-
glucosidase in adult and juvenile cases were studied. 
Somatic cell hybridization experiments were carried out to 
investigate whether different gene mutations were respon-
sible for the clinical heterogeneity in glycogenesis II. 
MATERIALS AND METHODS 
Seven patients with the infantile form of glycogenesis II 
(code 6-12) and five patients with the juvenile or adult 
form (code 1-5) have been studied (Table 1). 
Cell cultivation and hybridization 
Subcultures of fibroblast strains of about the same 
passage derived from controls and patients were grown in 
Ham's FlO medium supplemented with 15% fetal calf serum and 
antibiotics. Ten days after the gultures became confluent, 
they were trypsinized and 4 x 10 cells of eac~ strain were 
equally devided over four Falcon flasks (25 em ) . Each 
following week one of these flasks was harvested and cell 
homogenates were prepared by sonication in distilled water 
for measurements of thea-glucosidase activity and the 
glycogen content. During cultivation the medium was changed 
three times a week including the day before harvesting. 
Separate cultures were kept confluent for 15 days and were 
then used for enzyme kinetic, electrophoretic and immuno-
logical studies. 
Cell hybridization was carried out by fusing a million 
cells from each parental strain using inactivated Sendai 
virus (11). After 2-8 days of subsequent cultivation cell 
homogenates were prepared and the acid a-glucosidase 
activity of the mixed population of non fused mononuclear 
cells and of multiheterokaryons was measured. 
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Enzyme assays 
Acid a-glucosidase assays with 2,2 mM 4-methyl9IDhelliferyl-
a-D-glucopyranoside (MUGlu) (Koch-Light) were carried out 
:~dd~~c;ib:~b~~~~~= ~~ri~c~~~:i~~ ~~0~1(~;~~ ~~~~~:n~~e 
single binuclear cultured cells were performed by in-
cubating the cells in 0.08 ~l of MUGlu substrate and 
subsequent measurement of the concentration of methyl-
urnbelliferone by microscope fluorometry {12). The acid a-
glucosidase activity in 10 ~1 cell homogenate was also 
measured with maltose (50 ~l of 10 mg/ml, Baker) or 
glycogen (50 ~l of 50 mg/ml, GIBCO) as substrate, both 
dissolved in potassiumphosphate (0,2 M)-citrate (0,1 M) 
buffer pH 4.4. After incubation and heating for two 
minutes at 100°C the amount of liberated glucose was 
determined by adding 200 ~1 glucose reagent according to 
the procedure of Lloyd and Whelan, as modified by Koster 
et al. (14). pH profiles were made by mixing 10 ~l cell 
homogenate, so-~1 substrate, dissolved in water and 10 ~l 
of phosphate-citrate buffer of proper pH. Electrophoresis 
was carried out at 4°C with cellulose-acetate gels (Cello-
gel, Chemetron, Italy) in 50 mM potassium phosphate pH 
6.8 for two hours, 200V. 
Glycogen determination 
The amount of glycogen was determined according tc a 
modified procedure of· Huijing (15). The cell homogenates 
were heated for 2 minutes at 100°C. After cooling, a 50 ~ 
1 aliquot was incubated with 50 ~l of a mixture of a-
amylase (Diastase Hog Pancreas, Sigma 50 ~g/ml) and a-
glucosidase (15018 EGBC, Boehringer 1.25 g/ml) in sodium 
acetate pH 6.0 for one hour. The samples were then heated 
for 2 minutes at 100°C and the amount of liberated glucose 
was determined as described above. 
Immunological methods 
An antiserum against human liver acid a-glucosidase was 
prepared as described before (16). The IgG fraction was 
obtained by arnmoniumsulphate precipitation and used for 
the present studies. Crude cell homogenates were diluted 
with phosphate buffered (10mM pH 6.8) saline (0.9% NaCl) 
to an a-glucosidase activity of 20-50 n moles MU/hr/ml 
and 15 ~1 aliquots were then incUbated overnight at 4°C 
with 15 ~l of serially diluted antiserum. The immunecom-
plexes were spun down at 40,000 x g for 30' and the 
activity of unprecipitated a-glucosidase was measured in 
the supernatant using MUGlu substrate. 
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RESULTS 
Cell cultivation conditions were standardized to enable 
the Comparison of acid a-glucosidase activity in fibro-
blasts from control individuals and from patients with 
different clinical forms of glycogenesis II. As illus-
trated in Fig. 1 the specific activity of acid a-glucosi-
dase for each of the substrates increased in fibroblasts 
from controls arid from patients with the late onset form 
of glycogenesis II during the four weeks period of cul-
tivation. During this period about a doubling of the 
amount of protein per flask was found. The acid a-glucosi-
dase activity in fibroblasts from patients of the adult 
type (cases l to 4) ranges from 7 to 22 percent of the 
mean control value, independent of the substrate used 
(Fig. 1 and Table 1). The activity in the juvenile form 
TABLE 1. CLINICAL AND LABORATORY DATA OF PATIENTS WITH VARIOUS FORMS OF 
GLYCOGENOSIS TYPE II 
• ACTIVITY IN FIBROBLASTS 
CODE TYPE AGE MUSCLE •• AGE OF 
ONSET 
ACID CL 
GLUCODIDASE 
NEUTRAL a.-
GLUCOSIDASE GLYCOGEN 
1 adult 
.:!: 35 yr 56 yr 2. 1 74 
2 adult 
.:!: 35 yr 48 yr 3. 2 62 
3 adult 
.:!: 14 yr 32 yrt 1.6 77 107 
4 adult 
.:!: 11 yr 26 yr 1.4 59 622 
5 juvenile unknown 18 yrt <0. 2 61 
6-12 infantile 3 mnths <2 yrt <0. 2 66 1300 
(n=7) (n=7) 
Controls 14 69 32-79 
• 
(n=4) {n=13) 
Mean activities after 4 weeks cultivation; acid a-glucosidase measured 
with glycogen as substrate at pH 4.4, expressed as' x 10- 7 moles 
glucose/hr/mg protein; Ueutrala-glucosidase measured with MUGlu as 
substrate at pH 6.5, expressed as: x 10-~ moles MU/hr/mg prote~n. 
Amount expressed in ~g glycogen/mg protein 
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(case 5) was below the level of detection in the assays 
with maltose or glycogen but l to 2 percent residual 
activity was found with MUGlu as substrate which methud 
is more sensitive. In cells from all seven patients with 
the infantile form of glycogenosis II (cases 6 to 12) the 
activity was less than one percent for all three substrates. 
In conclusion, the residual activity of acid a-glucosidase 
at all periods of cultivation is higher in fibroblasts 
from patients who reached a more advanced age and the 
specific activities for maltose, glycogen and MUGlu are 
always reduced to the same extent. 
The mean glycogen content of f-ibroblasts from patients 
with glycogenesis II was 0,5 mg glycogen/mg protein, that 
of normal fibroblasts 0,25 rng/mg. No significant diffe-
rences in glycogen content were observed among cells from 
different types of patients. The accumulation of glycogen 
in skeletal muscle, however, was less in patients with a 
late onset of symptoms than in patients with the infantile 
type of glycogenosis II (Table 1). 
A pH profile was made of the a-glucosidase activity in 
the various cell strains, using three different substrates. 
Fig. 2 shows that the activity of the neutral enzyme is 
highest towards MUGlu substrate: with maltose the activity 
is much less and with glycogen its activity is not detect-
able. The pH profiles further demonstrate that the genetic 
defect in glycogenesis II only involves the acid a-
glucosidase. The activity of neutral a-glucosidase was 
similar in fibroblasts from the different types of patients 
and from control individuals (see also Table 1). By 
comparing the different pH profiles it is concluded that 
the activity measured at pH 4,4 in fibroblasts from adult 
patients must be due to residual actiVity of acid a-
glucosidase. 
80 
10 
' [ 
~ 60 
" 0 
, 50 
i 
. 
'S> '0 
~ 
' g 30 
j 20 
' .. 
0 
" 
0 
MUGLu 
" 
-" 0 
i 
~ 12 
" .§10 
" 
' 1 
f 6 
g 
~ § 
" 
' 2 
Maltose 
0 
i 
~' 
< 
. 
' ~ 
'3 0 
0 
c 
~ 
f2 
jj 
~ 
~ 
'' .. 
0 
Glycogen 
~ 
' 
' l 4 5 6 7 
' 3 4 5 6 7 3 I, 5 6 7 
'" '" 
'" 
~pH profile of a-glucosidase activity with" different substrates. MUGlu (left), 
maltose {middle) and glycogen (right). 
a--11 control, ......... adult patient, o-o infantile patient 
112 
The Krn values of acid a-glucosidase did not vary among 
the different adult patients: for MUGlu the mean Km was 
1,1 mM for maltose 11.9 mM and for glycogen 29.7 mg/ml. 
These values are comparable with those of acid a-glucosi-
dase in control cells. 
Also heat inactivation studies did not reveal a different 
behaviour of the normal and the "mutant 11 enzyme (Fig. 3). 
Fig. 3 
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Heat inactivation of acid a-glucosidase. Experimental conditions: 
56°C, 0. 2 M sodium ac'etate pH 4. 4, protein concentration in each 
of .the samples 1 mg/rnl . 
.--a controls {N) ,.__.adult patients. The numbers refer to the 
cases listed in Table 1. 
The electrophoretic pattern of the mutant enzyme in 
fibroblasts from the adult patients cannot be distin-
guished from normal acid a-glucosidase (Fig. 4). No band 
of activity was detected in a cell homogenate from the 
infantile type. 
Fig. 4 
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Cellulose acetate gel electrophoresis of acid ~-glucosidase. Ca 
and Cb = control strains; I = infantile form of glycogenesis type 
II; 1-4 = adult forms of glycogenesis type II. 
The nature of the residual acid a-glucosidase activity in 
adult patients with glycogenesis II was further investi-
gated immunologically with an antiserum raised against 
acid a-glucosidase from human liver. This antiserum does 
not crossreact with the neutral enzyme. Incre4sing 
amounts of antiserum were added to a fixed amount of a 
homogenate of cultured fibroblasts from patients with 
the adult and juvenile form and from controls. Starting 
with a comparable enzyme activity the mutant enzyme in 
all cases precipitates equally well as the normal enzyme 
(Fig. 5). However, in this situation the protein concen-
tration of the crude homogenate of mutant cells is higher 
than that of control cells. To equalize both the enzyme 
activity and the protein concentration of the cell homo-
genate from control and patients, cell homogenate from a 
patient with the infantile form was added to that of the 
control. Under these circumstances normal acid a-glucosi-
Fig. 5 
0 
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' amount of antiserum ( arb"itrary units) 
6 
Immune precipitation of acid a-glucosidase. Increasing amounts of 
IgG were added to a fixed amount of crude cell homogenate . 
.__.control fibroblast (protein concentration 1.6 mg/ml). 
G--Qmixture of control cells and cells from a patient with the 
infantile form of glycogenesis type II (protein cone. 6.1 mgjml) . 
.__.adult patients (protein cone. nr.l: 2.6 mg/ml, nr.2: 5. 7 mg/ml 
nr.3: 7.5 mg/ml, nr.4: 10.6 mg/rnl) .4..-....A. juvenile patient (protein 
cone. 15 mg/ml). The numbers refer to the cases listed in Table 1. 
dase precipitates only slightly better than the mutant 
enzyme. The immunological data indicate that the decrease 
in acid a-glucosidase activity is caused by a reduction 
of the number of enzyme molecules rather than by a 
reduced catalytic activity of each molecule. In cultured 
fibroblasts from patients with the infantile form of 
glycogenesis II no crossreactive acid a-glucosidase was 
found. 
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To investigate whether different gene mutations were 
involved in the various clinical forms of glycogenesis II 
complementation studies were performed after somatic cell 
hybridization. Fibroblasts from patients of the adult, 
juvenile and infantile type were fused in different 
combinations using inactivated Sendai virus. The activity 
of acida-glucosidase was measured after 2 to 8 days of 
subsequent cultivation after cell fusion. More than 20 
combinations were tested and the activity in each case 
was measured with MUGlu, maltose and glycogen as substrate. 
In none of these complementation experiments any increase 
of acid a-glucosidase activity was observed. 
DISCUSSION 
The present study shows that there is a significant 
difference in the level of residual acid a-glucosidase 
activity in cultured fibroblasts from patients with the 
aQult form and those with the infantile form of glycogeno~ 
sis II. In cells from the infantile form the activity 
always remained below 1% of the control values despite 
prolonged cultivation. In contrast, the activity in 
fibroblasts from patients with the adult form varied 
between 7 and 22%. The activity of acid a-glucosidase in 
the juvenile form (case 5) was very close to that of the 
infantile cases but no overlap with this latter category 
was found. It seems as if this inverse correlation between 
the level of residual activity and the severity of the 
disease even holds within the group of adult patients. 
The activity measured at pH 4.4 is not aue to the neutral 
enzyme as was demonstrated by the pH profile as well as 
by the fact that the activity at this pH was removed by 
the antiserum raised against purified acid a-glucosidase. 
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Normal activities of neutral a-glucosidase were found in 
fibroblasts from all types of patients. It therefore 
seems unlikely that the neutral enzyme plays a role in 
the clinical expression of glycogenesis II as was suggest-
ed by some investigators {6,17,18). 
As far as the characteristics of the residual acid a-
glucosidase are concerned, no differences could be detect-
ed between the physico-chemical properties of the enzyme 
in fibroblasts from adult patients with glycogenesis II 
and controls. Electrophoresis of the mutant enzyme showed 
one band with the same mobility as normal acid a-glucosida-
se. The activity of the mutant enzyme for malt0se and 
glycogen was reduced to the same extent. These combined 
data indicate that the muta~ion in the late onset form 
does not directly interfere with the eonfirmation of the 
different catalytic centres (19, 20, 23). 
Our immunological studies are in support of this view 
because the amount of croSs reacting material was de-
creased proportionally with the enzyme activity and a 
normal hydrolytic activity per molecule of enzyme was 
found. These data suggest that the acid a-glucosidase 
deficiency is caused by a decreased rate of synthesis of 
the enzyme or by a structural alteration resulting in an 
increased rate of degradation. The infantile form of 
glycogenesis II might represent an extreme example of this 
situation since hardly any enzymatic activity could be 
detected in fibroblasts nor any cross reacting immuno-
logical material. The latter has also been observed by 
others (21-23). 
The different levels of residual activity in fibroblasts 
from the adult, juvenile and infantile forms might in 
principle be the result of different allelic mutations. 
Our somatic cell hybridization stuqies did not provide any 
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evidence for genetic heterogeneity. No increase in acid 
a-glucosidase activity was found after fusion of cells 
from different clinical variants nor in biochemical ana-
lyses on cell homogenates containing non fused mononuclear 
cells and multi hete.rokaryons neither in microchemical 
assays on single binuclear cells (12). In other lysosomal 
storage diseases complementation analysis has proven to be 
useful in demonstrating different gene mutations (11,24,25). 
If the finding of residual a-glucosidase activity in fibro-
blasts from all patients with the adult type of glycogene-
sis II tested might be extrapolated to the activity in 
skeletal muscle, this would explain why accumulation of 
glycogen in this tissue is less severe in the adult form 
than in the infantile form (Table 1) (6,8-10). More inves-
tigations on the a-glucosidase activity in muscle biopsies 
from patients with late onset forms are required to allow 
definite conclusions. Cardiac involvement seems to be a 
quantitative rather than a qualitative difference between 
the adult and infantile form since patients have been 
described where the heart was "slightly" involved or 
where cardiac symptoms gradually developed with increasing 
age (7,26,27). In fibroblasts the glycogen accumulation 
was found to be similar in various types of glycogenesis 
II despite the different levels of acid a-glucosidase 
activity. However, the extent of glycogen storage in 
vivo, in various tissues, will not only depend on acid a-
glucosidase activity but also on carbohydrate supply, 
turnover of extra lysosomal glycogen, hormonal control 
and rate of cell renewal (28). The cultured fibroblast 
seems in this respect not a suitable model for studying 
glycogen storage but it provides a proper tool for the 
biochemical and genetic analysis of the normal and the 
mutant enzyme. 
118 
ACKNOWLEDGEMENTS 
We like to thank Dr. J. Jongbloed for his stimulating 
discussion, Mrs. E. de Wit-Verbeek and Miss R. Slee for 
their technical assistance and Mrs. E. Quartel, Mr. P. 
Hartwijk and Mr. J. Fengler for their help in the prepa-
ration of the figures and the manuscript. This study was 
supported in part by the Netherlands Organization for 
Fundamental Medical Research (FUNGO) . 
REFERENCES 
l. Pompe, J.S. (1932), Ned. Tijdschr. Geneesk. J..2., 304-311 
2. Cori, G.T. (1957), Mod. Probl. Paediat. l• 344-358 
3. Hers, H.G. (1963), Biochem. J., .§..§_, 11-16 
4. Hers, H.G. and De Barsy, Th. (1973), in: Lysosomes and Storage Diseases. 
Hers, H.G. and Van Hoof, F., eds. (Academic Press, New York) 197-
216 
5. McKusick, V.A. (1975), in: Mendelian inheritance in man. John Hopkins 
Univ. Press pp. 437-438 
6. Engel, A.G., Gomez, M.R., Seybold, M.E. and Lambert, E.H. (1973), 
Neurology ll• 95-106 
7. Hudgson, P. and Fulthorpe, J.J. (1975), J. Path. ill• 139-147 
8. Engel, A.G. (1970), Brain, 2.1• 599-616 
9. Hug, G., Schubert, W.K. and Soukup, S.W. (1973), New. Engl. J. Med., 
288, 216-217 
10. Mehler, M. and DiMauro, s. (1977), Neurology, 27, 178-184 
11. Ga1jaard, H., Hoogeveen, A., DeWit-Verbeek, H.A., Reuser, A.J.J., 
Keyzer, W., Westerveld, A. and ~ootsma, D. (1974), Expt. Cell Res. 
~. 444-448 
12. Reuser, A.J.J., Jongkind, J.F. and Galjaard, H. (1976), J. Histochem. 
Cytochem., £±, 578-586 
13. Galjaard, H., Mekes, M., De Josselin de Jong, J.E. and Niermeijer, M.F. 
(1973), Clin. Chim. Acta ~. 361~~75 
14. Koster, J.F., Slee, R.G. and HUlsmann, W.C. (1972), Europ. J. Clin. 
Invest. ~. 467-471 
15. Huijing, F. (1970), Clin. Chim. Acta, 1.Q., 567-572 
16. Koster, J.F., Slee, R.G., Vander Klei-van Moorsel, J.M., Rietra, 
P.J.G.M. and Lucas, C.J. {1976), Clin. Chim. Acta, ~. 49-58 
17. Angelini, C. and Engel, A.G. (1972), Arch. Neruol. ~. 344-349 
18. Angelini, C. and Engel, A. G. (1973), Arch. Biochem. Biophys., ~. 350-
355 
119 
19. Jeffrey, P.L., Brown, D.H. and Illingworth Brown, B. (1970), Biochemis-
try, ~' 1416-1422 
20. Palmer, T.N. (1971), Biochem. J., ~. 713-724 
21. De Barsy, Th., Jacquemin, P., Devos, P. and Hers, H.G. (1973), Eur. J. 
Biochem., ll• 156-165 
22. Brown, B.I., Murray, A.K. and Brown, O.H. (1975), ACS Symposium Series 
No. 15, Physiological Effects of Food Carbohydrates, pp. 223-234 
23. Koster, J.F. and Slee, R.G. (1977), Biochem. Biophys. Acta, 482, 89-97 
24. Thomas, G.H., Taylor, H.A., Miller, C.S., Axelrnan, J. and Migeon, B.R. 
(1974) Nature, l2Q, 580-582 
25. Galjaard, H., Hoogeveen, A., Keijzer, W., DeWit-Verbeek, H.A., Reuser, 
A.J.J., Ho, M.W. and Robinson, D. (1975}, Nature~, 60-62 
26. Smith, H.L., Amick, L.D. and Sidbury, J.B. (1966), Amer. J. Dis. Child. 
ill· 475-481 
27. Smith, J., Zellweger, H. and Afifi, A.K. (1967) Neurology ll, 537-549 
28. Rosenfeld, E.L. (1975) Path. Biol. ~. 71-84 
120 
PUBLICATION VII 
METHODS FOR ANALYSIS OF ACID a-1.4-GLUCOSIDASE ACTIVITY IN 
SINGLE (HYBRID) CELLS' 
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Departm<?nt of Cell Biolor;:v and Genetics. Mrdical Faculty, Erasmus University, Rotterdam, The Netherlands 
Received for publication September :1. 1975, and in revised form December 23, 1975 
Two methods are described which allow the quantitative assay of the lysosomal en-
zyme a-1,4-glucosidase in single fibroblasts. In the first procedure the substrate was 
maltose, and liberated glucose was measured with an enzymatic cycling procedure for 
reduced nicotinamide adenine dinucleotide phosphate. Single cultured fibroblasts were 
found to have enzyme activities in the range of 0.5-10 " 10" '' moles glucose/hr. In the 
second procedure the artificial substrate 4-methylumbelliferyl-u-l).glucopyranoside was 
used. It is hydrolyzed in a single step reaction to the fluorescent product 4-methyl-
umbelliferone (MU). By reducing the incubation volume and by measuring the fluorescence 
in microdroplets with a microscope fluorometer, a sensitivity of IO-" moles MU could be 
obtained. Activities wer:e found ranging from 0.5-10 x IO-" moles MU/hr/cell. Both 
procedUl'es for single cell analysis proved to be reliable when compared with conventional 
assays on cell homogenates. Cocultivation and cell fusion studies were performed to 
demonstrate that these methods can be used to study the metabolic and genetic inter-
action between normal and enzyme-deficient fibroblasts derived from patients with 
glycogenosis II. 
The biochemical analysis of lysosomal en-
zymes in cultured cells has received increasing 
attention in the last few years. Prenatal diag-
nosis of several lysosomal storage diseases is 
possible in early pregnancy by assay of enzyme 
activities in cultured amniotic fluid cells (24, 
26. 28). Enzyme assays in cultured cells have 
become an important tool in basic studies in 
cell biology and somatic cell genetics. Comple-
mentation analyses after somatic cell hybridiza-
tion have demonstrated the differences in 
genetic background of different clinical variants 
of hereditary metabolic defects (6, 22. 27. 31, 
32). The phenomenon of metabolic correction 
of enzyme-deficient cells in culture by uptake 
of enzyme secreted by normal cells in coculti-
vation studies or by uptake of partially purified 
enzymes from other sources has received in-
creasing attention in connection with enzyme 
therapy (1, 3, 9, 14. 33). 
Conventional biochemical assays on cell ho-
mogenates do not provide data on the different 
populations of cells which may be present in 
the same culture. Biochemical information from 
individual cells selected from the mixed popula-
1 This study was supported by the Netherlands 
Foundation for Fundamental Medical Research 
(FUNGO) with financial aid from the ~etherlands 
Organization for Pure Scientific Research (Z. W. 0.). 
tion would be of great interest. Analysis of indi-
viduaJ cells can be accomplished either by using 
specific cytochemical staining methods (17, 18, 
30) or by increasing the sensitivity of the ana-
lytical procedures so that the activities of single 
cells can be measured (4, 7, 15, 34). 
The present paper describes two methods for 
the quantitative assay of the lysosomal enzyme 
acid a-1,4-glucosidase in single human fibro-
blasts. These proce.dures were developed to 
investigate the genetic background of different 
clinical variarlts of glycogenosis II (2, 12) and to 
permit studies on the metabolic interaction be-
tween normal and enzyme-deficient fibroblasts 
in culture. Some examPles of application in 
these fields are presented. 
MATERIALS AND METHODS 
Cell cultivation: 
General procedures: Fibroblasts from normal indi-
viduals and from patients with glycogenosis II were 
grown in culture flasks in Ham's F -10 medium supple· 
mented with 15'\- fetal calf serum and antibiotics (100 
f.lg of streptomycin and 100 units of penicillin/mil. 
Ten days after the last subculture the cells were 
trypsinized and cell homogenates were prepared for 
enzyme assays. A small number of cells was reseeded 
in Petri dishes with a thin plastic foil bottom (Mylar 
dishes) at a ce!l density of/000 cells/cmz. After 1 more 
day of cultivation the medium was poured off, the 
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dishes were rinsed twice with 0.9% NaCl, quickly 
frozen in liquid nitrogen and freeze~dried in vacuo at 
-20"C. 
Single cells were isolated by microdissection ac-
cording to the method of Galjaard et al. (7). 
Cocu.ltiuation: Metabolic cooperation was studied 
by mixing equal numbers of normal fibroblasts and 
a-glucosidase-deficient fibroblasts from a patient 
with glycogenesis II. After 10 days of cocultivation the 
mixed cultures were trypsinized. Homogenates were 
made and part of the cells was reseeded in low density 
in Mylar dishes. After 24-30 hr of subsequent cultiva-
tion, individual fibroblasts were dissected at random 
and analyzed for a-glucosidase activity. 
Cell fusion: For complementation studies cells 
were hybridized using inactivated S~ndai virus (125 
hemagglutinating units/10" cells), according to the 
method of Harris and Watkins (11). Single binuclear 
cells were isolated 48 hr after fusion as described by 
Galjaard et al. (7). 
Biochemical assays: 
Maltose: The activity of acid a-1,4-glucosidase in 
cell homogenates was determined with either 10 mM 
maltose as substrate according to Nitowsky and 
Grunfeld (29) or 2.2 mM 4-methylumbelliferyl-a-D-
glucopyranoside as described by Galjaard et al. {8). 
The protein content of the samples was measured 
following the method of Lowry et al. (21). 
For the single cell assay wi'th maltose as substrate, 
enzymatic· cycling was carried out with the oil well 
technique as described by Lowry et al. {19, 20). A 
modification of the procedure of Matschinsky et a/. 
(23) was used for the determination of glucose. The 
procedure is summarized in detail in Table I. The 
reaction mixture was transferred from the oil well to a 
25-><1 Drummond glass capillary and reduced nicotin-
amide adenine dinucleotide phosphate (NADPH) 
concentration was measured with a Leitz microfluo-
rometer as described by Galjaard et al. (7). 
4-Methy/umbe/liferyl-a-o-glu.copyranoside: Incu-
bations performed with 4-methylumbelliferyl sub-
strate were carried out on a Teflon foil in microdrop-
lets which were covered with oil ( 40% hexadecane: 
60% paraffin oil) to prevent evaporation. After addi-
tion of carbonate buffer, pH 10.7, the fluorescence 
intensity of 4-methylumbelliferone was measured 
directly with a Leitz inverted type of microfluorome-
ter with Ploemopak epi-illumination, according to 
Jongkind et al. (15). 
Further details of both procedures will be given in 
Results. 
In all single cell assays empty pieces of Mylar were 
dissected and analyzed in the same way to serve as 
blanks. 
Mean blank values were calculated from about 20 
pieces. The enzyme activities were calculated from 
standard curves for glucose and methylumbelliferone 
after subtraction of the mean blank. Standard solu-
tions were prepared by weighing. 
All purified enzymes, coenzymes and the substrate 
glucose 6-phosphate were obtained from Boehringer; 
o-glucose was from BDH. Maltose (maximum, 0.1% 
w/w glucose) was obtained from Baker. Before use, 
the glucose content was reduced to 0.003% w/w by 
treatment with glucose oxidase. Bovine serum al-
bumin and a-ketoglutaric acid were obtained from 
Sigma; 4~methylumbelliferyl-a:-D-glucopyranoside 
and 4-methylumbelliferone were from Koch Light. 
RESULTS 
Methodology of acid a~l,4-glucosidase 
assay in single cultured cells: 
Maltose as a substrate: The a-1,4-glucosidase 
activity of single human fibroblasts varies from 
1-10 x 10- 13 moles glucose/hr when maltose is 
used as substrate. This amount of glucose is far 
too low to detect with conventional methods 
and just below the sensitivity of microfluoro-
metric procedures. Therefore, enzymatic cy-
cling Was used to assay the a-glucosidase activ-
ity of single cells. Detailed conditions are sum-
marized in Table I. Under the conditions used, 
the amplification achieved by cycling is about 
15,000-fold. 
Because of the low en~ymatic activity of 
single fibroblasts, even minor contamination of 
maltose with glucose causes unreliable assays. 
The glucose content of commercial maltose was 
lowered to 0.003% w/w by treatment with glu-
cose oxidase. With an incubation volume of 62 
nl, the amount of glucose present as impurity is 
0.36 x 10~ 13 moles. 
To test the reliability of the method, different 
amounts of glucose were dissolved in 62 nl 
acetate buffer containing 10 mM maltose. The 
results in Figure lA show a linear relationship 
between the amount of glucose in the sample, 
ranging from 0.5-20 x 10- n moles, and the 
fluorescence intensity of the final amount of 
~ADPH. The relatively high blank values were 
due to glucose impurity in the maltose and 
possible residual NADP after step four of the 
assay procedure. 
In several experiments single cells were iso~ 
lated from a culture of normal human fibro-
blasts and their acid a-glucosidase activity was 
measured. An example of such an experiment is 
illustrated in Figure lB. The fluorescence inten-
sities of the blanks, consisting of empty pieces 
of plastic foil dissected at random from the 
culture dishes, are indicated in the figure. The 
enzyme activities of single fibroblasts, as pre-
sented in Figure lB, were calculated from the 
TABLE I 
Detailed Conditiom of Acid u-1,4-Glucosidase Analy.~is, Using Malto.~e as a Sub.~trate, followed by NADPH Cycling" 
Step Volume Burfer Suhstrate Co!'ador., Enzymes Additions Time Temp-erature 
,, 
0.062 IO mM NaAc-HAc, Maltose, 10 mM BSA,~0.02% 2h' 
pH 4.:1 
2 3min 
3 0.4 2.') mM Tris-HCl, 1 mMMgCl, 5f!gHEX 0.5 mMDithio- 45min 
pH7.6 0.2mMATP 0.35 f!g GfiPDH/ml threitol 
O.OZ mMNADP BSA, 0.04% 
4 O.!J 0.2MNaOH 20min 
5 :u 0.1 M Tris-HCI, 5mMG6P O.ImMADP 0.2 mg GDH 10mMNH,-Ac )h, 
pH8.0 5mM a-Keto- 0.02 mg G6PDH/ml BSA, 0.02% 
glutaric acid 
6 IOmin 
7 5.!J 40 mM Tris-HCI, 2mMNADP 0.04 mg 6PGDH/ml O.lmMEDTA 45min 
pH7.fi 
"The scheme is based on the procedures described hy Matschinsky (2:3). 
• BSA, hovinr serum albumin; ATP, adenosine triphosphate; G6P, glucose 6-phosphate; ADP, adenosine diphosphate; HEX, hexokinase; EDTA, 
ethylenediaminctetraaceta1e; GDH, glu1amate dehydrogenase; G6POH, glucose-6-phos.phate dehydrogenase; 6PGDH, 6-phospho-gluconate dehydro-
genase. 
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FIG. 1. A, standard curve of glucose. Different amounts of glucose were dissolved in 0.06 p.l of the maltose 
substrate mixture. Fluorescence intensity of NADPH was measured, after enzymatic cycling, in a volume of 
about 10 ,u.l. Intensities are given in arbitrary units. Each point represents the mean value of five different 
samples. B, frequency distribution of acid o:-1,4-glucosidase activity in single fibroblasts, as measured with 
maltose as substrate. Fluorescence intensities are given in arbitrary units without subtraction of the mean 
blank. One unit corresponds with an activity of 16 x IO-" moles/hr/cell. Mean activity of65 cells, 5.6 x 10-" 
moles glucose/hr/celL --, blanks; --. normal fibroblasts. 
glucose standard curve after subtraction of the 
mean blank value. The mean activity of the 
cells in this experiment was 5.6 x 10- 13 moles 
glucose/hr/cell. As shown there is a considerable 
variation in enzyme activity among the individ-
ual cells which had been dissected at random 
from the same dish. Acid a-glucosidase activity 
in the cell homogenate Prepared from the tryp-
sinized cells that were reseeded for single cell 
analysis was found to be 4.3 x 10- 13 moles 
glucose/hr /cell. 
Methylumbelliferyl glycoside as a substrate: 
Onder the conditions used the activity of acid 
a·1,4-glucosidase is about 10 times lower for 
this artificial substrate than for maltose. Still a 
high sensitivity can be obtained because of the 
strong fluorescence of the reaction product 4-
methylumbeliiferone (MU). The enzyme activ-
ity of a single cultured fibroblast is 1-10 x 10-,. 
moles MU/hr. This small amount ofMU cannot 
be detected with a conventional fluorometer, 
but by reducing the final volume the concentra-
tion of MU was increased and the fluorescence 
could be measured accurately in submicroliter 
volumes with a microscope fluorometer. The 
best results were obtained by incubating the 
cells for 2 hr at 37°C in 0.06 ,u.l of 2.2 mM 
methylumbelliferyl substrate in 0.2 M acetate 
buffer, pH 4.3. Albumin was added to prevent 
surface denaturation at a concentration of 
0.02%. 
Microdroplets of substrate covered with oil 
were incubated on sheets of thin pltistic foil and 
the reaction was stopped by the addition of 0.3 
,u.l of 0.5 M carbonate buffer, pH 10.7. The 
fluorescence of the released MU was measured 
in the same microdroplets using an inverted 
microscope fluorometer with epi-illumination 
according to Jongkind et al. (15). 
A standard curve of different amounts of MU 
which were dissolved in the reaction mixture is 
illustrated in Figure 2A. A linear relationship 
was found between the amount of MU and 
fluorescence intensity in the range of 1-20 x 
10-1< moles MU. The blank value is due to 
slight fluorescence of the methylumbelliferyl 
substrate, spontaneous hydrolysis of the sub-
strate and aspecific fluorescence of the albumin 
added to the reaction mixture. Figure 2B shows 
the fluorescence intensities of randomly dis-
sected normal human fibroblasts. Again a con-
siderable variation in activity among the indi-
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FIG. 2. A, standard curve of methylumbelliferone (MU}. Different amounts of MU were dissolved in the 
4-methylumbelliferyl substrate mixture. Each point represents the mean value of five different samples. B, 
frequency distribution of acid a-1,4-glucosidase activity in single fibroblasts, as measured with methylumbel-
liferyl substrate. Fluorescence intensities are given in arbitrary units without subtraction of the mean blank. 
Forty units correspond with an activity of 1.83 x w-" moles;br/cell. Mean activity of 45 cells, 4.6 x w-,. moles 
MU/hr/cell.- , blanks;~-, normal fibroblasts. 
vidual cells was found. Activities were calcu-
lated using the MU standard curve after sub-
traction of the mean blank (empty pieces of 
plastic foil). The mean a-glucosidase activity of 
more than 40 cells was 4.6 x IQ- 14 moles 
MU/hr/cell. The enzyme activity calculated 
from the ceil homogenate was 6.4 X IQ- 14 
moles/hr/cell. 
Examples of application in metabolic and 
genetic interaction of cultured fibroblasts: 
Metabolic interaction: To study the meta-
bolic interaction between normal and a-glucosi-
dase-deficient cells, -confluent cultures were 
initiated with equal numbers of fibroblasts 
derived from normal individuals and patients 
with glycogenesis II and cultivated during dif-
ferent time intervals. Analysis of single cells was 
performed by harvesting the mixed conf1uent 
cultures with trypsin and reseeding on Mylar 
dishes. Single cells were isolated after l day 
more in culture as described in Materials and 
Methods. Acid a-glucosidase activity was mea-
sured using methylumbelliferyl substrate. Fig-
ure 3 illustrates the results of such an experi-
ment in which normal and enzyme-deficient 
fibroblasts had been cocultivated for 10 days. 
Enzyme assays were also performed on single 
cells of both types cultured separately under 
similar conditions. No enzyme activity could be 
detected in individual cells from a patient with 
glycogenesis II (Fig. 3B), as is shown by the fact 
that the fluorescence intensities of these cells 
are similar to those of the blanks (Fig. 3A). The 
a-glucosidase activity of normal fibroblasts 
shows a considerable variation. After a period of 
10 days of cocultivation in confluent growth and 
1 day of subsequent cultivation in a Mylar dish. 
single cells were selected at random from the 
mixed population. Figure 3C shows that the 
frequency distribution of enzyme activities was 
not significantly different from distributions 
derived from both parental strains. Even after 
10 days of cocultivation, both enzyme-deficient 
cells and cells with normal a-glucosidase activ-
ity were present. indicating that no intercellular 
exchange of acid a-glucosidase had occurred 
from normal to enzyme-deficient fibroblasts. 
Genetic interaction: Enzyme assays on single 
cultured cells are also of great potential interest 
in somatic cell hybridization studies. Normal 
human fibroblasts as well as fibroblasts derived 
from two patients with clinical variant types of 
glycogenesis II (infantile and adult) were hy-
bridized by using Sendai virus and binuclear 
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distribution of acid o:-1,4-glucosidase activity in sin-
gle fibroblasts. -, normal human fibroblasts; --, 
fibroblasts derived from a patient with glycogenosis 
II. C, frequency distribution of single human fibro-
blasts isolated at random from a mixed population of 
normal and enzyme-deficient cells. 
and mononuclear cells were isolated at random 
from the same Mylar dish. Their acid a-glucosi-
dase activity was measured with methylumbel-
liferyl substrate (Fig. 4). As a control, normal 
human fibroblasts were fused and mononuclear 
nonfused cells as well as binuclear hybrid cells 
were dissected. The frequency distributions of 
these two cell types are shown in Figure 4A and 
B. The a-glucosidase activity per cell is about 
twice as high in the binuclear cells as in 
mononuclear cells. Finally, the result of a fusion 
of fibroblasts derived from patients with the 
adult and infantile type of glycogenosis II is 
illustrated in Figure 4C. No significant levels of 
enzyme activity could be demonstrated in binu-
clear cells. Thus l}O genetic complementation 
occurs after hybridization of these two different 
cell strains. 
DISCUSSION 
Both precedures described here make possi-
ble the quantitative analysis of the acid a-
glucosidase activity in single cultured fibro-
blasts. From a practical point of view, the 
Frequency 
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30 130 
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FIG. 4. Frequency distribution of acid o:-
1,4-glucosidase activity in mono- and binuclear 
human fibroblasts isolated at random after cell fu-
sion. Fluorescence intensity is given in arbitrary 
units, without subtraction of the mean blank. Fifty 
units correspond with an activity of3 x 10"" moles/ 
hr/cell. A, mononuclear normal human fibroblasts. 
Mean activity of 24 cells, 3.3 x w-" moles MU/hr! 
cell. B, binuclear normal human fibroblasts from the 
same population. Mean activity of 39 cells, 5.8 x 
w-" mole/hr/cell. C, binuclear cells isolated at 
random after fusion of fibroblasts derived from two 
patients with different variants of glycogenosis II. No 
enzyme activity could be detected after subtraction of 
the mean blank. 
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two-step procedure with the artificial substrate 
4- methy lu m bellifery 1-a-n-gl ucopyranoside is 
advantageous. Especially in experiments where 
large numbers of cells have to be analyzed, the 
enzyme assay with maltose as substrate is much 
more time consuming. 
On the other hand, use of the natural sub-
strate is to be preferred in studies on the 
relationship between a specific enzyme defi-
ciency and the resulting pathologic and clinical 
manifestations in patients with inherited meta-
bolic disorders. The cycling procedure gives a 
somewhat better separation between blank val-
ues and enzyme activities found in single cells. 
Theoretically, the sensitivity of the cycling 
procedure can be further improved by using a 
higher cycling rate or by double cycling (19). 
The sensitivity of the methylumbelliferyl 
method can only be improved by decreasing the 
incubation volume and the final voluffie in 
which the f1uorescence intensity is measured (7, 
8, 15. 34). 
A disadvantage of the method, described by 
Wudl and Paigen (34). is the lack of visual 
control during isolation of the cells. The isola-
tion procedure used in the present study allows 
the selection of binuclear cells in order to 
investigate the quantitative aspects of genetic 
complementation. 
The relatively large variation in o:-glucosidase 
activity of single cultured fibroblasts observed 
with both assay procedures may be due in part 
to differences in total dry weight of the cells. 
Such differences have been observed by inter-
ference microscopic measurements on individ-
ual fibroblasts within the same culture (7. 16). 
The reliability of both methods described is 
illustrated by a reasonable correspondence be-
tween the mean activities obtained in single cell 
assays and the activities as measured in cell 
homogenates of the same cell strain. The cell 
cultivation conditions for enzyme assay on sin-
gle cells and cell homogenates are not the same, 
and it is well known that the activity of various 
lysosomal enzymes is affected by cell cultiva-
tion conditions (101. The enzyme activity of 
single cells may also vary during the cell cycle 
(:251. 
The ability to perform quantitative assays on 
single cultured fibroblasts allows new experi-
mental approaches to the study of metabolic 
and genetic interaction between different cell 
types within the same culture. The fmding that 
no exchange of acid a-1,4-glucosidase occurred 
after 10 days of. cocultivation of normal and 
enzyme-deftcient fibroblasts could not have 
been established by conventional biochemical 
assays on homogenates of these mixed cell 
populations. This result is inconsistent with the 
hypothesis of Hickman and :--J"eufeld ( 13)· about 
secretion and subsequent uptake of lysosomal 
enzymes via specific recognition sites. at least 
for acid a:-1,4-glucosidase. An alternative expla-
nation is that the enzyme deficiency in glycoge-
nesis II is caused by a mutation in a specific 
cellular membrane component which prevents 
uptake of the enzyme. Further, the exchange of 
the lysosomal enzyme )3-galactosidase between 
normal and enzyme-deficient cells in similar 
cocultivation experiments (9) could not be dem-
onstrated. 
The results of a-glucosidase assays on single 
binuclear cells after hybridization of two differ-
ent fibroblast strains show the feasibility of this 
approach in geneti-c complementation studies. 
Complementation has been demonstrated after 
hybridization of fibroblasts from clinically dif-
ferent patients with xeroderma pigmentosum 
(32), maple syrup urine disease (2:2) and GM2-
gangliosidvsis (6, 31). Recently, different gene 
mutations were found by complement\l.tion 
studies with different clinical variants of GMI-
gangliosidosis with the cell hybridization tech-
nique (5). All of these complementation studies, 
except that on xeroderma pigmentosum. were 
carried out with cell homogenates and therefore 
did not permit any conclusions about the quan-
titative aspects of complementation in these 
hybrid cells; Since there is no selective system 
for human hybrid cells. techniques for si.ngle 
cell analysis such as described in this paper 
seem to be the only means to Provide such data. 
These techniques are likely to contribute to 
other investigations where quantitative bio-
chemical analysis of different cell types within 
the same culture is required. 
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SUMMARY 
Intercellular exchange of N-acetyl-/l-D-glucosaminidase (EC 3.2.1.30) iJ-galac-
tosidase (EC 3.2.1.23) and acid a-glucosidase (EC 3.2.1.20) was studied after co-
cultivation of normal and enzyme deficient human fibroblasts in confluent cultures. 
Enzyme activities were measured in single cells using microchemical procedures. 
After co-cultivation of normal control fibroblasts and those from a patient with 
Sandhoff's disease an increase of activity of N-acetyl- fJ -D-glucosaminidase was 
found in Sandhoff cells, together with a decrease of activity in normal control 
cells. After co-cultivation of normal fibroblasts and those from patients with gly-
cogenesis II and GMl-gangliosidosis, no indication was found for intercellular 
transfer of acid a-glucosidase and f3 -galactosidase respectively. The significance 
of the results is discussed in respect of the hypothesis of Hickman and Neufeld 
about secretion and uptake of lysosomal enzymes~ 
INTRODUCTION 
Cultures of human fibroblasts have proven to be a. useful model system for the 
study of lysosomal storage diseases. Correction of the metabolic defect by admini-
stration of enzyme preparations to fibroblasts in cufture was reported in several 
studies (1-7}. It has been suggested that enzyme replacement might be a feasible 
therapy in lysosomal storage diseases. 
A more fundamental interest in uptake and secretion of lysosomal enzymes was 
raised in studies with cultured ce,lls from patients with !-cell disease. For several 
acid hydrolases increased levels of activity were found in the medium of cultured 
celfs from these patients, together with decreased levels of intracellular activities 
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(8, 9). Hickman and Neufeld suggested that lysosomal enzymes have to be secreted 
and subsequently are taken up via specific recognition sites in order to reach their 
lysosomal destination. 1-cell disease would be the result of a defective uptake. 
To investigate the general validity of this hypothesis we have studied the inter-
cellular exchange of three acid hydrolases in mixed confluent cultures of normal 
and enzyme deficient cells. In this way administration of enzyme preparations was· 
avoided whereas the conditions for transfer of enzyme were optimal by close con-
tact of donor and acceptor cells. The exchange of N-acetyl- [3 -0-glucosaminidase 
(further to be referred as hexosaminidase), j3-galactosidase and acid a-glucosidase 
was studied using fibroblasts from patients with deficiencies for these enzymes as 
acceptor cells. Enzyme activities were measured in single cells after co-cultiva-
tion with normal cells. 
METHODS 
Cell culture and isolation: Cells were cultured in Ham's FlO medium supplemented 
with 15% fetal calf serum and antibiotics. In addition to fibroblasts from control 
subjects fibroblasts were cultured from patients with Sandhoff's disease (deficient 
in both lysosomal forms of hexosaminidase), GM 1-gangl iosidosis type 1 (deficient 
in lysosomal p-golactosidose) and glycogenesis II (deficient in lysosomal ct-glu-
cosidase). Preceeding co-cultivation cells from different strains were labeled with 
either latex or carbon particles. Suspensions of latex particles were obtained from 
Servo (Qow latex, 0.79 p) and were added at a concentration of 0.02 ml to 
2 x 106 cells in lO ml culture medium. Suspensions of carbon particles were ob-
tained from George T Gurr (Indian Ink, cat no 51400) and were added at a con-
centration of 0.1 mi. The medium was removed after one day culturing, the cells 
were washed three times with 0.9% NaCI and trypsinized. Equal numbers of nor-
mal and enzyme deficient cells were mixed and confluent cultures were initiated. 
Growth in confluency was allowed for one to ten days. The cultures were trypsi-
nized after this period of co-cultivation and reseeded in low density in petri 
dishes with a thin plastic foil (mylar) bottom, to enable single cell analysis. After 
cultivation for 20 hrs. differently labeled cells were identified with phase con-
trast microscopy and localized using a micro grid. Cultures were then freeze dried, 
whereupon preselected cells could be isolated by microdissection as described by 
Galjaard et al. (11). 
Enzyme assays: 4-methylumbelliferyl-2-acetamido-2-deoxy- p -D-glucopyranoside, 
4-methylumbelliferyl- (', -D-galoctopyronoside and 4-methylumbell iferyl- a-D-
131 
glucopyranoside were used as substrates for the determination of hexosaminidase, 
{)-galactosidase and a-glucosidase activity respectively. Detailed conditions for 
the assay of {)-galactosidase are described by Galjaard et al (12). A method for 
the single cell analysis of a-glucosidase is described by Reuser et a! (13). To 
assay hexosaminidose activity single fibroblasts were incubated in 0.1 ~1 phosphate 
(20 mM)-citrate (10 mM) buffer pH 4.5 containing 5 mM substrate and 0.02%, 
heat inactivated, bovine serum albumin. The reaction was allowed to proceed for 
one hour at 370C and stopped by the addition of 1 !JI, 0.5 M carbonate buffer 
pH 10.7. Fluorescence was measured in glass capilleries as described for {)-galac-
tosidase. Enzyme activities were calculated using a standard curve of methylumbelli-
ferone (MU). Empty pieces of plastic foil were dissected to serve as blanks. 
RESULTS 
Normal control fibroblasts and enzyme deficient cells were labeled with either 
latex or carbon particles. Control experiments showed that marker material did not 
influence the enzyme activities measured. In several experiments equal numbers of 
fibroblasts from a control subject and from a patient with Sondhoff's disease locking 
both lysosomal forms of hexosaminidase were mixed and co-cultivated in confluent 
cultures for various time periods. As a control both cell lines were cultured seporo-
tely for the same p~riod. In the experiment described, the cells were co-cultivated 
for ten days as a confluent culture and then reseeded in low density in petri dishes. 
After a subsequent cultivation for 20 hours the cells were .localized, freeze dried 
and isolated selectively as described in Methods. Hexosaminidase activity was 
assayed in single cells of both types. 
Fig. lA shows the frequency distribution of hexosaminidase activity in fibroblastS 
from control subject and patient when cultured separately. Low residual activity 
-12 
was pr.esent in Sandhoff cells {mean activity 0.06 x 10 moles MU per hr) where-
• I r·b bl h . . 4 6 10-12 I MU h Af as m norma 1 ro asts t e mean act1v1ty was . x mo es per r. ter 
ten days of co-cultivation marked changes were noticed in the distributions as shown 
-12 
in Fig. lB. The mean activity of Sandhoff cells was increased to 0.7 x 10 
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Fig. 1. Frequency distributions of hexosaminidase activity in single human fibroblasts 
derived from a control subject and from a patient with Sandhoff's disease. 
A. Separate cultivation 
B. Co-cultivation for 10 days in confluency 
- patient -- control 
moles MU per hr whereas the mean activity of control cells was decreased to 
-12 1.7 x 10 moles MU per hr. The same effect was found after three days of co-
cultivation although less prominent. 
In similar experiments exchange cf ,6-golactosidase was studied. Fibroblasts from a 
patient with GMl-gangliosidosis, lacking lysosomal j3-galactosidase, were co-culti-
voted with normal human fibroblasts in equal numbers for eight days. The frequency 
distributions of enzyme activity for both types of cells when cultured separately are 
given in Fig. 2A. Distributions after co-cultivation are shown in Fig. 28. In neither 
case j3-gal actosidase activity could be demonstrated in fibroblasts from the patient. 
-13 -13 The mean activity of normal cells was 1.36 x 10 and 1.38 x 10 moles MU 
per hr. respectively. This indicates that no intercellular exchange of f3 -ga-
lactosidase occurred. 
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Fig. 2. Frequency distributions of f3 -galactosidase activity in single human fibro-
blasts derived from a control subject and from a patient with GM 1 ganglio-
sidosis. 
A. Separate cultivation 
B. Co-cultivation for 8 days in confluency 
- patient - control 
Fibroblasts from a patient with glycogenesis II lacking acid a-glucosidase were 
used as acceptor cells to study exchange of this enzyme. The experiments were 
done in a similar way as described above. Cells were co-cultivated for seven days. 
The frequency distributions of -Q-glucosidase activity of norma! and deficient cells 
in separate and mixed cultures are shown in Fig. 3A and 38 respectively. 
No enzyme activity could be demonstrated in fibroblasts from the patient with 
-14 
glycogenesis II. The mean activity of normal cells was 4.7 x 10 moles MU per 
hr. when cultured alone and 3.9 x 10- 14 after co-cultivation. 
No transfer of acid a-glucosidase activity from normal to deficient cells was found. 
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Fig. 3. Frequency distributions of acid a- -glucosidase activity in single human fi-
broblasts, derived from a control subject and from a patient with glycogene-
sis II. 
A. Separate cultivation 
B. Co-cultivation for 7 days. in confluency 
- patient - control 
DISCUSSION 
Selective and bulk pinocytosis are distinguished for uptake of extracellular mote-
rial. The former process requires specific recognition sites on the cell surface as well 
as on the molecule that is taken up (14). According to the hypothesis of Hickman 
and Neufeld (10) secretion followed by selective uptake is· essential for packaging 
of lysosomal enzymes. This implies the possibility of transfer of enzyme from one 
cell to another. Mutual correction of the metabolic defect in cultured fibroblasts 
from clinically different patients with mucopolysaccharidosis was demonstrated to be 
the result of free exchange of lysosomal enzymes {1, 2, 3). The hypothesis of Hick-
man and Neufeld is mainly based on studies with )-cells and the authors indicate 
135 
that the theory might not apply to all lysosomal enzymes. Strong evidence has been 
presented for the uptake of hexosaminidase via specific recognition sites (15). 
We have studied exchange of hexosaminidase, ~-galactosidase and a-glucosidase 
by co-cultivation of normal control and enzyme deficient cells in confluent cultu-
res thereby trying to approach the in vivo situation, avoiding the administration of 
enzymes in quantities far exceeding the intracellular activity. 
The clear transfer of hexosaminidase activity from normal cells to enzyme deficient 
cells fits in with the Hickman and Neufeld hypothesis. Interestingly the increase 
in hexosaminidase activity in Sandhoff cells, as a result of co-cultivation 1 is accom-
panied by a loss of activity in normal fibroblasts. No compensation seems to occur 
for the loss of intracellular activity from normal cells. 
No transfer of ~-galactosidase or a-glucosidase activity could be demonstrated 
in our experiments. This might indicate that for these enzymes the packaging into 
lysosomes is different compared to hexosaminidase. In this case the simultaneous lack 
of ,6-galactosidase and hexosaminidase in !-cell disease can not be explained by 
a mutation affecting recognition sites on the enzyme molecules. 
A different explanation for our results might be that the enzyme deficiencies in 
GMl-gangliosidosis and glycogenesis II are caused by a defect in the recognition 
sites on the cell surface, preventing uptake of ,6-galactosidase and a-glucosidase 
respectively. No cross-reacting material could be demonstrated in liver cells of a 
patient with glycogenesis II (16) which may support this hypothesis. Detection of 
cross-reacting material in the liver cells of a patient with GM 1-gangliosidosis (17) 
however, points to a structural mutation in the enzyme molecule rather than to a 
defect in the uptake of J3-galactosidase. 
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